<!DOCTYPE html>
<!--[if lt IE 7]>
    <html class="no-js lt-ie10 lt-ie9 lt-ie8 lt-ie7 is-ie" lang="en" data-application="loading" >
<![endif]--><!--[if IE 7]>
    <html class="no-js lt-ie10 lt-ie9 lt-ie8 is-ie" lang="en" data-application="loading" >
<![endif]--><!--[if IE 8]>
    <html class="no-js lt-ie10 lt-ie9 is-ie" lang="en" data-application="loading" >
<![endif]--><!--[if IE 9]>
    <html class="no-js lt-ie10 is-ie" lang="en" data-application="loading" >
<![endif]--><!--[if gt IE 9]>
    <html class="no-js is-ie" lang="en" data-application="loading" >
<![endif]--><!--[if (!IE)]><!--><html class="no-js" lang="en" data-application="loading"> <!--<![endif]-->        <head>     <meta charset="utf-8" />     <meta http-equiv="Content-Type" content="text/html;charset=UTF-8" />     <title>Hepatitis C virus drug resistance&ndash;associated substitutions: State of the art summary - Lontok - 2015 - Hepatology - Wiley Online Library</title> <script type="text/javascript" src="/dtagent_ICAp_6000500171012.js" data-dtconfig="rid=RID_853619070|rpid=-1265176198|domain=wiley.com|lab=1|reportUrl=dynaTraceMonitor|agentUri=/dtagent_ICAp_6000500171012.js"></script><link rel="shortcut icon" type="image/x-icon" href="/enhanced/static/images/brand/wiley/favicon.ico?version=1.15.0" />    <meta http-equiv="X-UA-Compatible" content="IE=edge, chrome=1" /> <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" /> <meta name="description" content="" /> <meta name="robots" content="noarchive" /> <meta name="citation_doi" content="10.1002/hep.27934" /> <meta name="citation_journal_title" content="Hepatology" /> <meta name="citation_title" content="Hepatitis C virus drug resistance&ndash;associated substitutions: State of the art summary" /> <meta name="citation_volume" content="62" /> <meta name="citation_issue" content="5" /> <meta name="citation_firstpage" content="1623" /> <meta name="citation_lastpage" content="1632" /> <meta name="citation_issn" content="1527-3350" /> <meta name="article_references" content="Lontok, E., Harrington, P., Howe, A., Kieffer, T., Lennerstrand, J., Lenz, O., McPhee, F., Mo, H., Parkin, N., Pilot&#x2010;Matias, T. and Miller, V. (2015), Hepatitis C virus drug resistance&ndash;associated substitutions: State of the art summary. Hepatology, 62: 1623&ndash;1632. doi:10.1002/hep.27934" /> <meta name="citation_language" content="en" /> <meta name="citation_publication_date" content="2015/11/01" /> <meta name="citation_online_date" content="2015/07/30" /> <meta name="citation_author" content="Lontok, Erik" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Forum for Collaborative HIV Research, University of California at Berkeley Washington DC" /> <meta name="citation_author" content="Harrington, Patrick" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Center for Drug Evaluation and Research, Office of Antimicrobial Products, Division of Antiviral Products, US Food and Drug Administration Silver Spring MD" /> <meta name="citation_author" content="Howe, Anita" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Merck Research Laboratories West Point PA" /> <meta name="citation_author" content="Kieffer, Tara" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Vertex Pharmaceuticals, Inc. Boston MA" /> <meta name="citation_author" content="Lennerstrand, Johan" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Uppsala University Department of Medical Sciences Uppsala Sweden" /> <meta name="citation_author" content="Lenz, Oliver" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Janssen Infectious Diseases Beerse Belgium" /> <meta name="citation_author" content="McPhee, Fiona" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Bristol&#x2010;Myers Squibb Research and Development Wallingford CT" /> <meta name="citation_author" content="Mo, Hongmei" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Gilead Sciences, Inc. Foster City CA" /> <meta name="citation_author" content="Parkin, Neil" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Data First Consulting, Inc. Belmont CA" /> <meta name="citation_author" content="Pilot&#x2010;Matias, Tami" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="AbbVie, Inc. Chicago IL" /> <meta name="citation_author" content="Miller, Veronica" /> <meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Forum for Collaborative HIV Research, University of California at Berkeley Washington DC" /> <meta name="citation_abstract_html_url" content="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/abstract" /> <meta name="citation_fulltext_html_url" content="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/full" /> <meta name="citation_pdf_url" content="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/pdf" /> <meta property="og:url" content="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/full" /> <meta property="og:type" content="article" /> <meta property="og:title" content="Hepatitis C virus drug resistance&ndash;associated substitutions: State of the art summary" /> <meta property="og:image" content="http://onlinelibrary.wiley.com/store/10.1002/hep.v62.5/asset/cover.gif?v=1&amp;s=3941e9b30af3a59d1590c3a2046d420afedad6c2" /> <meta property="og:description" content="Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon&#x2010;free, all&#x2010;oral combinations of direct&#x2010;acting antivirals. While the new regimens are potent and highly..." />  <link rel="stylesheet" media="screen" href="/enhanced/static/common/fonts/open-sans/open-sans.css?version=1.15.0" />    <!--[if lt IE 9]>
    <link rel="stylesheet" href="/enhanced/static/common/css/wol-common-ie.css?version=1.15.0"/>
    <link rel="stylesheet" href="/enhanced/static/css/wol-article-ie.css?version=1.15.0"/>
    <script src="/enhanced/static/common/js/patches/ie.js?version=1.15.0"></script>
<![endif]-->  <!--[if gt IE 8]><!-->     <link rel="stylesheet" href="/enhanced/static/common/css/wol-common.css?version=1.15.0" />     <link rel="stylesheet" href="/enhanced/static/css/wol-article.css?version=1.15.0" /> <!--<![endif]-->               <!--[if (gt IE 8) | (IEMobile)]><!-->         <link rel="stylesheet" href="http://cdn.wol2.wiley.com/external/aasld/shared/css/styles.css?version=1.15.0" />         <!--<![endif]-->         <!--[if (lt IE 9) & (!IEMobile)]>
        <link rel="stylesheet" href="http://cdn.wol2.wiley.com/external/aasld/shared/css/non-responsive.css?version=1.15.0" />
        <!<![endif]-->      <script src="/enhanced/static/common/js/vendor/modernizr.custom.js?version=1.15.0"></script>  <script>
    //<![CDATA[
    Modernizr.load([
        {
            test: window.matchMedia,
            nope: '/enhanced/static/common/js/vendor/polyfills/matchMedia.js?version=1.15.0'
        },
        {
            test: window.matchMedia && window.matchMedia( 'all' ).addListener,
            nope: '/enhanced/static/common/js/vendor/polyfills/matchMedia.addListener.js?version=1.15.0'
        }
    ]);
    //]]>
</script>       <script>
        Modernizr.load('http://content.readcube.com/wiley/epdf_linker.js');
    </script>           <script>
        //<![CDATA[
        wol2datalayer = window.wol2datalayer ? wol2datalayer : {};
                                    wol2datalayer.server="onlinelibrary.wiley.com";
                                                wol2datalayer.pageName="Hepatitis C virus drug resistance\u2013associated substitutions: State of the art summary - Lontok - 2015 - Hepatology";
                                                wol2datalayer.channel="JOURNALS";
                                                wol2datalayer.prop1="FULLTEXT";
                                                wol2datalayer.prop2="ENHANCED FULLTEXT_HTML";
                                                wol2datalayer.prop3="Hepatology";
                                                wol2datalayer.prop4="MD93,MDD2,MDU4,MD17,MD22,MD90,MD91";
                                                wol2datalayer.prop5="";
                                                wol2datalayer.prop7="Hepatitis C virus drug resistance\u2013associated substitutions: State of the art summary";
                                                wol2datalayer.prop8="62\/5";
                                                wol2datalayer.prop9="delayed-free";
                                                wol2datalayer.prop10="subscription";
                                                wol2datalayer.prop11="PDF and HTML";
                                                wol2datalayer.prop12="796";
                                                wol2datalayer.prop13="10.1002\/(ISSN)1527-3350";
                                                wol2datalayer.prop14="10.1002\/hep.27934";
                                                wol2datalayer.prop15="10.1002\/hep.v62.5";
                                                                    wol2datalayer.prop18="30 JUL 2015";
                                                wol2datalayer.prop33="MD93";
                                                wol2datalayer.prop35="AASLD";
                                                wol2datalayer.events="event60";
                                                wol2datalayer.prop26="Guest";
                            //]]>
    </script>   <script>
    //<![CDATA[
    digitalData       = window.digitalData ? digitalData       : {};
    digitalData.event = digitalData.event  ? digitalData.event : [];
    //]]>
</script>     <script>
        //<![CDATA[
            digitalData.customerIds=['EAL00000131590','EAL0000589','P#SWISS','ZURICH051S','ZURICH070S','B24499901S','ZURICH049S','ZURICH072S','ZURICH001S'];
        //]]>
    </script>      <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-d0317bde5157000144848f23fbb44a4de679c053.js"></script>       <script>
    var gs_channels = 'default';
</script> <script src="http://wiley.grapeshot.co.uk/main/channels.cgi?url=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1002%2Fhep.27934%2Ffull"></script>      <script>
        //<![CDATA[
        digitalData             = window.digitalData || {};
        digitalData.dartZone    = 'wly.gastro.hep_000059/hepatology_HEP';
        //]]>
    </script>          <script>
        var googletag       = googletag       || {};
        googletag.cmd       = googletag.cmd   || [];

        ( function () {
            var gads = document.createElement ( 'script' ) ,
                node = document.getElementsByTagName ( 'script' ) [ 0 ] ;
            gads.async  = true;
            gads.src    = document.location.protocol + '//www.googletagservices.com/tag/js/gpt.js';
            node.parentNode.insertBefore ( gads , node );
        }) ();
    </script>          <script>
        //<![CDATA[
        googletag.cmd.push ( function () {
            // Mapping for mobile images sizes
            var sizes = {
                    leaderboard : googletag.sizeMapping ()
                        .addSize ([ 300 , 100 ] , [ 300 , 50 ])
                        .addSize ([ 740 , 100 ] , [ 728 , 90 ])
                        .addSize ([ 0 , 0 ]     , 'fluid' )
                        .build () ,
                    skyscraper : googletag.sizeMapping ()
                        .addSize ([ 1200 , 0 ] , [ 160 , 600 ])
                        .addSize ([ 1200 , 0 ] , [ 160 , 320 ])
                        .addSize ([ 1200 , 0 ] , [ 160 , 160 ])
                        .addSize ([ 1200 , 0 ] , [ 120 , 600 ])
                        .build ()
                };

            googletag.pubads ()
                .setTargeting ( 'WOL-Page-Type'               , "FULLTEXT" )
                .setTargeting ( 'WOL-Page-Subtype'            , "ENHANCED FULLTEXT_HTML" )
                .setTargeting ( 'WOL-Subject-Codes'           , "MD93,MDD2,MDU4,MD17,MD22,MD90,MD91" )
                .setTargeting ( 'WOL-Article-Access-State'    , "delayed-free" )
                .setTargeting ( 'WOL-Pub-Access-Status'       , "subscription" )
                .setTargeting ( 'WOL-Article-Availability'    , "PDF and HTML" )
                .setTargeting ( 'WOL-Journal-DOI'             , "10.1002\/(ISSN)1527-3350" )
                .setTargeting ( 'WOL-Article-Chapter-DOI'     , "10.1002\/hep.27934" )
                .setTargeting ( 'WOL-Issue-DOI'               , "10.1002\/hep.v62.5" )
                .setTargeting ( 'WOL-Site-Search-Query'       , "" )
                .setTargeting ( 'WOL-User-login-Status'       , "Guest" )
                .setTargeting ( 'WOL-Primary-Subject-Code'    , "MD93" )
                .setTargeting ( 'WOL-Hub-ID'                  , "AASLD" )
                .setTargeting ( 'gs_cat'                      , gs_channels );

            googletag.defineSlot (
                    '/2215/wly.gastro.hep_000059/hepatology_HEP'  ,
                    'fluid'                     ,
                    'advert-leaderboard'
                )
                .defineSizeMapping ( sizes.leaderboard )
                .addService ( googletag.pubads ())
                .setCollapseEmptyDiv ( true );

            googletag.defineSlot (
                    '/2215/wly.gastro.hep_000059/hepatology_HEP'  ,
                    'fluid'                     ,
                    'advert-skyscraper'
                )
                .defineSizeMapping ( sizes.skyscraper )
                .addService ( googletag.pubads ())
                .setCollapseEmptyDiv ( true );

            // Enable services
            googletag.pubads ().enableSingleRequest ();
            googletag.enableServices ();
        });
        //]]>
    </script> </head> <body data-type="default" data-access="full">                <script>
    var dataLayer = window.dataLayer ? dataLayer : {};
    dataLayer.pageType = 'FULLTEXT';
    dataLayer.contentAvailability = 'PDF and HTML';
</script>    <div id="js-viewport-main" class="l-viewport-main prim-nav-container">     <div class="prim-nav-pusher st-pusher">         <div class="js-module notification" data-module="common_notification">                 <div class="l-notification">             <div class="notification__wrapper">                                     <p class="notification__message notification__message--eu-cookie">                         By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html" class="notification__link">About Cookies</a>                     </p>                                                     <p class="notification__message notification__message--maintenance-message">                         <span class="icon icon__notice"></span>                         <strong>Notice: </strong>Wiley Online Library will be unavailable on Saturday 7th Oct from 03.00 EDT / 08:00 BST / 12:30 IST / 15.00 SGT to 08.00 EDT / 13.00 BST / 17:30 IST / 20.00 SGT and Sunday 8th Oct from 03.00 EDT / 08:00 BST / 12:30 IST / 15.00 SGT to 06.00 EDT / 11.00 BST / 15:30 IST / 18.00 SGT for essential maintenance.  Apologies for the inconvenience.                     </p>                                 <a title="Remove maintenance message" class="js-notification__close-link notification__close-link" href="#">                     <span class="icon icon__close"></span>                     <span class="is-accessible">Remove maintenance message</span>                 </a>             </div>         </div>             </div>     <!-- RenderByLocation - structure: Hub Header - title: AASLD Hub Header - ident: 8defdc97-b511-4aa9-8ef4-f4c3805330cf --><header class="prim-nav" role="banner"> <div class="prim-nav__inner">                 <button class="button button--menu">Open navigation</button>                 <button class="button button--menu-search">Open search</button>                                                                                                                           <ul class="header__user-access u-horizontal-list">     <li>         <a href="#main-content" class="is-accessible header__user-access-skip-link">Skip to main content</a>     </li>     <li>             <a href="https://secure.onlinelibrary.wiley.com/secure/login/?originalUrl=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1002%2Fhep.27934%2Ffull&amp;wolSessionId=cbb66942b06944559b612e27189fc5b8" class="header__user-access-link">             <span class="icon icon__avatar"></span>             <span class="header__user-access-link-text">Log in / Register</span>         </a>         </li> </ul>                                                        <!-- RenderByLocation - structure: Hub Branding - title: AASLD Hub Branding - ident: 0af0e267-4fa8-4948-9ee5-8011dc316873 --> <h1 class="main-logo">  <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/">   <img src="http://cdn.wol2.wiley.com/external/aasld/images/header_branding.svg" onerror="this.src=this.src.replace('svg','png');" alt="American Association for the Study of Liver Diseases" class="main-logo__image" />  </a> </h1> <!--  End RenderByLocation (0af0e267-4fa8-4948-9ee5-8011dc316873) -->                   <nav class="prim-nav__menu js-wm-module" role="navigation" aria-label="AASLD Society Header" data-wm-module-name="primNav">                   <div class="prim-nav__wrapper">                     <button class="button button--close-style1">Close</button>                     <h2 class="prim-nav__header">Navigation</h2>                                            <!-- RenderByLocation - structure: Content (Generic) - title: AASLD Header Journal Menu - ident: 2dd0c22b-760d-4ccf-9442-87cfbe479a8c --> <h2 class="prim-nav__tab js-prim-nav__tab"><a href="#" class="prim-nav__tab-link js-sub-nav">Journals<span class="prim-nav__tab-drop-arrow"></span> </a></h2> <div class="prim-nav__menu-sub prim-nav__sub-container journal-menu"> <div class="prim-nav__menu-sub-inner"> <ul> <li><a href="http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)1527-3350/" title="HEPATOLOGY">HEPATOLOGY</a></li> <li><a href="http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)1527-6473/" title="Liver Transplantation"><i>Liver Transplantation</i></a></li> <li><a href="http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/" title="Clinical Liver Disease"><i>Clinical Liver Disease</i></a></li> <li><a href="http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2471-254X/" title="Hepatology Communications"><i>Hepatology Communications</i></a></li>   </ul> </div> </div> <!--  End RenderByLocation (2dd0c22b-760d-4ccf-9442-87cfbe479a8c) -->     <!-- RenderByLocation - structure: Content (Generic) - title: AASLD Header Topic Menu - ident: 8dff0ed6-6fb5-484a-bc80-0aa279fabdf0 --> <h2 class="prim-nav__tab js-prim-nav__tab">   <a href="#" class="prim-nav__tab-link js-sub-nav">     Topics<span class="prim-nav__tab-drop-arrow"></span>   </a> </h2>  <div class="prim-nav__menu-sub prim-nav__sub-container topics-menu">   <div class="prim-nav__menu-sub-inner">     <ul>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Acute-liver-injury-and-acute-liver-failure/">Acute Liver Injury and Acute Liver Failure</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Alcoholic-liver-disease/">Alcoholic Liver Disease</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Autoimmune-liver-disease/">Autoimmune Liver Disease</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Cholestatic-liver-disease/">Cholestatic Liver Disease</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Cirrhosis/">Cirrhosis</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Cystic-diseases-of-the-liver/">Cystic Diseases of the Liver</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Drug--induced-liver-injury/">Drug-induced Liver Injury</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Experimental-models-of-liver-disease/">Experimental Models of Liver Disease</a>       </li>     </ul>   </div>     <div class="prim-nav__menu-sub-inner">     <ul>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Gallbladder-diseases/">Gallbladder Diseases</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Genetic-liver-diseases/">Genetic liver Diseases</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Hepatic-involvement-of-systemic-diseases/">Hepatic Involvement of Systemic Diseases</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Hepatic-neoplasms/">Hepatic Neoplasms</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Infectious-liver-diseases-and-microbiome/">Infectious Liver Diseases and Microbiome</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Liver-development-and-regeneration/">Liver Development and Regeneration</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Liver-disease-in-pregnancy/">Liver Disease in Pregnancy</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Liver-transplantation/">Liver Transplantation</a>       </li>     </ul>   </div>   <div class="prim-nav__menu-sub-inner">     <ul>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Non--alcoholic-fatty-liver-disease/">Non-Alcoholic Fatty Liver Disease</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Nutritional-and-metabolic-liver-diseases/">Nutritional and Metabolic Liver Diseases</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Portal%20Hypertension/">Portal Hypertension </a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Primary-viral-hepatitides/">Primary Viral Hepatitides</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Public-health-aspects-of-liver-disease/">Public Health Aspects of Liver Disease</a>       </li>       <li>         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/Vascular-disorders-of-liver/">Vascular Disorders of Liver</a>       </li>     </ul>   </div> </div> <!--  End RenderByLocation (8dff0ed6-6fb5-484a-bc80-0aa279fabdf0) -->     <!-- RenderByLocation - structure: Content (Generic) - title: AASLD RH Hub Menu Items - ident: 7c5afa1e-6831-409a-94b1-e00aaaff3034 --> <div> <h2 class="prim-nav__tab"><a href="http://www.aasld.org/liver-learning" class="prim-nav__tab-link" target="_blank">Liver<em>Learning</em>&reg;</a></h2> </div> <ul class="prim-nav__links"> <li class="prim-nav__link-mem"><a href="http://www.aasld.org/membership" target="_blank">AASLD Membership</a></li> <li class="prim-nav__link-url"><a href="http://www.aasld.org/" target="_blank">AASLD.org</a></li> </ul> <ul class="prim-nav__links-style-2"> <li class="prim-nav__link-wol"><a href="http://onlinelibrary.wiley.com/"><span>Powered By </span>Wiley Online Library</a></li> </ul> <!--  End RenderByLocation (7c5afa1e-6831-409a-94b1-e00aaaff3034) -->                       </div>                 </nav>             </div>              <div class="prim-nav__search">               <div class="prim-nav__search-inner">       <!-- RenderByLocation - structure: Hierarchical Search Form - title: AASLD Hierarchical Search Form - ident: 0f04fe38-e5f7-42b6-8a41-9e3942a92185 --> <div class="js-wm-module search-wrap search-empty  " data-wm-module-name="searchForm">     <form action="http://aasldpubs.onlinelibrary.wiley.com/hub/results/" method="get" class="js-search-form search__form" autocomplete="off">          <span class="custom-select__selected-text js-custom-select__selected-text custom-select search__dropdown-container">All AASLD Journals</span>          <fieldset class="search__input-wrap">             <label class="is-accessible" for="search">Search</label>             <input type="search" name="search" id="search" class="js-search__input-text search__input-text" placeholder="Enter search terms, e.g. title, author, keyword" value="" maxlength="1000" data-placeholder="[&quot;Enter search terms, e.g. title, author, keyword&quot;, &quot;Search AASLD journals&quot;]" autocapitalize="off" />             <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/results/" class="js__button-remove button--remove button button--remove-no-js">Clear All</a>         </fieldset>          <label class="is-accessible custom-select__select-label" for="search-select">Search in</label>         <select id="search-select" class="js-search__sort-select custom-select__select js-wm-module" data-wm-module-name="customSelect" name="journal-doi">                                         <option value="all" data-journal="all-aasld-journals" selected="selected">All AASLD Journals</option>                             <option value="10.1002/(ISSN)1527-3350" data-journal="hepatology">HEPATOLOGY</option>                             <option value="10.1002/(ISSN)1527-6473" data-journal="liver-transplantation">Liver Transplantation</option>                             <option value="10.1002/(ISSN)2046-2484" data-journal="clinical-liver-disease">Clinical Liver Disease</option>                             <option value="10.1002/(ISSN)2471-254X" data-journal="hepatology-communications">Hepatology Communications</option>                     </select>          <button type="reset" class="js__button-remove button--remove button button--remove-js">Clear All</button>          <button type="submit" class="js__search-submit button--search button button--search-form disabled" data-report-path="http://onlinelibrary.wiley.com/createReportingEvent/?doi=&amp;event=SEARCH_SITE">Search</button>      </form>     <a href="#" class="search__advanced-search-link js-advanced-search__link">Advanced Search</a> </div> <!--  End RenderByLocation (0f04fe38-e5f7-42b6-8a41-9e3942a92185) -->                 </div>             </div>                                                                                                       <div class="advanced-search__wrapper">     <div class="js-wm-module js-advanced-search advanced-search" data-wm-module-name="advancedSearch">         <h2>Advanced Search</h2>         <form method="get" action="http://aasldpubs.onlinelibrary.wiley.com/hub/results/" name="advSearchFrm">             <fieldset class="advanced-search__criteria advanced-search__criteria--text">                 <legend class="advanced-search__criteria-title">Search For</legend>                 <ul class="advanced-search__criteria-list js-advanced-search__criteria-list--text">                     <li>                         <label class="hidden" for="search1">Search Term</label>                         <input type="text" id="search1" name="search1" placeholder="Enter search string" class="js-advanced-search__search-text advanced-search__search-text advanced-search__search-text--wider" />                         <label class="hidden" for="field1">Search restriction</label>                         <select id="field1" name="field1" class="js-advanced-search__search-field advanced-search__search-field">                             <option value="all-fields" selected="selected">All fields</option>                             <option value="document-title">Article Titles</option>                             <option value="publication-title">Publication Titles</option>                             <option value="author">Author</option>                             <option value="fulltext">Full Text</option>                             <option value="abstract">Abstract</option>                             <option value="affiliation">Author Affiliation</option>                             <option value="keyword">Keywords</option>                             <option value="funding-agency">Funding Agency</option>                             <option value="issn">ISSN</option>                             <option value="doi">Article DOI</option>                             <option value="bibliography">References</option>                         </select>                     </li>                     <li>                         <label class="hidden" for="operator2">And, Or and Not</label>                         <select id="operator2" name="operator2" class="js-advanced-search__logic-operator advanced-search__logic-operator">                             <option value="and" selected="selected">and</option>                             <option value="or">or</option>                             <option value="not">not</option>                         </select>                         <label class="hidden" for="search2">Search Term</label>                         <input type="text" id="search2" name="search2" placeholder="Enter search string" class="js-advanced-search__search-text advanced-search__search-text advanced-search__search-text--wide" />                         <label class="hidden" for="field2">Search restriction</label>                         <select id="field2" name="field2" class="js-advanced-search__search-field advanced-search__search-field">                             <option value="all-fields" selected="selected">All fields</option>                             <option value="document-title">Article Titles</option>                             <option value="publication-title">Publication Titles</option>                             <option value="author">Author</option>                             <option value="fulltext">Full Text</option>                             <option value="abstract">Abstract</option>                             <option value="affiliation">Author Affiliation</option>                             <option value="keyword">Keywords</option>                             <option value="funding-agency">Funding Agency</option>                             <option value="issn">ISSN</option>                             <option value="doi">Article DOI</option>                             <option value="bibliography">References</option>                         </select>                         <button type="button" class="js-advanced-search__criteria--remove button button--remove advanced-search__action--remove hidden">close</button>                     </li>                     <li>                         <label class="hidden" for="operator3">And, Or and Not</label>                         <select id="operator3" name="operator3" class="js-advanced-search__logic-operator advanced-search__logic-operator">                             <option value="and" selected="selected">and</option>                             <option value="or">or</option>                             <option value="not">not</option>                         </select>                         <label class="hidden" for="search3">Search Term</label>                         <input type="text" id="search3" name="search3" placeholder="Enter search string" class="js-advanced-search__search-text advanced-search__search-text advanced-search__search-text--wide" />                         <label class="hidden" for="field3">Search restriction</label>                         <select id="field3" name="field3" class="js-advanced-search__search-field advanced-search__search-field">                             <option value="all-fields" selected="selected">All fields</option>                             <option value="document-title">Article Titles</option>                             <option value="publication-title">Publication Titles</option>                             <option value="author">Author</option>                             <option value="fulltext">FullText</option>                             <option value="abstract">Abstract</option>                             <option value="affiliation">Author Affiliation</option>                             <option value="keyword">Keywords</option>                             <option value="funding-agency">Funding Agency</option>                             <option value="issn">ISSN</option>                             <option value="doi">Article DOI</option>                             <option value="bibliography">References</option>                         </select>                         <button type="button" class="js-advanced-search__criteria--remove button button--remove advanced-search__action--remove hidden">close</button>                     </li>                 </ul>                 <button type="button" class="js-advanced-search__criteria--add advanced-search__action--add">+ add more</button>                 <div class="advanced-search__error advanced-search__error--text js-advanced-search__error--text"></div>             </fieldset>                           <fieldset class="advanced-search__criteria advanced-search__criteria--date">                 <legend class="advanced-search__criteria-title">Search Within</legend>                 <ul class="advanced-search__criteria-list js-advanced-search__criteria-list--date">                     <li>                         <input type="radio" id="allDates" value="all" name="dateType" checked="checked" class="advanced-search__date-radio" />                         <label for="allDates">All Dates</label>                     </li>                     <li>                         <input type="radio" id="set" value="set" name="dateType" class="advanced-search__date-radio" />                         <label for="set">In the last</label>                         <label class="hidden" for="dateMonths">In the Last</label>                         <select id="dateMonths" name="dateMonths" class="js-advanced-search__last-month advanced-search__last-month">                             <option value="1">1 Month</option>                             <option value="3">3 Months</option>                             <option value="6" selected="selected">6 Months</option>                             <option value="12">12 Months</option>                         </select>                     </li>                     <li>                         <input type="radio" id="between" value="between" name="dateType" class="advanced-search__date-radio" />                         <label for="between">Between</label>                         <label class="hidden" for="dateFrom">Start Year</label>                         <input type="text" id="dateFrom" class="js-advanced-search__date-input--start advanced-search__date-input" name="dateFrom" placeholder="dd/mm/yyyy" />                         <label class="hidden" for="dateTo">End Year</label>                         <input type="text" id="dateTo" class="js-advanced-search__date-input--end advanced-search__date-input" name="dateTo" placeholder="dd/mm/yyyy" />                         <div class="advanced-search__error advanced-search__error--date js-advanced-search__error--date"></div>                     </li>                 </ul>             </fieldset>             <div>                 <input type="hidden" name="advancedSearch" value="true" />                 <input type="button" class="js-advanced-search__panel-close advanced-search__button advanced-search__button--close" value="close" />                 <input type="submit" disabled="disabled" class="js-advanced-search__search-submit advanced-search__button advanced-search__button--submit disabled" value="search" />             </div>         </form>     </div> </div>                     </header><!--  End RenderByLocation (8defdc97-b511-4aa9-8ef4-f4c3805330cf) --> <img class="is-accessible" src="http://onlinelibrary.wiley.com/createAccessReportingEvent?doi=10.1002%2Fhep.27934" alt="" />                   <aside class="advert-leaderboard__container">         <div id="advert-leaderboard" class="advert" role="complementary">             <div class="advert-leaderboard__title">Advertisement</div>             <script>
                googletag.cmd.push ( function () {
                    googletag.display ( 'advert-leaderboard' );
                });
            </script>             <noscript>
                <a href="http://pubads.g.doubleclick.net/gampad/jump?iu=/2215/wly.gastro.hep_000059/hepatology_HEP&amp;sz=728x90&amp;tile=1&amp;c=204890235" target="_blank">
                    <img src="http://pubads.g.doubleclick.net/gampad/ad?iu=/2215/wly.gastro.hep_000059/hepatology_HEP&amp;sz=728x90&amp;tile=1&amp;c=204890235" />
                </a>
            </noscript>         </div>     </aside>  <div class="l-main main citations--available" role="main">     <div class="l-article">          <ul class="meta-navigation u-list-plain">     <li class="meta-navigation__item">         <a id="wol1backlink" href="http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.27934/full" class="meta-navigation__return">             <span class="icon icon__return"></span>             <span>Go to old article view</span>         </a>     </li> </ul>          <div id="js-viewport-mini" class="l-viewport-mini">               <div id="js-article-nav" class="l-article-nav js-module" data-module="toolbar">     <div id="js-article-tools" class="article-tools" role="navigation">         <ul class="article-tools__bar" aria-label="Resize text, share article">     <li class="article-tools__tool article-tools__tool--set js-module" data-module="textresize"></li>     <li class="article-tools__tool article-tools__tool--set article-tools__tool--share js-module" data-module="add-this" data-doi="10.1002/hep.27934"></li>     </ul>         <ul class="article-tools__list">                             <li>                     <a href="#article-nav" id="article-nav-menu" class="article-tools__item-link article-tools__item-link--menu" data-tool-type="article-nav" title="Article navigation">                         <span class="article-tools__item-link-text">Go To<span class="icon icon__chevron-right"></span></span>                         <span class="is-accessible"> article navigation</span>                     </a>                     <nav id="article-nav" class="article-tools__article-nav js-module" data-module="article-nav" role="navigation" aria-label="AA Article Navigation">                         <p class="article-tools__article-nav-title">Navigate this article</p>                          <div class="article-tools__article-nav-scrollpane">                             <ul class="article-tools__article-nav-list">                                                                                                                                              <li class="article-tools__article-nav-item">                                                                                             <a href="#abstract" class="js-scrollto article-tools__article-nav-item-link">                                                     <span class="icon icon__chevron"></span>Abstract                                                 </a>                                                                                     </li>                                                                             <li class="article-tools__article-nav-item">                                                                                             <a href="#hep27934-sec-0002" class="js-scrollto article-tools__article-nav-item-link">HCV Resistance to DAAs</a>                                                                                     </li>                                                                             <li class="article-tools__article-nav-item">                                                                                             <a href="#hep27934-sec-0003" class="js-scrollto article-tools__article-nav-item-link">Methodology</a>                                                                                     </li>                                                                             <li class="article-tools__article-nav-item">                                                                                             <a href="#hep27934-sec-0004" class="js-scrollto article-tools__article-nav-item-link">NS3/4A Protease Inhibitors</a>                                                                                     </li>                                                                             <li class="article-tools__article-nav-item">                                                                                             <a href="#hep27934-sec-0012" class="js-scrollto article-tools__article-nav-item-link">NS5A Inhibitors</a>                                                                                     </li>                                                                             <li class="article-tools__article-nav-item">                                                                                             <a href="#hep27934-sec-0017" class="js-scrollto article-tools__article-nav-item-link">NS5B Polymerase Inhibitors</a>                                                                                     </li>                                                                             <li class="article-tools__article-nav-item">                                                                                             <a href="#hep27934-sec-0022" class="js-scrollto article-tools__article-nav-item-link">Conclusion</a>                                                                                     </li>                                                                             <li class="article-tools__article-nav-item">                                                                                             <a href="#hep27934-sec-0023" class="js-scrollto article-tools__article-nav-item-link">Acknowledgment</a>                                                                                     </li>                                                                                                                  <li>                                             <hr />                                         </li>                                                                                                                                                                         <li class="article-tools__article-nav-item">                                                                                     <a href="#footer-support-info" data-analytics-revealed-panel="references" class="js-scrollto article-tools__article-nav-item-link article-tools__article-nav-item-link--panel-reveal">Supporting Information</a>                                                                             </li>                                                                     <li class="article-tools__article-nav-item">                                                                                     <a href="#references-section" data-analytics-revealed-panel="references" class="js-scrollto article-tools__article-nav-item-link article-tools__article-nav-item-link--panel-reveal">References</a>                                                                             </li>                                                                                                                                       <li class="article-tools__article-nav-item">                                         <a href="#related-content" data-analytics-revealed-panel="related-content" class="js-scrollto article-tools__article-nav-item-link article-tools__article-nav-item-link--panel-reveal">Related Content</a>                                     </li>                                                                  <li class="article-tools__article-nav-item citations__link">                                     <a href="#footer-citing" data-analytics-revealed-panel="footer-citing" class="js-scrollto article-tools__article-nav-item-link article-tools__article-nav-item-link--panel-reveal">Citing Literature</a>                                 </li>                             </ul>                         </div>                     </nav>                 </li>                     </ul>     </div> </div>                          <article class="journal js-journal">                                         <header class="journal-header">                     <a class="journal-header__name journal-header__name--normal" href="http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)1527-3350">                 <div class="journal-header__name-link">                     <strong class="journal-header__name-title">Hepatology</strong>                                         <div class="journal-header__link">Explore this journal &gt;</div>                                     </div>             </a>                             <ul class="u-horizontal-list">                 <li>                     <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)1527-3350" class="journal-header__logo">                         <img src="http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002(ISSN)1527-3350/images/journal_branding.png" alt="Hepatology" class="journal-header__logo-img" />                                                 <div class="journal-header__link">Explore this journal &gt;</div>                                             </a>                 </li>             </ul>                      </header>                                                  <article class="issue">                                                                              <div class="issue-header js-module" data-module="issue-header">     <nav class="issue-header__nav" role="navigation" aria-label="AA Issue Browser">         <div class="issue-header__nav-control">                                                      <div class="issue-header__image-wrapper">                                                                 <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/issue/10.1002/hep.v62.5" class="issue-header__image-link">                     <img src="http://onlinelibrary.wiley.com/store/10.1002/hep.v62.5/asset/cover.gif?v=1&amp;s=3941e9b30af3a59d1590c3a2046d420afedad6c2" class="issue-header__image" alt="Hepatology" />                 </a>                 <ol class="u-list-plain">                                             <li>                             <a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1002/hep.28140" class="issue-header__arrow--left issue-header__arrow">                                 <span class="icon icon__arrow icon__arrow--left"></span>                                 <span class="is-accessible">Previous article in issue: Changing nomenclature for PBC: From &lsquo;cirrhosis&rsquo; to &lsquo;cholangitis&rsquo;</span>                             </a>                             <p class="issue-header__tooltip issue-header__tooltip--left">                                 <span class="icon icon__chevron-up"></span>                                 <span class="issue-header__tooltip-header">Previous article in issue:</span>                                 Changing nomenclature for PBC: From &lsquo;cirrhosis&rsquo; to &lsquo;cholangitis&rsquo;                             </p>                         </li>                                                                 <li>                             <a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1002/hep.27947" class="issue-header__arrow--right issue-header__arrow">                                 <span class="icon icon__arrow icon__arrow--right"></span>                                 <span class="is-accessible">Next article in issue: Hepatitis C virus addiction to liver miR-122 takes its Toll on the host</span>                             </a>                             <p class="issue-header__tooltip issue-header__tooltip--right">                                 <span class="icon icon__chevron-up"></span>                                 <span class="issue-header__tooltip-header">Next article in issue:</span>                                 Hepatitis C virus addiction to liver miR-122 takes its Toll on the host                             </p>                         </li>                                     </ol>             </div>                              <p class="issue-header__description">                                             <span class="state__small--off">View: </span>                                         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/issue/10.1002/hep.v62.5" class="issue-header__link">                                                     <span class="state__small--on">                                                 View&nbsp;                                                     </span>                                                 issue TOC                     </a>                                             <span class="state__small--on">                                         <br />                                             Volume 62, Issue 5<br />                         November 2015                                                     <br /> Pages 1623&ndash;1632                                                                                                                                    <br />or<br />                         </span>                                                 <span class="state__small--off separator"> | </span>                         <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/issue/10.1002/(ISSN)1527-3350(CAT)VirtualIssues(VI)HepatologyReviews" class="js__analytics" data-analytics="virtual-issue" title="Hepatology Reviews">                             <span class="state__small--on">Browse </span>Virtual Issue</a>                                     </p>                      </div>     </nav> </div>                                                              <article id="main-content" class="article js-module" data-module="Article"><header class="js-module article-header" data-module="ArticleHeader"><div class="article-header__intro"><span class="article-header__category article-category">Review</span><h1 class="article-header__title">Hepatitis C virus drug resistance&ndash;associated substitutions: State of the art summary</h1><div class="article-header__authors-container"><h2 class="is-accessible">Authors</h2><ul class="article-header__authors_list js-module" data-module="keyboardHover"><li class="article-header__authors-item" data-hover-container="author1" data-author-name="Erik Lontok"><h3 class="article-header__authors-name" data-hover-control="author1">Erik Lontok,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author1"><ol class="article-header__authors-item-aff-addr"><li>Forum for Collaborative HIV Research, University of California at Berkeley, Washington, DC</li></ol><span class="article-header__authors-item-current-aff">Current affiliation:</span><ol class="article-header__authors-item-current-aff-addr"><li>E. Lontok's current address is: FasterCures, A Center of the Milken Institute, Washington, DC</li></ol><span class="after-author-correspondence" data-author-name="Erik Lontok"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Erik%20Lontok%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Erik Lontok"></span></div></li><li class="article-header__authors-item" data-hover-container="author2" data-author-name="Patrick Harrington"><h3 class="article-header__authors-name" data-hover-control="author2">Patrick Harrington,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author2"><ol class="article-header__authors-item-aff-addr"><li>Center for Drug Evaluation and Research, Office of Antimicrobial Products, Division of Antiviral Products, US Food and Drug Administration, Silver Spring, MD</li></ol><span class="after-author-correspondence" data-author-name="Patrick Harrington"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Patrick%20Harrington%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Patrick Harrington"></span></div></li><li class="article-header__authors-item" data-hover-container="author3" data-author-name="Anita Howe"><h3 class="article-header__authors-name" data-hover-control="author3">Anita Howe,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author3"><ol class="article-header__authors-item-aff-addr"><li>Merck Research Laboratories, West Point, PA</li></ol><span class="after-author-correspondence" data-author-name="Anita Howe"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Anita%20Howe%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Anita Howe"></span></div></li><li class="article-header__authors-item" data-hover-container="author4" data-author-name="Tara Kieffer"><h3 class="article-header__authors-name" data-hover-control="author4">Tara Kieffer,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author4"><ol class="article-header__authors-item-aff-addr"><li>Vertex Pharmaceuticals, Inc., Boston, MA</li></ol><span class="after-author-correspondence" data-author-name="Tara Kieffer"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Tara%20Kieffer%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Tara Kieffer"></span></div></li><li class="article-header__authors-item" data-hover-container="author5" data-author-name="Johan Lennerstrand"><h3 class="article-header__authors-name" data-hover-control="author5">Johan Lennerstrand,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author5"><ol class="article-header__authors-item-aff-addr"><li>Department of Medical Sciences, Uppsala University, Uppsala, Sweden</li></ol><span class="after-author-correspondence" data-author-name="Johan Lennerstrand"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Johan%20Lennerstrand%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Johan Lennerstrand"></span></div></li><li class="article-header__authors-item" data-hover-container="author6" data-author-name="Oliver Lenz"><h3 class="article-header__authors-name" data-hover-control="author6">Oliver Lenz,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author6"><ol class="article-header__authors-item-aff-addr"><li>Janssen Infectious Diseases, Beerse, Belgium</li></ol><span class="after-author-correspondence" data-author-name="Oliver Lenz"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Oliver%20Lenz%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Oliver Lenz"></span></div></li><li class="article-header__authors-item" data-hover-container="author7" data-author-name="Fiona McPhee"><h3 class="article-header__authors-name" data-hover-control="author7">Fiona McPhee,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author7"><ol class="article-header__authors-item-aff-addr"><li>Bristol-Myers Squibb Research and Development, Wallingford, CT</li></ol><span class="after-author-correspondence" data-author-name="Fiona McPhee"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Fiona%20McPhee%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Fiona McPhee"></span></div></li><li class="article-header__authors-item" data-hover-container="author8" data-author-name="Hongmei Mo"><h3 class="article-header__authors-name" data-hover-control="author8">Hongmei Mo,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author8"><ol class="article-header__authors-item-aff-addr"><li>Gilead Sciences, Inc., Foster City, CA</li></ol><span class="after-author-correspondence" data-author-name="Hongmei Mo"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Hongmei%20Mo%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Hongmei Mo"></span></div></li><li class="article-header__authors-item" data-hover-container="author9" data-author-name="Neil Parkin"><h3 class="article-header__authors-name" data-hover-control="author9">Neil Parkin,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author9"><ol class="article-header__authors-item-aff-addr"><li>Data First Consulting, Inc., Belmont, CA</li></ol><span class="after-author-correspondence" data-author-name="Neil Parkin"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Neil%20Parkin%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Neil Parkin"></span></div></li><li class="article-header__authors-item" data-hover-container="author10" data-author-name="Tami Pilot&#x2010;Matias"><h3 class="article-header__authors-name" data-hover-control="author10">Tami Pilot-Matias,</h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author10"><ol class="article-header__authors-item-aff-addr"><li>AbbVie, Inc., Chicago, IL</li></ol><span class="after-author-correspondence" data-author-name="Tami Pilot&#x2010;Matias"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Tami%20Pilot%E2%80%90Matias%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Tami Pilot&#x2010;Matias"></span></div></li><li class="article-header__authors-item" data-hover-container="author11" data-author-name="Veronica Miller"><h3 class="article-header__authors-name" data-hover-control="author11">Veronica Miller<span class="icon icon__article-header icon__email"></span></h3><div class="article-header__author-content js-module" data-module="contentRevealer" data-hover-content="author11"><span class="article-header__corresponding-auth">Corresponding author</span><ol class="article-header__authors-item-aff-addr"><li>Forum for Collaborative HIV Research, University of California at Berkeley, Washington, DC</li></ol><ul class="article-header__authors-item-corresp-addr"><li><i class="icon icon__authors-corresp-addr"></i><p>Address reprint requests to: Veronica Miller, Ph.D., Forum for Collaborative HIV Research, 1608 Rhode Island Ave, NW, Suite 212, Washington, DC 20036. E-mail: <a href="mailto:veronicam@berkeley.edu" title="Link to email address">veronicam@berkeley.edu</a>; tel: +1-202-974-6290; fax: +1-202-872-4316.</p></li></ul><span class="after-author-correspondence" data-author-name="Veronica Miller"></span><a class="article-header__search-for-papers" href="http://onlinelibrary.wiley.com/advanced/search/results?searchRowCriteria%5B0%5D.fieldName=author&amp;start=1&amp;resultsPerPage=20&amp;searchRowCriteria%5B0%5D.queryString=%22Veronica%20Miller%22">Search for more papers by this author</a><span class="author-content-bottom" data-author-name="Veronica Miller"></span></div></li></ul></div><div class="article-header__meta-info-container"><ul id="header-meta-info-container" class="article-header__meta-info-list"><li class="article-header__meta-info-item"><span class="article-header__meta-info-label">First published: </span><time class="article-header__meta-info-data" datetime="2015-07-30" id="first-published-date">30 July 2015</time><a href="#publication-history" class="article-header__meta-info-2nd-data js-publication-history">Full publication history</a></li><li class="article-header__meta-info-item"><span class="article-header__meta-info-label" id="header-section-doi">DOI: </span><span class="article-header__meta-info-data">10.1002/hep.27934</span>         &nbsp;<a href="/enhanced/exportCitation/doi/10.1002/hep.27934" class="article-header__meta-info-2nd-data analytics-view-citation js-module" data-module="fragment">View/save citation</a></li><li class="article-header__meta-info-item js-module" data-module="citations"><span class="article-header__meta-info-label">Cited by (CrossRef): </span><span class="article-header__meta-info-data"><span id="js-citations__count">73</span> articles</span><a href="http://onlinelibrary.wiley.com/enhanced/refreshCitedBy?doi=10.1002/hep.27934&amp;refreshCitedByCounter=true" id="js-citations__refresh" class="citations__refresh article-header__meta-info-2nd-data"><span class="icon icon__refresh"></span>      Check for updates     </a><div id="citation-tools" class="article-header__meta-info-2nd-data citation-tools dialogue js-module" data-module="dialogue"><button type="button" class="button__link dialogue__action--set"><span class="icon icon__tools"></span>                     Citation tools      <span class="icon icon__chevron-down--sml"></span></button><div class="dialogue__popup" role="dialog" aria-labelledby="citation-tools"><div class="dialogue__head"></div><div class="dialogue__body"><ul class="u-list-plain"><li><form action="http://onlinelibrary.wiley.com/enhanced/alerts/citations/doi/10.1002/hep.27934" class="js-module" method="POST" data-module="citation-alert" data-user-profile="http://onlinelibrary.wiley.com/myprofile/alertManager" data-state="off" data-login="https://secure.onlinelibrary.wiley.com/secure/login/?originalUrl=http%3A%2F%2Fonlinelibrary.wiley.com%2Fenhanced%2Falerts%2Fcitations%2Fdoi%2F10.1002%2Fhep.27934&amp;wolSessionId=cbb66942b06944559b612e27189fc5b8" data-registration="http://onlinelibrary.wiley.com/user-registration"><input name="method" type="hidden" value="POST" /><button class="button__link dialogue__list-item" type="submit"><span class="icon icon__bell"></span>                                                     Set citation alert                                                 </button></form></li><li class="citations__link"><a href="#footer-citing" class="js-scrollto dialogue__list-item"><span class="icon icon__info"></span>                                     Citing literature                                 </a></li></ul></div></div></div></li><li class="article-header__meta-info-item"><div data-module="alt-metrics" class="js-module altmetric-embed" data-badge-type="1" data-doi="10.1002/hep.27934" data-badge-popover="bottom" data-link-target="_blank"></div></li></ul></div></div><hr /><div class="article-header__references-container"><ul class="article-header__references-list"><li id="hep27934-note-0004" class="article-header__references-item"> <p>Potential conflict of interest: Dr. Pilot-Matias is employed by and owns stock in AbbVie; Dr. Mo is employed by and owns stock in Merck; Dr. Kieffer is employed by and owns stock in Vertex; Dr. Lennerstrand consults for Medivir and received grants from Bristol-Myers Squibb; Dr. McPhee is employed by and owns stock in Bristol-Myers Squibb; Dr. Parkin consults for Gilead, Monogram, and Abbott; Dr. Lenz is employed by and owns stock in Janssen; Dr. Howe is employed by Merck; Dr. Lontok received grants from Abbott, AbbVie, Achillion, Alere, Astellas, Biogen, BioRAD, Boehringer Ingelheim, Bristol-Myers Squibb, Cenotron, DDL Diagnostics, DiaPharma, Exalenz, Fibrogen, Galactin, Genentech, Genfit, Gilead, GlaxoSmithKline, HIVMA, Idenix, Illumina, Intercept, Janssen, Kaiser Permanente, LabCorp, Lilly, Medscape, Medivir, Merck, Microbiotix, Monogram, Mylan, NGM, Novartis, Orasure, Pacific Biosciences, PPD, Presidio, Quest, Quintiles, Resonance, Roche, Rooivant, SeraCare, Schinazi Family Foundation, Tobira, Vertex, ViiV, and VLVBio; Dr. Miller received grants from Abbott, AbbVie, Achillion, Alere, Astellas, Biogen, BioRAD, Boehringer Ingelheim, Bristol-Myers Squibb, Cenotron, DDL Diagnostics, DiaPharma, Exalenz, Fibrogen, Galactin, Genentech, Genfit, Gilead, GlaxoSmithKline, HIVMA, Idenix, Illumina, Intercept, Janssen, Kaiser Permanente, LabCorp, Lilly, Medscape, Medivir, Merck, Microbiotix, Monogram, Mylan, NGM, Novartis, Orasure, Pacific Biosciences, PPD, Presidio, Quest, Quintiles, Resonance, Roche, Rooivant, SeraCare, Schinazi Family Foundation, Tobira, Vertex, ViiV, and VLVBio.</p></li><li id="hep27934-note-0001" class="article-header__references-item"> <p>Supported by unrestricted grants received by the Forum for Collaborative HIV Research for the HCV Drug Development Advisory Group Project (to E.L., V.M.).</p></li><li id="hep27934-note-0002" class="article-header__references-item"> <p>Disclaimer: The views expressed in this report are those of the author and do not necessarily represent official policy of the US Food and Drug Administration.</p></li></ul></div></header><section id="abstract" class="article-section article-section--abstract"><div class="article-section__content mainAbstract"><h2 class="article-section__header">Abstract</h2><p>Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon-free, all-oral combinations of direct-acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. In this report, we discuss the viral proteins targeted by HCV direct-acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials. <em>Conclusion</em>: This report provides a comprehensive, systematic review of all resistance information available from sponsors&rsquo; trials as a tool to inform the HCV drug development field. (H<span class="smallCaps">epatology</span> 2015;62:1623&ndash;1632)</p></div></section><span id="after-abstract"></span><section id="pdf-section" class="article-section article-section__pdf-container article-section__pdf-container--journal js-pdf-content"><ul class="box-actions__wrapper"><li class="box-actions box-actions--readcube"><a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/epdf" class="js-article-section__pdf-container-link article-section__pdf-container-link"><span class="icon icon__readcube"></span><span class="js-article-section__pdf-container-title box-actions__title">Enhanced PDF</span></a></li><li class="box-actions"><a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/pdf" class="js-article-section__pdf-container-link article-section__pdf-container-link"><span class="icon icon__pdf"></span><span class="js-article-section__pdf-container-title box-actions__title">Standard PDF</span><span class="js-article-section__pdf-container-size box-actions__meta">                                         (822.4 KB)                                     </span></a></li></ul></section><div class="definitionList">Abbreviations<dl class="hh" id="hep27934-lp-0001"><dt>DAA</dt><dd><p>direct-acting antiviral</p></dd><dt>HCV</dt><dd><p>hepatitis C virus</p></dd><dt>PI</dt><dd><p>protease inhibitor</p></dd><dt>SVR</dt><dd><p>sustained virological response</p></dd></dl></div><section class="article-section article-body-section" id="hep27934-sec-0001"><p>Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon-free, all-oral combinations of direct-acting antivirals (DAAs) in the United States, Europe, Japan, and other countries.[<a href="#hep27934-bib-0001" rel="references:#hep27934-bib-0001" class="link__reference js-link__reference" title="Link to bibliographic citation">1</a>] Current regimens are potent and highly efficacious; however, the long-term effects of drug resistance remain unclear&mdash;as opposed to its importance in human immunodeficiency virus treatment. The high error rate of the HCV polymerase coupled with virion production that is 100-fold higher than that of human immunodeficiency virus results in a complex mixture of viral genetic populations (termed &ldquo;quasi-species&rdquo;) that preexist within an infected individual before treatment initiation.[<a href="#hep27934-bib-0002" rel="references:#hep27934-bib-0002 #hep27934-bib-0003 #hep27934-bib-0004" class="link__reference js-link__reference" title="Link to bibliographic citations">2-4</a>] While the selection of preexisting viruses with reduced susceptibility to administered drugs plays a role in treatment failure, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. Thus, a comprehensive summary of existing information on clinically relevant HCV drug resistance will facilitate a review of what is and will be observed in postmarketing studies and clinical practice to help address the needs of the upcoming cohort of patients who do not achieve a sustained virological response (SVR) outside the context of clinical trials.</p><p>This review by the Drug Resistance Working Group of the Forum for Collaborative HIV Research's HCV Drug Development Advisory Group[<a href="#hep27934-bib-0005" rel="references:#hep27934-bib-0005" class="link__reference js-link__reference" title="Link to bibliographic citation">5</a>] summarizes clinically relevant HCV DAA resistance data to provide a systematic review of all resistance information available from sponsors&rsquo; trials. This report is an update from a previously published version and includes DAAs approved by regulatory bodies in the United States, the European Union, and Japan as well as drugs in phase 3 clinical trials as of November 2014.[<a href="#hep27934-bib-0006" rel="references:#hep27934-bib-0006" class="link__reference js-link__reference" title="Link to bibliographic citation">6</a>] The information is presented in two formats: a graphic summary of clinically relevant polymorphisms and substitutions (Figs. <a href="#hep27934-fig-0002" rel="references:#hep27934-fig-0002 #hep27934-fig-0003 #hep27934-fig-0004" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figures">2-4</a>) and abbreviated tables listing available phenotypic fold-changes in susceptibility compared to wild type for HCV replicons carrying the resistance-associated substitutions (Tables <a href="#hep27934-tbl-0001" rel="references:#hep27934-tbl-0001 #hep27934-tbl-0002 #hep27934-tbl-0003" class="tableLink link__table js-link__table js-scrollto" title="Link to tables">1-3</a>.</p><div data-module="Table" class="table__overflow js-module"><table class="table table--article-section" id="hep27934-tbl-0001"><caption class="table__caption"><span class="table__caption-label">Table&nbsp;1.&nbsp;</span>Mean Fold-Change in Resistance Compared to Wild-Type Replicon of Clinically Relevant NS3 Protease Resistance&ndash;Associated Substitutions</caption><thead class="table__header table__header-data--bottom"><tr class="table__row"><th colspan="3" class="table__header-data table__header-data--center ">&nbsp;</th><th colspan="6" class="table__header-data table__header-data--center table-border--bottom "><b>Mean Fold Change in Resistance Compared to Wild-Type Replicon</b></th></tr><tr class="table__row"><th class="table__header-data table-border--bottom "><b>HCV NS3 Protease AA and Position</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Resistance-Associated Substitution(s)</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Replicon Vector Genotype</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Boceprevir</b><a href="#hep27934-note-0006" rel="references:#hep27934-note-0006" class="js-link__note link__note" title="Link to note">a</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Telaprevir</b><a href="#hep27934-note-0007" rel="references:#hep27934-note-0007" class="js-link__note link__note" title="Link to note">b</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Simeprevir</b><a href="#hep27934-note-0008" rel="references:#hep27934-note-0008" class="js-link__note link__note" title="Link to note">c</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Asunaprevir</b><a href="#hep27934-note-0009" rel="references:#hep27934-note-0009" class="js-link__note link__note" title="Link to note">d</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Paritaprevir</b><a href="#hep27934-note-0010" rel="references:#hep27934-note-0010" class="js-link__note link__note" title="Link to note">e</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Vaniprevir</b><a href="#hep27934-note-0011" rel="references:#hep27934-note-0011" class="js-link__note link__note" title="Link to note">f</a></th></tr></thead><tfoot class="table__footer"><tr class="table__row"><td colspan="9" class="table__data"><ol><li id="hep27934-note-0005"> <p>Please see the <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" title="Link to external resource: http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" target="_blank">Supporting Information</a> for detailed site-directed mutagenesis data. Values were rounded to whole numbers; empty cells indicate no data available from patients who experienced treatment failure.</p></li><li id="hep27934-note-0006"><span class="bullet"><sup><i>a</i></sup></span> <p>Boceprevir data were generated by quantitative polymerase chain reaction.</p></li><li id="hep27934-note-0007"><span class="bullet"><sup><i>b</i></sup></span> <p>Telaprevir data were generated by quantitative polymerase chain reaction, branched DNA, and luciferase assays.</p></li><li id="hep27934-note-0008"><span class="bullet"><sup><i>c</i></sup></span> <p>Simeprevir data were generated by luciferase assay.</p></li><li id="hep27934-note-0009"><span class="bullet"><sup><i>d</i></sup></span> <p>Asunaprevir data were generated by luciferase assay.</p></li><li id="hep27934-note-0010"><span class="bullet"><sup><i>e</i></sup></span> <p>Paritaprevir data were generated by luciferase assay.</p></li><li id="hep27934-note-0011"><span class="bullet"><sup><i>f</i></sup></span> <p>Vaniprevir data were generated by quantitative polymerase chain reaction.</p></li></ol></td></tr></tfoot><tbody class="table__body table__data--top"><tr class="table__row"><td class="table__data ">V36</td><td class="table__data ">V36M</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">3</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">2</td><td class="table__data table__data--center ">2</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">V36M +R155K</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">55</td><td class="table__data table__data--center ">79</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">V36M +R155K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">64</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">72</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">T54</td><td class="table__data ">T54S</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">2</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">T54S</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">3</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">V55</td><td class="table__data ">V55A</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">3</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td rowspan="2" class="table__data ">Y56</td><td class="table__data ">Y56H+D168V</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">561</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">Y56H+D168V</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">2472</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">Q80</td><td class="table__data ">Q80K</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">11</td><td class="table__data table__data--center ">3</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80K+R155K</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1830</td><td class="table__data table__data--center ">60</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80H</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">3</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">8</td><td class="table__data table__data--center ">1</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80R</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">6</td><td class="table__data table__data--center ">1</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80K+R155K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">420</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80H+D168E</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">145</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80R+D168A</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">2660</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80R+D168E</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">418</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80R+R155K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">305</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">S122</td><td class="table__data ">S122A</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">0.9</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">S122G</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">0.5</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">S122R</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">21</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">I132</td><td class="table__data ">I132V</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">2</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">R155</td><td class="table__data ">R155K</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">5</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">86</td><td class="table__data table__data--center ">21</td><td class="table__data table__data--center ">37</td><td class="table__data table__data--center ">&gt;1000</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">V36M +R155K</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">55</td><td class="table__data table__data--center ">79</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80K+R155K</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1830</td><td class="table__data table__data--center ">60</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">R155G</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">7</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">R155K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">7</td><td class="table__data table__data--center ">32</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">R155M</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">5</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">R155T</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">20</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">V36M +R155K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">64</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">72</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80K+R155K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">420</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80R+R155K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">305</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">A156</td><td class="table__data ">A156F</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">&gt;62</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">A156G</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">19</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">16.0</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">A156N</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">&gt;93</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">A156S</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">13</td><td class="table__data table__data--center ">9.6</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">A156T</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">&gt;62</td><td class="table__data table__data--center ">37</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">A156V</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">&gt;62</td><td class="table__data table__data--center ">196</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">D168</td><td class="table__data ">D168A</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">23</td><td class="table__data table__data--center ">50</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168E</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">58</td><td class="table__data table__data--center ">14</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168V</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">373</td><td class="table__data table__data--center ">96</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168Y</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">622</td><td class="table__data table__data--center ">219</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Y56+D168V</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">561</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168A</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">784</td><td class="table__data table__data--center ">127</td><td class="table__data table__data--center ">27</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168E</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">38</td><td class="table__data table__data--center ">78</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168H</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">401</td><td class="table__data table__data--center ">98</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168I</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1800</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168K</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">882</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168N</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">0.6</td><td class="table__data table__data--center ">5.5</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168T</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">334</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168V</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">3100</td><td class="table__data table__data--center ">280</td><td class="table__data table__data--center ">159</td><td class="table__data table__data--center ">725</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">D168Y</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">651</td><td class="table__data table__data--center ">238</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80R+D168A</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">2660</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Y56H+D168V</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">2472</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80H+D168E</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">145</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">Q80R+D168E</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">418</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">V170</td><td class="table__data ">V170A</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">7.9</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr></tbody></table></div><div data-module="Table" class="table__overflow js-module"><table class="table table--article-section" id="hep27934-tbl-0002"><caption class="table__caption"><span class="table__caption-label">Table&nbsp;2.&nbsp;</span>Mean Fold-Change in Resistance Compared to Wild-Type Replicon of Clinically Relevant NS5A Resistance&ndash;Associated Substitutions</caption><thead class="table__header table__header-data--bottom"><tr class="table__row"><th colspan="3" class="table__header-data table__header-data--center ">&nbsp;</th><th colspan="3" class="table__header-data table__header-data--center table-border--bottom "><b>Mean Fold-Change in Resistance Compared to Wild-Type Replicon</b></th></tr><tr class="table__row"><th class="table__header-data table-border--bottom "><b>HCV NS5A Amino Acid and Position</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Resistance-Associated Substitution(s)</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Replicon Vector Genotype</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Daclatasvir</b><a href="#hep27934-note-0013" rel="references:#hep27934-note-0013" class="js-link__note link__note" title="Link to note">a</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Ledipasvir</b><a href="#hep27934-note-0014" rel="references:#hep27934-note-0014" class="js-link__note link__note" title="Link to note">b</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Ombitasvir</b><a href="#hep27934-note-0015" rel="references:#hep27934-note-0015" class="js-link__note link__note" title="Link to note">c</a></th></tr></thead><tfoot class="table__footer"><tr class="table__row"><td colspan="6" class="table__data"><ol><li id="hep27934-note-0012"> <p>Please see the <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" title="Link to external resource: http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" target="_blank">Supporting Information</a> for detailed site-directed mutagenesis data. Values were rounded to whole numbers; empty cells indicate no data available from patients who experienced treatment failure.</p></li><li id="hep27934-note-0013"><span class="bullet"><sup><i>a</i></sup></span> <p>Daclatasvir data were generated by luciferase assay.</p></li><li id="hep27934-note-0014"><span class="bullet"><sup><i>b</i></sup></span> <p>Ledipasvir data were generated by luciferase assay.</p></li><li id="hep27934-note-0015"><span class="bullet"><sup><i>c</i></sup></span> <p>Ombitasvir data were generated by luciferase assay.</p></li></ol></td></tr></tfoot><tbody class="table__body table__data--top"><tr class="table__row"><td class="table__data ">M28</td><td class="table__data table__data--center ">M28T</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">205</td><td class="table__data table__data--center ">61</td><td class="table__data table__data--center ">8965</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">M28V</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">58</td></tr><tr class="table__row"><td class="table__data ">Q30</td><td class="table__data table__data--center ">Q30E</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">7500</td><td class="table__data table__data--center ">5458</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">Q30H</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">435</td><td class="table__data table__data--center ">183</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">Q30R</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">365</td><td class="table__data table__data--center ">632</td><td class="table__data table__data--center ">800</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">Q30R+Y93C</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1046</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">L31</td><td class="table__data table__data--center ">L31M</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">105</td><td class="table__data table__data--center ">554</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">L31V</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">1000</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">L31M</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">3</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">L31V</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">15</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">L31M+Y93H</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">4227</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">L31V+Y93H</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">5425</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">H58</td><td class="table__data table__data--center ">H58D</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1127</td><td class="table__data table__data--center ">243</td></tr><tr class="table__row"><td class="table__data ">Y93</td><td class="table__data table__data--center ">Y93C</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">555</td><td class="table__data table__data--center ">1602</td><td class="table__data table__data--center ">1675</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">Y93H</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">1600</td><td class="table__data table__data--center ">1677</td><td class="table__data table__data--center ">41,383</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">Y93N</td><td class="table__data table__data--center ">1a</td><td class="table__data table__data--center ">14,100</td><td class="table__data table__data--center ">&gt;14,706</td><td class="table__data table__data--center ">66,740</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">Q30R+Y93C</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1046</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">Y93H</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">12</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">77</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">L31M+Y93H</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">4227</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">L31V+Y93H</td><td class="table__data table__data--center ">1b</td><td class="table__data table__data--center ">5425</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr></tbody></table></div><div data-module="Table" class="table__overflow js-module"><table class="table table--article-section" id="hep27934-tbl-0003"><caption class="table__caption"><span class="table__caption-label">Table&nbsp;3.&nbsp;</span>Mean Fold-Change in Resistance Compared to Wild-Type Replicon of Clinically Relevant NS5B Polymerase Resistance&ndash;Associated Substitutions</caption><thead class="table__header table__header-data--bottom"><tr class="table__row"><th colspan="3" class="table__header-data table__header-data--center ">&nbsp;</th><th colspan="3" class="table__header-data table__header-data--center table-border--bottom "><b>Mean Fold-Change in Resistance Compared to Wild-Type Replicon</b></th></tr><tr class="table__row"><th rowspan="2" class="table__header-data table__header-data--center table-border--bottom "><b>HCV NS5B Polymerase Amino Acid and Position</b></th><th rowspan="2" class="table__header-data table__header-data--center table-border--bottom "><b>Resistance-Associated Substitution(s)</b></th><th rowspan="2" class="table__header-data table__header-data--center table-border--bottom "><b>Replicon Vector Genotype</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Nucleotide Analog</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Nonnucleoside Analog: Palm I</b></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Nonnucleoside Analog: Thumb Pocket I</b></th></tr><tr class="table__row"><th class="table__header-data table__header-data--center table-border--bottom "><b>Sofosbuvir</b><a href="#hep27934-note-0017" rel="references:#hep27934-note-0017" class="js-link__note link__note" title="Link to note">a</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Dasabuvir</b><a href="#hep27934-note-0018" rel="references:#hep27934-note-0018" class="js-link__note link__note" title="Link to note">b</a></th><th class="table__header-data table__header-data--center table-border--bottom "><b>Beclabuvir</b><a href="#hep27934-note-0019" rel="references:#hep27934-note-0019" class="js-link__note link__note" title="Link to note">c</a></th></tr></thead><tfoot class="table__footer"><tr class="table__row"><td colspan="6" class="table__data"><ol><li id="hep27934-note-0016"> <p>Please see the <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" title="Link to external resource: http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" target="_blank">Supporting Information</a> for detailed site-directed mutagenesis data. Values were rounded to whole numbers, while empty cells indicate no data available from patients who experienced treatment failure.</p></li><li id="hep27934-note-0017"><span class="bullet"><sup><i>a</i></sup></span> <p>Sofosbuvir data were generated by luciferase assay.</p></li><li id="hep27934-note-0018"><span class="bullet"><sup><i>b</i></sup></span> <p>Dasabuvir data were generated by luciferase assay.</p></li><li id="hep27934-note-0019"><span class="bullet"><sup><i>c</i></sup></span> <p>Beclabuvir data were generated by luciferase assay.</p></li><li id="hep27934-note-0020"><span class="bullet"><sup><i>d</i></sup></span> <p>The mean fold change in EC50 values for L159F range from 1.2 to 1.8 versus wild-type across multiple genotypes.</p></li></ol></td></tr></tfoot><tbody class="table__body table__data--top"><tr class="table__row"><td class="table__data ">L159</td><td class="table__data ">L159F<a href="#hep27934-note-0020" rel="references:#hep27934-note-0020" class="js-link__note link__note" title="Link to note">d</a></td><td class="table__data table__data--center ">3a</td><td class="table__data table__data--center ">1</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">S282</td><td class="table__data ">S282T</td><td class="table__data table__data--center ">2a</td><td class="table__data table__data--center ">2</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">S282T</td><td class="table__data table__data--center ">2b</td><td class="table__data table__data--center ">16</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">C316</td><td class="table__data ">C316Y</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1472</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">C316Y</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">1569</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">V321</td><td class="table__data ">V321A</td><td class="table__data table__data--center ">3a</td><td class="table__data table__data--center ">1</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">M414</td><td class="table__data ">M414I</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">8</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">M414T</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">32</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">Y448</td><td class="table__data ">Y448H</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">975</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">P495</td><td class="table__data ">P495A</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">12</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">P495L</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">31</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">P495S</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">67</td></tr><tr class="table__row"><td class="table__data ">A553</td><td class="table__data ">A553T</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">152</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">G554</td><td class="table__data ">G554S</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">198</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">S556</td><td class="table__data ">S556G</td><td class="table__data table__data--center ">1a</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">30</td><td class="table__data ">&nbsp;</td></tr><tr class="table__row"><td class="table__data ">&nbsp;</td><td class="table__data ">S556G</td><td class="table__data table__data--center ">1b</td><td class="table__data ">&nbsp;</td><td class="table__data table__data--center ">11</td><td class="table__data ">&nbsp;</td></tr></tbody></table></div></section><section class="article-section article-body-section" id="hep27934-sec-0002"><h2>HCV Resistance to DAAs</h2><p>Nonstructural proteins of HCV are the primary targets of DAAs that are either approved or in advanced development: (1) NS3/4A protease inhibitors (PIs) bind to the active site of the NS3/4A protease; (2) NS5A inhibitors interact with domain 1 of the NS5A dimer, although the exact mechanism of NS5A inhibition remains to be fully elucidated; (3) nucleos(t)ide analog NS5B polymerase inhibitors are incorporated into the nascent RNA chain and result in chain termination by compromising binding of the next incoming nucleotide; (4) nonnucleoside NS5B polymerase inhibitors interact with either the thumb 1, thumb 2, palm 1, or palm 2 domain of NS5B and inhibit polymerase activity by allosteric mechanisms of action.[<a href="#hep27934-bib-0007" rel="references:#hep27934-bib-0007 #hep27934-bib-0008 #hep27934-bib-0009 #hep27934-bib-0010" class="link__reference js-link__reference" title="Link to bibliographic citations">7-10</a>]</p><p>The substitutions observed in treated individuals described in this summary include variants isolated and sequenced from patients who experienced on- or posttreatment virological failure. The likelihood that a DAA will select for and allow outgrowth of viral populations carrying resistance-associated substitutions depends on the DAA's genetic barrier to resistance (the number and type of base pair mutation[s] needed to result in amino acid substitution[s] that confer resistance), the level of drug exposure, and the viral fitness (replicative capacity) of the resistant variant. Genetic barriers to resistance can vary both within and between DAA classes and by HCV genotype and subtype.[<a href="#hep27934-bib-0011" rel="references:#hep27934-bib-0011 #hep27934-bib-0012" class="link__reference js-link__reference" title="Link to bibliographic citations">11, 12</a>] The prevalence of baseline polymorphisms, which are natural substitutions that may differ in their prevalence by genotype, subtype, and subtype clade, can also greatly affect the efficacy of specific DAAs.[<a href="#hep27934-bib-0013" rel="references:#hep27934-bib-0013" class="link__reference js-link__reference" title="Link to bibliographic citation">13</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0003"><h2>Methodology</h2><p>The HCV Drug Development Advisory Group Drug Resistance Working Group is composed of a volunteer panel of experts from academia, industry, patient advocacy organizations, and regulatory agencies.[<a href="#hep27934-bib-0014" rel="references:#hep27934-bib-0014" class="link__reference js-link__reference" title="Link to bibliographic citation">14</a>] Based on working group consensus, industry sponsors were asked to submit a pooled analysis of DAA resistance&ndash;associated substitutions from completed phase 2 and phase 3 trials. Amino acid substitutions detected in &gt;1% of patients whose treatment failed are included in the figures and ordered based on their prevalence in patients whose treatment failed with detection in &gt;10% or &lt;10% of patients (Fig. <a href="#hep27934-fig-0001" rel="references:#hep27934-fig-0001" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">1</a>). Amino acid deletions are designated with an <em>X</em>. The HCV genotype and subtype are color-coded: 1a, red; 1b, blue; 2, brown; 3a, green; 4, orange. Resistance-associated protease substitutions are illustrated in Fig. <a href="#hep27934-fig-0002" rel="references:#hep27934-fig-0002" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">2</a>, NS5A substitutions are illustrated in Fig. <a href="#hep27934-fig-0003" rel="references:#hep27934-fig-0003" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">3</a>, and NS5B substitutions are illustrated in Fig. <a href="#hep27934-fig-0004" rel="references:#hep27934-fig-0004" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">4</a>. Compounds approved for clinical use are designated by an asterisk.</p><section id="hep27934-fig-0001" class="article-section article-section--inline-figure"><figure class="inline-figure"><div class="inline-figure__image-wrap"><a class="inline-figure__image-link" href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0001-m.png?v=1&amp;t=j8cuk5da&amp;s=01da324c7b036c7540cc88bd214414eda38bb3ee" data-support-type="figure-viewer" data-actions="loadFigureViewer" data-figure-id="hep27934-fig-0001" title="Open Figure&nbsp;1. "><noscript><img class="inline-figure__image" alt="Figure&nbsp;1. " src="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0001.png?v=1&amp;t=j8cuk5da&amp;s=291da9c9397c7d6b6404b477f535c0b24fb1f4b6" height="73" width="468" /></noscript><img class="inline-figure__image inline-figure__image--js " alt="Figure&nbsp;1. " src="/enhanced/static/images/lazyload.gif" data-original="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0001.png?v=1&amp;t=j8cuk5da&amp;s=291da9c9397c7d6b6404b477f535c0b24fb1f4b6" width="468" height="73" /></a></div><figcaption class="inline-figure__caption"><div class="inline-figure__caption-block"><h4 class="inline-figure__title">Figure&nbsp;1. </h4><ul class="inline-figure__list u-horizontal-list"><li class="inline-figure__open-figure"><a href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0001-m.png?v=1&amp;t=j8cuk5da&amp;s=01da324c7b036c7540cc88bd214414eda38bb3ee">Open Figure</a></li><li class="inline-figure__list-item--powerpoint"><a href="http://api.onlinelibrary.wiley.com/asset/v1/doi/10.1002%2Fhep.27934/powerpoint/image_n%2Fhep27934-fig-0001.png?l=SkaBT8QEx2r3B7QphT2A074CoTl4N4WSeaWMLn9zNBi%2BSLzrRuQfL2LZB85mCsjlYySAF5kIp%2Bk%3D&amp;s=%22cbb66942b06944559b612e27189fc5b8%22&amp;a=wol">Download Powerpoint slide</a></li></ul></div><p>Resistance figure notations. Wild-type amino acids and positions are placed above the viral protein image. Substitution positions detected in &lt;10% of patients whose treatment failed are visualized with an empty oval, while substitution positions detected in &ge;10% are visualized with a filled oval. Below the viral protein image, substitutions detected in &lt;10% of patients whose treatment failed are listed, while substitutions detected in &ge;10% are listed and encircled. Amino acid deletions are designated with an <em>X</em>. Substitutions are ordered based on their prevalence in patients who failed treatment, with &ge;10% listed first, then in alphabetical order, followed by &lt;10%, then in alphabetical order. Substitutions are color-coded based on genotype and subtype: 1a, red; 1b, blue; 2, brown; 3a, green; 4, orange.</p></figcaption></figure></section><section id="hep27934-fig-0002" class="article-section article-section--inline-figure"><figure class="inline-figure"><div class="inline-figure__image-wrap"><a class="inline-figure__image-link" href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0002-m.png?v=1&amp;t=j8cuk5da&amp;s=a146212da9a84e14b855e26184a9264c14b1ac08" data-support-type="figure-viewer" data-actions="loadFigureViewer" data-figure-id="hep27934-fig-0002" title="Open Figure&nbsp;2. "><noscript><img class="inline-figure__image" alt="Figure&nbsp;2. " src="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0002.png?v=1&amp;t=j8cuk5db&amp;s=2189517fefb17589f12ec4d55cbd6988defcc95f" height="520" width="602" /></noscript><img class="inline-figure__image inline-figure__image--js " alt="Figure&nbsp;2. " src="/enhanced/static/images/lazyload.gif" data-original="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0002.png?v=1&amp;t=j8cuk5db&amp;s=2189517fefb17589f12ec4d55cbd6988defcc95f" width="602" height="520" /></a></div><figcaption class="inline-figure__caption"><div class="inline-figure__caption-block"><h4 class="inline-figure__title">Figure&nbsp;2. </h4><ul class="inline-figure__list u-horizontal-list"><li class="inline-figure__open-figure"><a href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0002-m.png?v=1&amp;t=j8cuk5db&amp;s=fe347ad893381653e609d41c90c539d9eab395cb">Open Figure</a></li><li class="inline-figure__list-item--powerpoint"><a href="http://api.onlinelibrary.wiley.com/asset/v1/doi/10.1002%2Fhep.27934/powerpoint/image_n%2Fhep27934-fig-0002.png?l=SkaBT8QEx2r3B7QphT2A074CoTl4N4WSeaWMLn9zNBi%2BSLzrRuQfL%2BQdSCSkhKsnEBwGIQShB%2Bo%3D&amp;s=%22cbb66942b06944559b612e27189fc5b8%22&amp;a=wol">Download Powerpoint slide</a></li></ul></div><p>NS3 resistance-associated substitutions observed with treatment. *Compounds approved for clinical use. Substitutions are color-coded based on genotype and subtype: 1a, red; 1b, blue; 2, brown; 3a, green; 4, orange. See Fig. 1 legend.</p></figcaption></figure></section><section id="hep27934-fig-0003" class="article-section article-section--inline-figure"><figure class="inline-figure"><div class="inline-figure__image-wrap"><a class="inline-figure__image-link" href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0003-m.png?v=1&amp;t=j8cuk5db&amp;s=e4dc35f189194ff4dc6513a27d2defd55b6e5a7c" data-support-type="figure-viewer" data-actions="loadFigureViewer" data-figure-id="hep27934-fig-0003" title="Open Figure&nbsp;3. "><noscript><img class="inline-figure__image" alt="Figure&nbsp;3. " src="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0003.png?v=1&amp;t=j8cuk5db&amp;s=de71bb833c1e3945b97c496c4d9cad9cda9fbf40" height="287" width="633" /></noscript><img class="inline-figure__image inline-figure__image--js " alt="Figure&nbsp;3. " src="/enhanced/static/images/lazyload.gif" data-original="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0003.png?v=1&amp;t=j8cuk5db&amp;s=de71bb833c1e3945b97c496c4d9cad9cda9fbf40" width="633" height="287" /></a></div><figcaption class="inline-figure__caption"><div class="inline-figure__caption-block"><h4 class="inline-figure__title">Figure&nbsp;3. </h4><ul class="inline-figure__list u-horizontal-list"><li class="inline-figure__open-figure"><a href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0003-m.png?v=1&amp;t=j8cuk5db&amp;s=e4dc35f189194ff4dc6513a27d2defd55b6e5a7c">Open Figure</a></li><li class="inline-figure__list-item--powerpoint"><a href="http://api.onlinelibrary.wiley.com/asset/v1/doi/10.1002%2Fhep.27934/powerpoint/image_n%2Fhep27934-fig-0003.png?l=SkaBT8QEx2r3B7QphT2A074CoTl4N4WSeaWMLn9zNBi%2BSLzrRuQfL6rZdSoRoWmyjyOb7tpWhH0%3D&amp;s=%22cbb66942b06944559b612e27189fc5b8%22&amp;a=wol">Download Powerpoint slide</a></li></ul></div><p>NS5A resistance-associated substitutions observed with treatment. *Compounds approved for clinical use. Amino acid deletions are designated with an <em>X</em>. Substitutions are color-coded based on genotype and subtype: 1a, red; 1b, blue; 2, brown; 3a, green; 4, orange (daclatasvir 4, ombitasvir 4d). See Fig. 1 legend.</p></figcaption></figure></section><section id="hep27934-fig-0004" class="article-section article-section--inline-figure"><figure class="inline-figure"><div class="inline-figure__image-wrap"><a class="inline-figure__image-link" href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0004-m.png?v=1&amp;t=j8cuk5dc&amp;s=bfbcd77a16050db36b0bfebc81978d20ba1302d3" data-support-type="figure-viewer" data-actions="loadFigureViewer" data-figure-id="hep27934-fig-0004" title="Open Figure&nbsp;4. "><noscript><img class="inline-figure__image" alt="Figure&nbsp;4. " src="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0004.png?v=1&amp;t=j8cuk5dc&amp;s=5b8a7e5030e30d3802a43e3cfad30743ce97b08a" height="256" width="600" /></noscript><img class="inline-figure__image inline-figure__image--js " alt="Figure&nbsp;4. " src="/enhanced/static/images/lazyload.gif" data-original="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_n/hep27934-fig-0004.png?v=1&amp;t=j8cuk5dc&amp;s=5b8a7e5030e30d3802a43e3cfad30743ce97b08a" width="600" height="256" /></a></div><figcaption class="inline-figure__caption"><div class="inline-figure__caption-block"><h4 class="inline-figure__title">Figure&nbsp;4. </h4><ul class="inline-figure__list u-horizontal-list"><li class="inline-figure__open-figure"><a href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/image_m/hep27934-fig-0004-m.png?v=1&amp;t=j8cuk5dc&amp;s=bfbcd77a16050db36b0bfebc81978d20ba1302d3">Open Figure</a></li><li class="inline-figure__list-item--powerpoint"><a href="http://api.onlinelibrary.wiley.com/asset/v1/doi/10.1002%2Fhep.27934/powerpoint/image_n%2Fhep27934-fig-0004.png?l=SkaBT8QEx2r3B7QphT2A074CoTl4N4WSeaWMLn9zNBi%2BSLzrRuQfL2bhfxQ%2BAiGU0hbz9HP8T5M%3D&amp;s=%22cbb66942b06944559b612e27189fc5b8%22&amp;a=wol">Download Powerpoint slide</a></li></ul></div><p>NS5B resistance-associated substitutions observed with treatment. *Compounds approved for clinical use. Amino acid deletions are designated with an X. Substitutions are color-coded based on genotype and subtype: 1a, red; 1b, blue; 2, brown; 3a, green. NS5B inhibitors are subdivided based on site of interaction: sofosbuvir, nucleotide analog, NS5B active site; dasabuvir, nonnucleoside analog, NS5B palm 1 site; beclabuvir, nonnucleoside analog, NS5B thumb pocket 1. See Fig. 1 legend.</p></figcaption></figure></section><p>Sponsors also provided available phenotypic characterization of specific resistance substitutions for each DAA, based on site-directed mutagenesis HCV replicon assays. Tables <a href="#hep27934-tbl-0001" rel="references:#hep27934-tbl-0001 #hep27934-tbl-0002 #hep27934-tbl-0003" class="tableLink link__table js-link__table js-scrollto" title="Link to tables">1-3</a> list the mean fold-changes in susceptibility, relative to wild-type replicons, conferred by resistance-associated substitutions. Of note, small differences in HCV replicon phenotype results between different drugs should be interpreted with caution as data were generated by different sponsors using different assay conditions and readouts (e.g., quantitative polymerase chain reaction versus luciferase reporter, see table footnotes). Nevertheless, reporting all site-directed mutant replicon results relative to a wild-type replicon reference should help account for some of these differences and allow reasonable comparisons to be made. The <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" title="Link to external resource: http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" target="_blank">Supporting Information</a> contains more detailed phenotype assay information including replicon genotype/subtype, assay cell type, mean 50% effective concentration value, mean fold-change in resistance, and assay readout.[<a href="#hep27934-bib-0011" rel="references:#hep27934-bib-0011 #hep27934-bib-0012 #hep27934-bib-0015 #hep27934-bib-0016 #hep27934-bib-0017 #hep27934-bib-0018 #hep27934-bib-0019 #hep27934-bib-0020 #hep27934-bib-0021 #hep27934-bib-0022 #hep27934-bib-0023 #hep27934-bib-0024 #hep27934-bib-0025 #hep27934-bib-0026 #hep27934-bib-0027" class="link__reference js-link__reference" title="Link to bibliographic citations">11, 12, 15-27</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0004"><h2>NS3/4A Protease Inhibitors</h2><p>The NS3/4A serine protease cleaves the HCV polyprotein at four major sites, generating the NS3, NS4A, NS4B, NS5A, and NS5B nonstructural proteins.[<a href="#hep27934-bib-0007" rel="references:#hep27934-bib-0007" class="link__reference js-link__reference" title="Link to bibliographic citation">7</a>] The NS3 PIs function by interacting with the protease substrate binding site and preventing viral polyprotein cleavage. The HCV protease is characterized by a solvent-exposed substrate binding site, requiring small molecule inhibitors to rely on few specific interactions to achieve tight binding with the enzyme.[<a href="#hep27934-bib-0028" rel="references:#hep27934-bib-0028" class="link__reference js-link__reference" title="Link to bibliographic citation">28</a>] This resulted in a low genetic barrier to resistance and considerable cross-resistance within the first generation of PIs, boceprevir and telaprevir, involving amino acid positions V36, T54, R155, and A156 (Fig. <a href="#hep27934-fig-0002" rel="references:#hep27934-fig-0002" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">2</a>). More recently developed PIs such as simeprevir, asunaprevir, paritaprevir, and vaniprevir exhibit improved genetic barriers to resistance and enhanced antiviral activity against different HCV genotypes. However, the activities of these PIs are still substantially reduced by substitutions at amino acids R155 and D168 (Fig. <a href="#hep27934-fig-0002" rel="references:#hep27934-fig-0002" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">2</a>).[<a href="#hep27934-bib-0013" rel="references:#hep27934-bib-0013 #hep27934-bib-0028 #hep27934-bib-0029" class="link__reference js-link__reference" title="Link to bibliographic citations">13, 28, 29</a>]</p><section class="article-section article-body-section" id="hep27934-sec-0005"><section class="article-section article-body-section" id="hep27934-sec-0006"><h4>Boceprevir (MK-3034)</h4><p>The NS3 amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were V36M, T54S, and R155K. The NS3 amino acid substitutions most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR were T54A/S, V55A, A156S, and V170A.[<a href="#hep27934-bib-0030" rel="references:#hep27934-bib-0030 #hep27934-bib-0031" class="link__reference js-link__reference" title="Link to bibliographic citations">30, 31</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0007"><h4>Telaprevir (VX-950)</h4><p>The NS3 amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were V36M and R155K. The NS3 amino acid substitutions most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR were V36A, T54A, and A156S.[<a href="#hep27934-bib-0016" rel="references:#hep27934-bib-0016 #hep27934-bib-0032" class="link__reference js-link__reference" title="Link to bibliographic citations">16, 32</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0008"><h4>Simeprevir (TMC-435)</h4><p>The most commonly observed substitutions in genotype 1a&ndash;infected patients who did not achieve SVR were R155K and D168E/V. The NS3 amino acid substitutions most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR were Q80R and D168E/V. For both subtypes, the substitutions Q80K/R, S122A/G/I/T, R155Q, and D168F were not observed at the time of virological failure alone but rather in combination with other substitutions at positions 80, 122, 155, and/or 168.[<a href="#hep27934-bib-0018" rel="references:#hep27934-bib-0018 #hep27934-bib-0033 #hep27934-bib-0034 #hep27934-bib-0035" class="link__reference js-link__reference" title="Link to bibliographic citations">18, 33-35</a>]</p><p>The presence of the Q80K polymorphism substantially reduced SVR rates in genotype 1a&ndash;infected patients treated with simeprevir in combination with pegylated interferon alfa and ribavirin compared to patients without the variant, while in a 12-week interferon-free regimen the effect was less pronounced in patients with cirrhosis and no effect of Q80K on SVR rates was observed in patients who did not have cirrhosis. In patients with Q80K at baseline who did not achieve SVR, additional resistance-associated substitutions (mainly R155K) were selected during treatment failure (Fig. <a href="#hep27934-fig-0002" rel="references:#hep27934-fig-0002" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">2</a>).[<a href="#hep27934-bib-0033" rel="references:#hep27934-bib-0033 #hep27934-bib-0034 #hep27934-bib-0036 #hep27934-bib-0037 #hep27934-bib-0038 #hep27934-bib-0039" class="link__reference js-link__reference" title="Link to bibliographic citations">33, 34, 36-39</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0009"><h4>Asunaprevir (BMS-650032)</h4><p>The NS3 amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were R155K and D168E. The NS3 amino acid substitutions most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR were D168E/V/Y.[<a href="#hep27934-bib-0040" rel="references:#hep27934-bib-0040 #hep27934-bib-0041 #hep27934-bib-0042 #hep27934-bib-0043 #hep27934-bib-0044" class="link__reference js-link__reference" title="Link to bibliographic citations">40-44</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0010"><h4>Paritaprevir (ABT-450)</h4><p>The NS3 amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were D168A/V/Y. The NS3 amino acid substitutions most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR were Y56H and D168V. The NS3 amino acid substitution most commonly observed in genotype 4d&ndash;infected patients who did not achieve SVR was D168V.[<a href="#hep27934-bib-0024" rel="references:#hep27934-bib-0024 #hep27934-bib-0045 #hep27934-bib-0046 #hep27934-bib-0047 #hep27934-bib-0048 #hep27934-bib-0049" class="link__reference js-link__reference" title="Link to bibliographic citations">24, 45-49</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0011"><h4>Vaniprevir (MK-7009)</h4><p>The NS3 amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were R155K and D168T/V/Y. The NS3 amino acid substitutions most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR were D168H/T/V.[<a href="#hep27934-bib-0050" rel="references:#hep27934-bib-0050 #hep27934-bib-0051" class="link__reference js-link__reference" title="Link to bibliographic citations">50, 51</a>]</p></section></section></section><section class="article-section article-body-section" id="hep27934-sec-0012"><h2>NS5A Inhibitors</h2><p>The NS5A protein is involved in viral replication, assembly and release of HCV particles, as well as several host interactions.[<a href="#hep27934-bib-0009" rel="references:#hep27934-bib-0009 #hep27934-bib-0052 #hep27934-bib-0053" class="link__reference js-link__reference" title="Link to bibliographic citations">9, 52, 53</a>] Localized on endoplasmic reticulum&ndash;derived membranes, NS5A exists in basally phosphorylated (p56) and hyperphosphorylated (p58) forms. The exact mechanism by which NS5A regulates viral replication or participates in viral packaging and assembly is unknown; as a result, the mechanism of action of NS5A inhibitors is not fully understood. Current NS5A inhibitors are characterized by their broad genotypic coverage and relatively low barriers to resistance. Certain key resistance-associated substitutions like Y93H are also detected as natural baseline polymorphisms in some patients (Fig. <a href="#hep27934-fig-0003" rel="references:#hep27934-fig-0003" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">3</a>).[<a href="#hep27934-bib-0012" rel="references:#hep27934-bib-0012 #hep27934-bib-0054 #hep27934-bib-0055 #hep27934-bib-0056 #hep27934-bib-0057" class="link__reference js-link__reference" title="Link to bibliographic citations">12, 54-57</a>]</p><section class="article-section article-body-section" id="hep27934-sec-0013"><section class="article-section article-body-section" id="hep27934-sec-0014"><h4>Daclatasvir (BMS-790052)</h4><p>The NS5A amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were M28T, Q30E/H/R, L31M, H58D, and Y93H/N. The NS5A amino acid substitutions most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR were L31M/V and Y93H. The NS5A amino acid substitutions most commonly observed in genotype 4&ndash;infected patients who did not achieve SVR were Q30H/S.[<a href="#hep27934-bib-0055" rel="references:#hep27934-bib-0055 #hep27934-bib-0058 #hep27934-bib-0059" class="link__reference js-link__reference" title="Link to bibliographic citations">55, 58, 59</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0015"><h4>Ledipasvir (GS-5885)</h4><p>The NS5A amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were Q30E/R, L31M, and Y93C/H/N. The NS5A amino acid substitution most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR was Y93H.[<a href="#hep27934-bib-0060" rel="references:#hep27934-bib-0060 #hep27934-bib-0061 #hep27934-bib-0062" class="link__reference js-link__reference" title="Link to bibliographic citations">60-62</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0016"><h4>Ombitasvir (ABT-267)</h4><p>The NS5A amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were M28T and Q30R. The NS5A amino acid substitution most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR was Y93H. The NS5A amino acid substitution most commonly observed in genotype 4d&ndash;infected patients who did not achieve SVR was L28V.[<a href="#hep27934-bib-0025" rel="references:#hep27934-bib-0025 #hep27934-bib-0045 #hep27934-bib-0046 #hep27934-bib-0047 #hep27934-bib-0048 #hep27934-bib-0049" class="link__reference js-link__reference" title="Link to bibliographic citations">25, 45-49</a>]</p></section></section></section><section class="article-section article-body-section" id="hep27934-sec-0017"><h2>NS5B Polymerase Inhibitors</h2><p>NS5B is the RNA-dependent RNA polymerase (catalytic subunit) of the membrane-associated HCV replication complex.[<a href="#hep27934-bib-0008" rel="references:#hep27934-bib-0008" class="link__reference js-link__reference" title="Link to bibliographic citation">8</a>] NS5B is structurally organized in a characteristic &ldquo;right-hand motif&rdquo; containing palm and thumb domains.[<a href="#hep27934-bib-0063" rel="references:#hep27934-bib-0063" class="link__reference js-link__reference" title="Link to bibliographic citation">63</a>] Nucleos(t)ide inhibitors have broad activity against different HCV genotypes, have a high resistance barrier, and function by mimicking polymerase nucleotide substrates that are incorporated into the nascent RNA chain and result in chain termination.[<a href="#hep27934-bib-0029" rel="references:#hep27934-bib-0029 #hep27934-bib-0064" class="link__reference js-link__reference" title="Link to bibliographic citations">29, 64</a>] The NS5B nonnucleoside analog inhibitors bind outside of the polymerase active site and can be further subclassified based on their allosteric binding sites (Palm 1, Palm 2, Thumb 1, and Thumb 2).[<a href="#hep27934-bib-0010" rel="references:#hep27934-bib-0010" class="link__reference js-link__reference" title="Link to bibliographic citation">10</a>] Given their different mechanisms and sites of interaction, no cross-resistance is observed across currently approved and phase 3 nucleotide and nonnucleoside polymerase inhibitors (Fig. <a href="#hep27934-fig-0004" rel="references:#hep27934-fig-0004" class="figureLink link__figure js-link__figure js-scrollto" title="Link to figure">4</a>).[<a href="#hep27934-bib-0048" rel="references:#hep27934-bib-0048 #hep27934-bib-0057" class="link__reference js-link__reference" title="Link to bibliographic citations">48, 57</a>]</p><section class="article-section article-body-section" id="hep27934-sec-0018"><section class="article-section article-body-section" id="hep27934-sec-0019"><h4>Sofosbuvir (GS-7977, Nucleotide Analog Inhibitor)</h4><p>In the ELECTRON sofosbuvir monotherapy study, the S282T substitution was detected in a patient infected with HCV genotype 2 who relapsed at week 4 posttreatment.[<a href="#hep27934-bib-0065" rel="references:#hep27934-bib-0065" class="link__reference js-link__reference" title="Link to bibliographic citation">65</a>] In a pooled analysis of sofosbuvir phase 3 trials involving patients infected with HCV genotype 3 who did not achieve SVR, the substitutions L159F and V321A were selected postbaseline in several subjects; however, these variants alone have been shown to confer 1.2- to 1.6-fold reduced phenotypic susceptibility to sofosbuvir <em>in vitro</em> and require further investigation to elucidate their association with viral resistance (Table <a href="#hep27934-tbl-0003" rel="references:#hep27934-tbl-0003" class="tableLink link__table js-link__table js-scrollto" title="Link to table">3</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" title="Link to external resource: http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/suppinfo" target="_blank">Supporting Information</a>).[<a href="#hep27934-bib-0066" rel="references:#hep27934-bib-0066 #hep27934-bib-0067 #hep27934-bib-0068" class="link__reference js-link__reference" title="Link to bibliographic citations">66-68</a>] C316N/H/F was present at baseline in six subjects infected with HCV genotype 1b whose treatment failed and was observed on treatment in one patient infected with HCV genotype 1a who experienced relapse; however, more studies are needed to assess the substitution's role in resistance to sofosbuvir.[<a href="#hep27934-bib-0067" rel="references:#hep27934-bib-0067" class="link__reference js-link__reference" title="Link to bibliographic citation">67</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0020"><h4>Dasabuvir (ABT-333, Nonnucleoside Analog Inhibitor, Palm I)</h4><p>The NS5B amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were M414T and S556G. The N5SB amino acid substitution most commonly observed in genotype 1b&ndash;infected patients who did not achieve SVR was S556G.[<a href="#hep27934-bib-0026" rel="references:#hep27934-bib-0026 #hep27934-bib-0045 #hep27934-bib-0046 #hep27934-bib-0047 #hep27934-bib-0048" class="link__reference js-link__reference" title="Link to bibliographic citations">26, 45-48</a>]</p></section><section class="article-section article-body-section" id="hep27934-sec-0021"><h4>Beclabuvir (BMS-791325, Nonnucleoside Analog Inhibitor, Thumb Pocket I)</h4><p>The NS5B amino acid substitutions most commonly observed in genotype 1a&ndash;infected patients who did not achieve SVR were A421V and P495L/S.[<a href="#hep27934-bib-0043" rel="references:#hep27934-bib-0043 #hep27934-bib-0069" class="link__reference js-link__reference" title="Link to bibliographic citations">43, 69</a>] To date, no patients infected with genotype 1b have experienced virological escape.</p></section></section></section><section class="article-section article-body-section" id="hep27934-sec-0022"><h2>Conclusion</h2><p>This review provides a comprehensive and systematic summary of resistance-associated substitutions for current late-stage and approved HCV DAAs. Differences between our findings and published resistance reviews may rely on different methodologies for the compilation of clinically relevant substitutions.[<a href="#hep27934-bib-0070" rel="references:#hep27934-bib-0070 #hep27934-bib-0071" class="link__reference js-link__reference" title="Link to bibliographic citations">70, 71</a>] Furthermore, the conclusions in this review rely directly on data generated by and provided by the sponsor, which include data not previously available in the public domain.</p><p>As drugs enter clinical practice, the sponsor data presented here will be complemented and expanded in phase 4 trials and observational cohorts such as the Hepatitis C Therapeutic Registry and Research Network.[<a href="#hep27934-bib-0072" rel="references:#hep27934-bib-0072" class="link__reference js-link__reference" title="Link to bibliographic citation">72</a>] The extent to which detection of resistance-associated substitutions may play a role in determining the ideal retreatment regimen for HCV-infected individuals is an active field of research. Regimen selection may need to take into account the differing half-lives of resistant variants selected in patients who do not achieve SVR on a DAA-based therapy. For example, resistance-associated variants in patients who did not achieve SVR with a telaprevir and pegylated interferon alfa and ribavirin regimen were estimated to revert to a predominantly wild-type population with a median time of about 11 months posttreatment in genotype 1a&ndash;infected patients and about 1 month in genotype 1b&ndash;infected patients.[<a href="#hep27934-bib-0016" rel="references:#hep27934-bib-0016" class="link__reference js-link__reference" title="Link to bibliographic citation">16</a>] On the other hand, NS5A resistance-associated substitutions have been shown to persist for at least 1 year posttreatment failure and may impact retreatment with some NS5A inhibitor&ndash;containing regimens.[<a href="#hep27934-bib-0073" rel="references:#hep27934-bib-0073" class="link__reference js-link__reference" title="Link to bibliographic citation">73</a>]</p><p>In this rapidly evolving field, coordination among stakeholders to assess real-life treatment failure rates and retreatment success rates is needed to inform the field as efficiently as possible regarding regimen selection and the potential need for baseline resistance testing. The clinical recommendations developed by the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Japan Society of Hepatology serve as the guides for best clinical practice.[<a href="#hep27934-bib-0074" rel="references:#hep27934-bib-0074 #hep27934-bib-0075 #hep27934-bib-0076" class="link__reference js-link__reference" title="Link to bibliographic citations">74-76</a>] It is the goal of the HCV Drug Development Advisory Group Drug Resistance Working Group to contribute to these discussions with the comprehensive data set provided here, while facilitating the continued and breathtaking progress of HCV DAA-only therapy.</p></section><section class="article-section article-body-section" id="hep27934-sec-0023"><h2>Acknowledgment</h2><p>We thank Rob J. Besaw, Dr. Chansom Brumme, Dr. Richard Harrigan, Dr. Jules O'Rear, and Nivedha Panneer for helpful manuscript suggestions and discussion.</p></section><section class="article-section article-body-section" id="hep27934-sec-0122"><p>Author names in bold designate shared co-first authorship.</p></section><footer class="article-footer js-module" data-module="Footer"><h2 class="is-accessible">Ancillary</h2><section id="footer-article-info" class="article-footer__section"><h3 class="article-footer__section-title js-footer-title"><i class="icon icon__double-chevron"></i>Article Information</h3><div class="article-info__section-content js-footer-info js-article-info"><div class="article-info__doi-container"><h4 class="article-info__section-sub-title">DOI</h4><span class="article-info__section-doi-data">10.1002/hep.27934</span><ul class="article-info__list u-list-plain"><li class="article-info__citations-item"><a href="/enhanced/exportCitation/doi/10.1002/hep.27934" class="article-header__meta-info-2nd-data analytics-view-citation js-module" data-module="fragment">View/save citation</a></li></ul></div><div class="article-info__format-container article-format"><h4 class="article-info__section-sub-title">Format Available</h4><span class="article-info__section-format-data">Full text: HTML | PDF</span></div><footer class="article-info__copyright-container" id="copyright"><p class="article-info__copyright">&copy; 2015 by the American Association for the Study of Liver Diseases</p></footer><p class="request-permissions"><a href="https://s100.copyright.com/AppDispatchServlet?publisherName=Wiley&amp;publication=HEP&amp;title=Hepatitis%20C%20virus%20drug%20resistance%E2%80%93associated%20substitutions%3A%20State%20of%20the%20art%20summary&amp;publicationDate=30%20JUL%202015&amp;author=Erik%20Lontok%2CPatrick%20Harrington%2CAnita%20Howe%2CTara%20Kieffer%2CJohan%20Lennerstrand%2COliver%20Lenz%2CFiona%20McPhee%2CHongmei%20Mo%2CNeil%20Parkin%2CTami%20Pilot%E2%80%90Matias%2CVeronica%20Miller&amp;startPage=1623&amp;endPage=1632&amp;copyright=%C2%A9%202015%20by%20the%20American%20Association%20for%20the%20Study%20of%20Liver%20Diseases&amp;contentID=10.1002%2Fhep.27934&amp;orderSource=Wileyonline&amp;orderBeanReset=true" class="js-module" data-module="rights-link" target="_blank"><span class="icon-aa icon-aa__permission"></span>                Request Permissions             </a></p><div class="article-info__keywords-plus-wrapper"><span id="after-keywords"></span></div><div class="article-info__publication-history-container" id="publication-history"><h4 class="article-info__section-sub-title">Publication History</h4><ul class="article-info__publication-history-list u-list-plain"><li class="article-info__publication-history-item"><span class="article-info__publication-history-label">Issue online: </span><time datetime="2015-10-20" class="article-info__publication-history-data">20 October 2015</time></li><li class="article-info__publication-history-item"><span class="article-info__publication-history-label">Version of record online: </span><time datetime="2015-07-30" class="article-info__publication-history-data">30 July 2015</time></li><li class="article-info__publication-history-item"><span class="article-info__publication-history-label">Accepted manuscript online: </span><time datetime="2015-06-10" class="article-info__publication-history-data">10 June 2015</time></li><li class="article-info__publication-history-item"><span class="article-info__publication-history-label">Manuscript Accepted: </span><time datetime="2015-06-06" class="article-info__publication-history-data">6 June 2015</time></li><li class="article-info__publication-history-item"><span class="article-info__publication-history-label">Manuscript Received: </span><time datetime="2014-12-09" class="article-info__publication-history-data">9 December 2014</time></li></ul></div><span id="after-funding-information"></span></div></section><section id="footer-support-info" class="article-footer__section"><h3 class="article-footer__section-title js-footer-title"><i class="icon icon__double-chevron"></i>Supporting Information             </h3><div class="article-supp-info__section-content js-footer-info" id=""><p class="article-info__intro">Additional Supporting Information may be found at <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep27934/suppinfo" title="Link to external resource: http://onlinelibrary.wiley.com/doi/10.1002/hep27934/suppinfo" target="_blank">http://onlinelibrary.wiley.com/doi/10.1002/hep27934/suppinfo</a>.</p><div class="support-info__table-wrapper"><table class="support-info__table"><thead><tr><th id="article-filename" scope="col">Filename</th><th id="article-description" scope="col">Description</th></tr></thead><tbody><tr><td headers="article-filename"><a href="http://onlinelibrary.wiley.com/store/10.1002/hep.27934/asset/supinfo/hep27934-sup-0001-suppinfo01.pdf?v=1&amp;s=f8d426726530f77db082078649528a832da32d59">hep27934-sup-0001-suppinfo01.pdf</a><span class="support-info__file-ext">286K</span></td><td headers="article-description"> <p>Supporting Information</p></td></tr></tbody></table></div><p class="support-info__disclaimer">Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.</p></div></section><section class="article-footer__section article-section__references" id="references-section"><h3 class="article-footer__section-title js-footer-title"><i class="icon icon__double-chevron"></i>References</h3><div class="article-info__section-content js-footer-info"><ul class="article-section__references-list"><li id="hep27934-bib-0001"><span class="bullet">1</span><cite id="hep27934-cit-0001">  <span class="author">Chung RT</span>, <span class="author">Baumert TF.</span> <span class="articleTitle">Curing chronic hepatitis C&ndash;the arc of a medical triumph</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2014</span>;<span class="vol">370</span>:<span class="pageFirst">1576</span>-<span class="pageLast">1578</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMp1400986">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24720678">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXnt1Grsrw%253D&amp;md5=544502437d92400ae78f8d5cfb85f859">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000336120500003&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 44</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Curing%20chronic%20hepatitis%20C%E2%80%93the%20arc%20of%20a%20medical%20triumph&amp;rft.volume=370&amp;rft.spage=1576&amp;rft.epage=1578&amp;rft.date=2014&amp;rft.aulast=Chung&amp;rft.aufirst=RT&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0002"><span class="bullet">2</span><cite id="hep27934-cit-0002">  <span class="author"><b>Neumann</b> AU</span>, <span class="author"><b>Lam</b> NP</span>, <span class="author">Dahari H</span>, <span class="author">Gretch DR</span>, <span class="author">Wiley TE</span>, <span class="author">Layden TJ</span>, <span class="author">Perelson AS.</span> <span class="articleTitle">Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy</span>. <span class="journalTitle">Science</span> <span class="pubYear">1998</span>;<span class="vol">282</span>:<span class="pageFirst">103</span>-<span class="pageLast">107</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1126%2Fscience.282.5386.103">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/9756471">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000076294900048&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 1357</a> | </li><li><a target="_blank" href="http://adsabs.harvard.edu/abs/1998Sci...282..103N">ADS</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=Hepatitis%20C%20viral%20dynamics%20in%20vivo%20and%20the%20antiviral%20efficacy%20of%20interferon%E2%80%90alpha%20therapy&amp;rft.volume=282&amp;rft.spage=103&amp;rft.epage=107&amp;rft.date=1998&amp;rft.aulast=Neumann&amp;rft.aufirst=AU&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0003"><span class="bullet">3</span><cite id="hep27934-cit-0003">  <span class="author">Mansky LM</span>, <span class="author">Temin HM.</span> <span class="articleTitle">Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase</span>. <span class="journalTitle">J Virol</span> <span class="pubYear">1995</span>;<span class="vol">69</span>:<span class="pageFirst">5087</span>-<span class="pageLast">5094</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/7541846">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=A1995RH85400060&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 697</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Virol&amp;rft.atitle=Lower%20in%20vivo%20mutation%20rate%20of%20human%20immunodeficiency%20virus%20type%201%20than%20that%20predicted%20from%20the%20fidelity%20of%20purified%20reverse%20transcriptase&amp;rft.volume=69&amp;rft.spage=5087&amp;rft.epage=5094&amp;rft.date=1995&amp;rft.aulast=Mansky&amp;rft.aufirst=LM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0004"><span class="bullet">4</span><cite id="hep27934-cit-0004">  <span class="author">Ogata N</span>, <span class="author">Alter HJ</span>, <span class="author">Miller RH</span>, <span class="author">Purcell RH.</span> <span class="articleTitle">Nucleotide sequence and mutation rate of the H strain of hepatitis C virus</span>. <span class="journalTitle">Proc Natl Acad Sci USA</span> <span class="pubYear">1991</span>;<span class="vol">88</span>:<span class="pageFirst">3392</span>-<span class="pageLast">3396</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1073%2Fpnas.88.8.3392">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/1849654">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDyaK38Xhs1ersQ%253D%253D&amp;md5=1eecbd950d10742da3c140d17ec95b3f">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=A1991FG91300089&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 476</a> | </li><li><a target="_blank" href="http://adsabs.harvard.edu/abs/1991PNAS...88.3392O">ADS</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proc%20Natl%20Acad%20Sci%20USA&amp;rft.atitle=Nucleotide%20sequence%20and%20mutation%20rate%20of%20the%20H%20strain%20of%20hepatitis%20C%20virus&amp;rft.volume=88&amp;rft.spage=3392&amp;rft.epage=3396&amp;rft.date=1991&amp;rft.aulast=Ogata&amp;rft.aufirst=N&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0005"><span class="bullet">5</span><cite id="hep27934-cit-0005">  <span class="author">Hutchison C</span>, <span class="author">Kwong A</span>, <span class="author">Ray S</span>, <span class="author">Struble K</span>, <span class="author">Swan T</span>, <span class="author">Miller V.</span> <span class="articleTitle">Accelerating drug development through collaboration: the hepatitis C drug development advisory group</span>. <span class="journalTitle">Clin Pharmacol Ther</span> <span class="pubYear">2014</span>;<span class="vol">96</span>:<span class="pageFirst">162</span>-<span class="pageLast">165</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list" data-on-platform="true" data-doi="10.1038/clpt.2014.113"><li><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1038/clpt.2014.113">Wiley Online Library</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24853733">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000339602900026&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 5</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Pharmacol%20Ther&amp;rft.atitle=Accelerating%20drug%20development%20through%20collaboration%3A%20the%20hepatitis%20C%20drug%20development%20advisory%20group&amp;rft.volume=96&amp;rft.spage=162&amp;rft.epage=165&amp;rft.date=2014&amp;rft.aulast=Hutchison&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0006"><span class="bullet">6</span><cite id="hep27934-cit-0006"><span class="groupName">HCV Phenotype Working Group of the HCV Drug Development Advisory Group</span>. <span class="articleTitle">Clinically Relevant HCV Drug Resistance Mutations Fig. and Tables</span>. <span class="journalTitle">Ann Forum Collab HIV Res</span> <span class="pubYear">2012</span>;<span class="vol">14</span>:<span class="pageFirst">10</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Ann%20Forum%20Collab%20HIV%20Res&amp;rft.atitle=Clinically%20Relevant%20HCV%20Drug%20Resistance%20Mutations%20Fig.%20and%20Tables&amp;rft.volume=14&amp;rft.spage=10&amp;rft.date=2012&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0007"><span class="bullet">7</span><cite id="hep27934-cit-0007">  <span class="author">Lin C</span><span class="chapterTitle">: HCV NS3-4A Serine Protease</span>. In: <span class="editor">Tan SL</span>, ed. <span class="bookTitle">Hepatitis C Viruses: Genomes and Molecular Biology</span>. <span class="publisherLocation">Norfolk (UK)</span>, <span class="pubYear">2006</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Hepatitis%20C%20Viruses%3A%20Genomes%20and%20Molecular%20Biology&amp;rft.atitle=%3A%20HCV%20NS3%E2%80%904A%20Serine%20Protease&amp;rft.date=2006&amp;rft.aulast=Lin&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0008"><span class="bullet">8</span><cite id="hep27934-cit-0008">  <span class="author">Ranjith-Kumar CT</span>, <span class="author">Kao CC</span>: <span class="chapterTitle">Biochemical Activities of the HCV NS5B RNA-Dependent RNA Polymerase</span>. In: <span class="editor">Tan SL</span>, ed. <span class="bookTitle">Hepatitis C Viruses: Genomes and Molecular Biology</span>. <span class="publisherLocation">Norfolk (UK)</span>, 2006. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Hepatitis%20C%20Viruses%3A%20Genomes%20and%20Molecular%20Biology&amp;rft.atitle=Biochemical%20Activities%20of%20the%20HCV%20NS5B%20RNA%E2%80%90Dependent%20RNA%20Polymerase&amp;rft.aulast=Ranjith%E2%80%90Kumar&amp;rft.aufirst=CT&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0009"><span class="bullet">9</span><cite id="hep27934-cit-0009">  <span class="author">Pawlotsky JM.</span> <span class="articleTitle">NS5A inhibitors in the treatment of hepatitis C</span>. <span class="journalTitle">J Hepatol</span> <span class="pubYear">2013</span>;<span class="vol">59</span>:<span class="pageFirst">375</span>-<span class="pageLast">382</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.jhep.2013.03.030">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23567084">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXovVSltrk%253D&amp;md5=53a0ad492e977c47e9d9ab6c54b50431">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000322097400025&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 57</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Hepatol&amp;rft.atitle=NS5A%20inhibitors%20in%20the%20treatment%20of%20hepatitis%20C&amp;rft.volume=59&amp;rft.spage=375&amp;rft.epage=382&amp;rft.date=2013&amp;rft.aulast=Pawlotsky&amp;rft.aufirst=JM.&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0010"><span class="bullet">10</span><cite id="hep27934-cit-0010">  <span class="author">Gerber L</span>, <span class="author">Welzel TM</span>, <span class="author">Zeuzem S.</span> <span class="articleTitle">New therapeutic strategies in HCV: polymerase inhibitors</span>. <span class="journalTitle">Liver Int</span> <span class="pubYear">2013</span>;<span class="vol">33</span> <span class="citedIssue">Suppl 1</span>:<span class="pageFirst">85</span>-<span class="pageLast">92</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list" data-on-platform="true" data-doi="10.1111/liv.12068"><li><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/liv.12068">Wiley Online Library</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23286851">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXktVGrs7g%253D&amp;md5=93267391c4ebed47aa72137c92c7c195">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000312999400013&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 13</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Liver%20Int&amp;rft.atitle=New%20therapeutic%20strategies%20in%20HCV%3A%20polymerase%20inhibitors&amp;rft.volume=33&amp;rft.issue=Suppl%201&amp;rft.spage=85&amp;rft.epage=92&amp;rft.date=2013&amp;rft.aulast=Gerber&amp;rft.aufirst=L&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0011"><span class="bullet">11</span><cite id="hep27934-cit-0011">  <span class="author">Fridell RA</span>, <span class="author">Qiu D</span>, <span class="author">Wang C</span>, <span class="author">Valera L</span>, <span class="author">Gao M.</span> <span class="articleTitle">Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2010</span>;<span class="vol">54</span>:<span class="pageFirst">3641</span>-<span class="pageLast">3650</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.00556-10">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20585111">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3cXht12kt7fF&amp;md5=ebcca3285b6fe4441ec5d7d86fe6aa1f">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000281005900018&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 142</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=Resistance%20analysis%20of%20the%20hepatitis%20C%20virus%20NS5A%20inhibitor%20BMS%E2%80%90790052%20in%20an%20in%20vitro%20replicon%20system&amp;rft.volume=54&amp;rft.spage=3641&amp;rft.epage=3650&amp;rft.date=2010&amp;rft.aulast=Fridell&amp;rft.aufirst=RA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0012"><span class="bullet">12</span><cite id="hep27934-cit-0012">  <span class="author">Gao M.</span> <span class="articleTitle">Antiviral activity and resistance of HCV NS5A replication complex inhibitors</span>. <span class="journalTitle">Curr Opin Virol</span> <span class="pubYear">2013</span>;<span class="vol">3</span>:<span class="pageFirst">514</span>-<span class="pageLast">520</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.coviro.2013.06.014">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23896281">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXhtF2iu7jL&amp;md5=adc2e3008c890d426d83552fd6ee12d7">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000326136300006&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 39</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Curr%20Opin%20Virol&amp;rft.atitle=Antiviral%20activity%20and%20resistance%20of%20HCV%20NS5A%20replication%20complex%20inhibitors&amp;rft.volume=3&amp;rft.spage=514&amp;rft.epage=520&amp;rft.date=2013&amp;rft.aulast=Gao&amp;rft.aufirst=M.&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0013"><span class="bullet">13</span><cite id="hep27934-cit-0013">  <span class="author">Paolucci S</span>, <span class="author">Fiorina L</span>, <span class="author">Piralla A</span>, <span class="author">Gulminetti R</span>, <span class="author">Novati S</span>, <span class="author">Barbarini G</span>, <span class="author">Sacchi P</span>, et al. <span class="articleTitle">Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients</span>. <span class="journalTitle">Virol J</span> <span class="pubYear">2012</span>;<span class="vol">9</span>:<span class="pageFirst">245</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1186%2F1743-422X-9-245">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23095680">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC38XhvVequ7bP&amp;md5=710e7035293b2d727886ee067543170a">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000311126700002&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 22</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Virol%20J&amp;rft.atitle=Naturally%20occurring%20mutations%20to%20HCV%20protease%20inhibitors%20in%20treatment%E2%80%90naive%20patients&amp;rft.volume=9&amp;rft.spage=245&amp;rft.date=2012&amp;rft.aulast=Paolucci&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0014"><span class="bullet">14</span><cite id="hep27934-cit-0014">  <span class="author">Kwong AD</span>, <span class="author">Najera I</span>, <span class="author">Bechtel J</span>, <span class="author">Bowden S</span>, <span class="author">Fitzgibbon J</span>, <span class="author">Harrington P</span>, <span class="author">Kempf D</span>, et al. <span class="articleTitle">Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG</span>. <span class="journalTitle">Gastroenterology</span> <span class="pubYear">2011</span>;<span class="vol">140</span>:<span class="pageFirst">755</span>-<span class="pageLast">760</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1053%2Fj.gastro.2011.01.029">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/21255574">PubMed</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Sequence%20and%20phenotypic%20analysis%20for%20resistance%20monitoring%20in%20hepatitis%20C%20virus%20drug%20development%3A%20recommendations%20from%20the%20HCV%20DRAG&amp;rft.volume=140&amp;rft.spage=755&amp;rft.epage=760&amp;rft.date=2011&amp;rft.aulast=Kwong&amp;rft.aufirst=AD&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0015"><span class="bullet">15</span><cite id="hep27934-cit-0015">  <span class="author">Tong X</span>, <span class="author">Chase R</span>, <span class="author">Skelton A</span>, <span class="author">Chen T</span>, <span class="author">Wright-Minogue J</span>, <span class="author">Malcolm BA.</span> <span class="articleTitle">Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034</span>. <span class="journalTitle">Antiviral Res</span> <span class="pubYear">2006</span>;<span class="vol">70</span>:<span class="pageFirst">28</span>-<span class="pageLast">38</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.antiviral.2005.12.003">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/16448708">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BD28Xjs1Wmu7w%253D&amp;md5=7bda9ca9e0ad7a8eb2397861d731a382">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000237444300004&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 165</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antiviral%20Res&amp;rft.atitle=Identification%20and%20analysis%20of%20fitness%20of%20resistance%20mutations%20against%20the%20HCV%20protease%20inhibitor%20SCH%20503034&amp;rft.volume=70&amp;rft.spage=28&amp;rft.epage=38&amp;rft.date=2006&amp;rft.aulast=Tong&amp;rft.aufirst=X&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0016"><span class="bullet">16</span><cite id="hep27934-cit-0016">  <span class="author">Kieffer TL</span>, <span class="author">De Meyer S</span>, <span class="author">Bartels DJ</span>, <span class="author">Sullivan JC</span>, <span class="author">Zhang EZ</span>, <span class="author">Tigges A</span>, <span class="author">Dierynck I</span>, et al. <span class="articleTitle">Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials</span>. <span class="journalTitle">PLoS One</span> <span class="pubYear">2012</span>;<span class="vol">7</span>:<span class="pageFirst">e34372</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1371%2Fjournal.pone.0034372">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/22511937">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000305338600023&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 52</a> | </li><li><a target="_blank" href="http://adsabs.harvard.edu/abs/2012PLoSO...734372K">ADS</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLoS%20One&amp;rft.atitle=Hepatitis%20C%20viral%20evolution%20in%20genotype%201%20treatment%E2%80%90naive%20and%20treatment%E2%80%90experienced%20patients%20receiving%20telaprevir%E2%80%90based%20therapy%20in%20clinical%20trials&amp;rft.volume=7&amp;rft.spage=e34372&amp;rft.date=2012&amp;rft.aulast=Kieffer&amp;rft.aufirst=TL&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0017"><span class="bullet">17</span><cite id="hep27934-cit-0017">  <span class="author">Jiang M</span>, <span class="author">Mani N</span>, <span class="author">Lin C</span>, <span class="author">Ardzinski A</span>, <span class="author">Nelson M</span>, <span class="author">Reagan D</span>, <span class="author">Bartels D</span>, et al. <span class="articleTitle">In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2013</span>;<span class="vol">57</span>:<span class="pageFirst">6236</span>-<span class="pageLast">6245</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.01578-13">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24100495">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXhvVCjur%252FN&amp;md5=712b8e20fae3e8c3d50860c8e9bfd327">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000328959900052&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 9</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=In%20vitro%20phenotypic%20characterization%20of%20hepatitis%20C%20virus%20NS3%20protease%20variants%20observed%20in%20clinical%20studies%20of%20telaprevir&amp;rft.volume=57&amp;rft.spage=6236&amp;rft.epage=6245&amp;rft.date=2013&amp;rft.aulast=Jiang&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0018"><span class="bullet">18</span><cite id="hep27934-cit-0018">  <span class="author">Lenz O</span>, <span class="author">Verbinnen T</span>, <span class="author">Lin TI</span>, <span class="author">Vijgen L</span>, <span class="author">Cummings MD</span>, <span class="author">Lindberg J</span>, <span class="author">Berke JM</span>, et al. <span class="articleTitle">In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2010</span>;<span class="vol">54</span>:<span class="pageFirst">1878</span>-<span class="pageLast">1887</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.01452-09">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20176898">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3cXmtFelsrc%253D&amp;md5=535910b53ba2ea4dec5a9998521e588c">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000276804300031&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 132</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=In%20vitro%20resistance%20profile%20of%20the%20hepatitis%20C%20virus%20NS3%2F4A%20protease%20inhibitor%20TMC435&amp;rft.volume=54&amp;rft.spage=1878&amp;rft.epage=1887&amp;rft.date=2010&amp;rft.aulast=Lenz&amp;rft.aufirst=O&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0019"><span class="bullet">19</span><cite id="hep27934-cit-0019">  <span class="author">Liverton NJ</span>, <span class="author">Carroll SS</span>, <span class="author">Dimuzio J</span>, <span class="author">Fandozzi C</span>, <span class="author">Graham DJ</span>, <span class="author">Hazuda D</span>, <span class="author">Holloway MK</span>, et al. <span class="articleTitle">MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2010</span>;<span class="vol">54</span>:<span class="pageFirst">305</span>-<span class="pageLast">311</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.00677-09">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/19841155">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3cXht1Shs7w%253D&amp;md5=f7ac1e8d2e93fc6a9ec39aa506745a2b">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000272931200039&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 81</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=MK%E2%80%907009%2C%20a%20potent%20and%20selective%20inhibitor%20of%20hepatitis%20C%20virus%20NS3%2F4A%20protease&amp;rft.volume=54&amp;rft.spage=305&amp;rft.epage=311&amp;rft.date=2010&amp;rft.aulast=Liverton&amp;rft.aufirst=NJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0020"><span class="bullet">20</span><cite id="hep27934-cit-0020">  <span class="author">Lam AM</span>, <span class="author">Espiritu C</span>, <span class="author">Bansal S</span>, <span class="author">Micolochick Steuer HM</span>, <span class="author">Niu C</span>, <span class="author">Zennou V</span>, <span class="author">Keilman M</span>, et al. <span class="articleTitle">Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2012</span>;<span class="vol">56</span>:<span class="pageFirst">3359</span>-<span class="pageLast">3368</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.00054-12">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/22430955">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC38XnslWrurc%253D&amp;md5=169f8bbd891de3fa51f5919345e33fe0">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000304432800074&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 68</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=Genotype%20and%20subtype%20profiling%20of%20PSI%E2%80%907977%20as%20a%20nucleotide%20inhibitor%20of%20hepatitis%20C%20virus&amp;rft.volume=56&amp;rft.spage=3359&amp;rft.epage=3368&amp;rft.date=2012&amp;rft.aulast=Lam&amp;rft.aufirst=AM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0021"><span class="bullet">21</span><cite id="hep27934-cit-0021">  <span class="author">Gao M</span>, <span class="author">Nettles RE</span>, <span class="author">Belema M</span>, <span class="author">Snyder LB</span>, <span class="author">Nguyen VN</span>, <span class="author">Fridell RA</span>, <span class="author">Serrano-Wu MH</span>, et al. <span class="articleTitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span>. <span class="journalTitle">Nature</span> <span class="pubYear">2010</span>;<span class="vol">465</span>:<span class="pageFirst">96</span>-<span class="pageLast">100</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1038%2Fnature08960">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20410884">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3cXltVGhtbo%253D&amp;md5=62e1cffbcfa56be2bddcb5dd1380d237">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000277311900038&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 455</a> | </li><li><a target="_blank" href="http://adsabs.harvard.edu/abs/2010Natur.465...96G">ADS</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature&amp;rft.atitle=Chemical%20genetics%20strategy%20identifies%20an%20HCV%20NS5A%20inhibitor%20with%20a%20potent%20clinical%20effect&amp;rft.volume=465&amp;rft.spage=96&amp;rft.epage=100&amp;rft.date=2010&amp;rft.aulast=Gao&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0022"><span class="bullet">22</span><cite id="hep27934-cit-0022">  <span class="author">Poordad F</span>, <span class="author">Lawitz E</span>, <span class="author">Kowdley KV</span>, <span class="author">Cohen DE</span>, <span class="author">Podsadecki T</span>, <span class="author">Siggelkow S</span>, <span class="author">Heckaman M</span>, et al. <span class="articleTitle">Exploratory study of oral combination antiviral therapy for hepatitis C</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2013</span>;<span class="vol">368</span>:<span class="pageFirst">45</span>-<span class="pageLast">53</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1208809">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23281975">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXlvFajtw%253D%253D&amp;md5=61e91db1e4afb39c7929c57045fac0d2">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000312930600004&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 146</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Exploratory%20study%20of%20oral%20combination%20antiviral%20therapy%20for%20hepatitis%20C&amp;rft.volume=368&amp;rft.spage=45&amp;rft.epage=53&amp;rft.date=2013&amp;rft.aulast=Poordad&amp;rft.aufirst=F&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0023"><span class="bullet">23</span><cite id="hep27934-cit-0023">  <span class="author">McPhee F</span>, <span class="author">Friborg J</span>, <span class="author">Levine S</span>, <span class="author">Chen C</span>, <span class="author">Falk P</span>, <span class="author">Yu F</span>, <span class="author">Hernandez D</span>, et al. <span class="articleTitle">Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2012</span>;<span class="vol">56</span>:<span class="pageFirst">3670</span>-<span class="pageLast">3681</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.00308-12">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/22508297">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC38XpsV2is7s%253D&amp;md5=8f20a5870a563f8c4ec4860dda575307">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000305673000029&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 44</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=Resistance%20analysis%20of%20the%20hepatitis%20C%20virus%20NS3%20protease%20inhibitor%20asunaprevir&amp;rft.volume=56&amp;rft.spage=3670&amp;rft.epage=3681&amp;rft.date=2012&amp;rft.aulast=McPhee&amp;rft.aufirst=F&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0024"><span class="bullet">24</span><cite id="hep27934-cit-0024">  <span class="author">Pilot-Matias TJ</span>, <span class="author">Tripathi, R.L.</span>, <span class="author">Dekhtyar, T</span>, <span class="author">Menon, R.M.</span>, <span class="author">Gaultier, I.A.</span>, <span class="author">Cohen, D.E.</span>, <span class="author">Podsadecki, T.J.</span>, <span class="author">Bernstein, B.M.</span>, <span class="author">Collins, C.A.</span> Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450. EASL 2011 Conference <span class="pubYear">2011</span>:Abstract #1229. </cite></li><li id="hep27934-bib-0025"><span class="bullet">25</span><cite id="hep27934-cit-0025">  <span class="author">Krishnan P</span>, <span class="author">Beyer, J.</span>, <span class="author">Mistry, N.</span>, <span class="author">Koev, G.</span>, <span class="author">Reisch, T.</span>, <span class="author">Mondal, R.</span>, <span class="author">Liu, D.</span>, <span class="author">Pratt, J.</span>, <span class="author">DeGoey, D.</span>, <span class="author">Wagner, R.</span>, <span class="author">Maring, C.</span>, <span class="author">Kati, W.</span>, <span class="author">Molla, A.</span>, <span class="author">Campbell, A.</span>, <span class="author">Bernstein, B.</span>, <span class="author">Williams, L.</span>, <span class="author">Collins, C.</span>, <span class="author">Pilot-Matias, T.</span> Antiviral activity and resistance profiles for ABT-267, a novel HCV NS5A inhibitor, in vitro and during 3-day monotherapy in HCV genotype-1 (GT1)-infected treatment-na&iuml;ve subjects. AASLD 2012 Conference <span class="pubYear">2012</span>. </cite></li><li id="hep27934-bib-0026"><span class="bullet">26</span><cite id="hep27934-cit-0026">  <span class="author">Middleton T</span>, <span class="author">He, Y.</span>, <span class="author">Beyer, J.</span>, <span class="author">Menon, R.</span>, <span class="author">Klein, C.E.</span>, <span class="author">Cohen, D.</span>, <span class="author">Collins, C.</span> Resistance profile of ABT-333 and relationship to viral load decrease in patients treated in combination with peg-interferon and ribavirin for 28 days. EASL 2010 Conference 2010. </cite></li><li id="hep27934-bib-0027"><span class="bullet">27</span><cite id="hep27934-cit-0027">  <span class="author">Lemm JA</span>, <span class="author">Liu M</span>, <span class="author">Gentles RG</span>, <span class="author">Ding M</span>, <span class="author">Voss S</span>, <span class="author">Pelosi LA</span>, <span class="author">Wang YK</span>, et al. <span class="articleTitle">Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2014</span>;<span class="vol">58</span>:<span class="pageFirst">3485</span>-<span class="pageLast">3495</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.02495-13">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24733465">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhtlCntLjF&amp;md5=8cb9d976b2ed83bee22e986610c9baa3">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000338776900062&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 17</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=Preclinical%20characterization%20of%20BMS%E2%80%90791325%2C%20an%20allosteric%20inhibitor%20of%20hepatitis%20C%20Virus%20NS5B%20polymerase&amp;rft.volume=58&amp;rft.spage=3485&amp;rft.epage=3495&amp;rft.date=2014&amp;rft.aulast=Lemm&amp;rft.aufirst=JA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0028"><span class="bullet">28</span><cite id="hep27934-cit-0028">  <span class="author">Romano KP</span>, <span class="author">Ali A</span>, <span class="author">Aydin C</span>, <span class="author">Soumana D</span>, <span class="author">Ozen A</span>, <span class="author">Deveau LM</span>, <span class="author">Silver C</span>, et al. <span class="articleTitle">The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors</span>. <span class="journalTitle">PLoS Pathog</span> <span class="pubYear">2012</span>;<span class="vol">8</span>:<span class="pageFirst">e1002832</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1371%2Fjournal.ppat.1002832">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/22910833">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000306837700047&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 45</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLoS%20Pathog&amp;rft.atitle=The%20molecular%20basis%20of%20drug%20resistance%20against%20hepatitis%20C%20virus%20NS3%2F4A%20protease%20inhibitors&amp;rft.volume=8&amp;rft.spage=e1002832&amp;rft.date=2012&amp;rft.aulast=Romano&amp;rft.aufirst=KP&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0029"><span class="bullet">29</span><cite id="hep27934-cit-0029">  <span class="author">Schinazi R</span>, <span class="author">Halfon P</span>, <span class="author">Marcellin P</span>, <span class="author">Asselah T.</span> <span class="articleTitle">HCV direct-acting antiviral agents: the best interferon-free combinations</span>. <span class="journalTitle">Liver Int</span> <span class="pubYear">2014</span>;<span class="vol">34</span> <span class="citedIssue">Suppl 1</span>:<span class="pageFirst">69</span>-<span class="pageLast">78</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list" data-on-platform="true" data-doi="10.1111/liv.12423"><li><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/liv.12423">Wiley Online Library</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24373081">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXkslSr&amp;md5=b75050f57cc52f08b55de94cabe0f53a">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000337524000012&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 83</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Liver%20Int&amp;rft.atitle=HCV%20direct%E2%80%90acting%20antiviral%20agents%3A%20the%20best%20interferon%E2%80%90free%20combinations&amp;rft.volume=34&amp;rft.issue=Suppl%201&amp;rft.spage=69&amp;rft.epage=78&amp;rft.date=2014&amp;rft.aulast=Schinazi&amp;rft.aufirst=R&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0030"><span class="bullet">30</span><cite id="hep27934-cit-0030">  <span class="author">Sarrazin C</span>, <span class="author">Zeuzem S.</span> <span class="articleTitle">Resistance to direct antiviral agents in patients with hepatitis C virus infection</span>. <span class="journalTitle">Gastroenterology</span> <span class="pubYear">2010</span>;<span class="vol">138</span>:<span class="pageFirst">447</span>-<span class="pageLast">462</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1053%2Fj.gastro.2009.11.055">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/20006612">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3cXivVCgu7c%253D&amp;md5=3fd8c99aaffd275ac3d5246a1d579c49">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000274300900012&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 326</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Resistance%20to%20direct%20antiviral%20agents%20in%20patients%20with%20hepatitis%20C%20virus%20infection&amp;rft.volume=138&amp;rft.spage=447&amp;rft.epage=462&amp;rft.date=2010&amp;rft.aulast=Sarrazin&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0031"><span class="bullet">31</span><cite id="hep27934-cit-0031">  <span class="author">Welsch C</span>, <span class="author">Jesudian A</span>, <span class="author">Zeuzem S</span>, <span class="author">Jacobson I.</span> <span class="articleTitle">New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives</span>. <span class="journalTitle">Gut</span> <span class="pubYear">2012</span>;<span class="vol">61</span> <span class="citedIssue">Suppl 1</span>:<span class="pageFirst">i36</span>-<span class="pageLast">46</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1136%2Fgutjnl-2012-302144">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/22504918">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC38Xptl2ju7o%253D&amp;md5=69f5e460075439e5e4de8aae148a122e">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000302792300005&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 94</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gut&amp;rft.atitle=New%20direct%E2%80%90acting%20antiviral%20agents%20for%20the%20treatment%20of%20hepatitis%20C%20virus%20infection%20and%20perspectives&amp;rft.volume=61&amp;rft.issue=Suppl%201&amp;rft.spage=i36&amp;rft.epage=46&amp;rft.date=2012&amp;rft.aulast=Welsch&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0032"><span class="bullet">32</span><cite id="hep27934-cit-0032">  <span class="author">Sullivan JC</span>, <span class="author">De Meyer S</span>, <span class="author">Bartels DJ</span>, <span class="author">Dierynck I</span>, <span class="author">Zhang EZ</span>, <span class="author">Spanks J</span>, <span class="author">Tigges AM</span>, et al. <span class="articleTitle">Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials</span>. <span class="journalTitle">Clin Infect Dis</span> <span class="pubYear">2013</span>;<span class="vol">57</span>:<span class="pageFirst">221</span>-<span class="pageLast">229</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1093%2Fcid%2Fcit226">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23575197">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXhtVeisLbP&amp;md5=d351fb699108db36aa0ae7d90d20adf3">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000321051600010&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 49</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Infect%20Dis&amp;rft.atitle=Evolution%20of%20treatment%E2%80%90emergent%20resistant%20variants%20in%20telaprevir%20phase%203%20clinical%20trials&amp;rft.volume=57&amp;rft.spage=221&amp;rft.epage=229&amp;rft.date=2013&amp;rft.aulast=Sullivan&amp;rft.aufirst=JC&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0033"><span class="bullet">33</span><cite id="hep27934-cit-0033">  <span class="author">Jacobson IM</span>, <span class="author">Dore GJ</span>, <span class="author">Foster GR</span>, <span class="author">Fried MW</span>, <span class="author">Radu M</span>, <span class="author">Rafalsky VV</span>, <span class="author">Moroz L</span>, et al. <span class="articleTitle">Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial</span>. <span class="journalTitle">Lancet</span> <span class="pubYear">2014</span>;<span class="vol">384</span>:<span class="pageFirst">403</span>-<span class="pageLast">413</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2FS0140-6736%2814%2960494-3">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24907225">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXpslCnuro%253D&amp;md5=05bf64facd8daefd4f53e1c33dd76a5e">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000340195800024&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 146</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Simeprevir%20with%20pegylated%20interferon%20alfa%202a%20plus%20ribavirin%20in%20treatment%E2%80%90naive%20patients%20with%20chronic%20hepatitis%20C%20virus%20genotype%201%20infection%20%28QUEST%E2%80%901%29%3A%20a%20phase%203%2C%20randomised%2C%20double%E2%80%90blind%2C%20placebo%E2%80%90controlled%20trial&amp;rft.volume=384&amp;rft.spage=403&amp;rft.epage=413&amp;rft.date=2014&amp;rft.aulast=Jacobson&amp;rft.aufirst=IM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0034"><span class="bullet">34</span><cite id="hep27934-cit-0034">  <span class="author">Manns M</span>, <span class="author">Marcellin P</span>, <span class="author">Poordad F</span>, <span class="author">de Araujo ES</span>, <span class="author">Buti M</span>, <span class="author">Horsmans Y</span>, <span class="author">Janczewska E</span>, et al. <span class="articleTitle">Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial</span>. <span class="journalTitle">Lancet</span> <span class="pubYear">2014</span>;<span class="vol">384</span>:<span class="pageFirst">414</span>-<span class="pageLast">426</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2FS0140-6736%2814%2960538-9">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24907224">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXpslCnur0%253D&amp;md5=61e15d67953466717a51c8bbd15b3b76">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000340195800025&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 130</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Simeprevir%20with%20pegylated%20interferon%20alfa%202a%20or%202b%20plus%20ribavirin%20in%20treatment%E2%80%90naive%20patients%20with%20chronic%20hepatitis%20C%20virus%20genotype%201%20infection%20%28QUEST%E2%80%902%29%3A%20a%20randomised%2C%20double%E2%80%90blind%2C%20placebo%E2%80%90controlled%20phase%203%20trial&amp;rft.volume=384&amp;rft.spage=414&amp;rft.epage=426&amp;rft.date=2014&amp;rft.aulast=Manns&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0035"><span class="bullet">35</span><cite id="hep27934-cit-0035">  <span class="author">Forns X</span>, <span class="author">Lawitz E</span>, <span class="author">Zeuzem S</span>, <span class="author">Gane E</span>, <span class="author">Bronowicki JP</span>, <span class="author">Andreone P</span>, <span class="author">Horban A</span>, et al. <span class="articleTitle">Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial</span>. <span class="journalTitle">Gastroenterology</span> <span class="pubYear">2014</span>;<span class="vol">146</span>:<span class="pageFirst">1669</span>-<span class="pageLast">1679 e1663</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1053%2Fj.gastro.2014.02.051">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24602923">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXoslClt7g%253D&amp;md5=deb7f72d9d9f99e279bd1abec93effce">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000336500900022&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 89</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Simeprevir%20with%20peginterferon%20and%20ribavirin%20leads%20to%20high%20rates%20of%20SVR%20in%20patients%20with%20HCV%20genotype%201%20who%20relapsed%20after%20previous%20therapy%3A%20a%20phase%203%20trial&amp;rft.volume=146&amp;rft.spage=1669&amp;rft.epage=1679%20e1663&amp;rft.date=2014&amp;rft.aulast=Forns&amp;rft.aufirst=X&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0036"><span class="bullet">36</span><cite id="hep27934-cit-0036"><span class="groupName">US Food and Drug Administration</span>. Simeprevir product insert. <span class="pubYear">2013</span>;<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf" title="Link to external resource: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf</a>. </cite></li><li id="hep27934-bib-0037"><span class="bullet">37</span><cite id="hep27934-cit-0037">  <span class="author">Lawitz E</span>, <span class="author">Sulkowski MS</span>, <span class="author">Ghalib R</span>, <span class="author">Rodriguez-Torres M</span>, <span class="author">Younossi ZM</span>, <span class="author">Corregidor A</span>, <span class="author">DeJesus E</span>, et al. <span class="articleTitle">Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study</span>. <span class="journalTitle">Lancet</span> <span class="pubYear">2014</span>;<span class="vol">384</span>:<span class="pageFirst">1756</span>-<span class="pageLast">1765</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2FS0140-6736%2814%2961036-9">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25078309">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhtlSru7vM&amp;md5=b74d43be8bad90f2d4ac99a75404b99f">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000345116400026&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 184</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Simeprevir%20plus%20sofosbuvir%2C%20with%20or%20without%20ribavirin%2C%20to%20treat%20chronic%20infection%20with%20hepatitis%20C%20virus%20genotype%201%20in%20non%E2%80%90responders%20to%20pegylated%20interferon%20and%20ribavirin%20and%20treatment%E2%80%90naive%20patients%3A%20the%20COSMOS%20randomised%20study&amp;rft.volume=384&amp;rft.spage=1756&amp;rft.epage=1765&amp;rft.date=2014&amp;rft.aulast=Lawitz&amp;rft.aufirst=E&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0038"><span class="bullet">38</span><cite id="hep27934-cit-0038">  <span class="author">Lenz O</span>, <span class="author">Verbinnen T</span>, <span class="author">Fevery B</span>, <span class="author">Tambuyzer L</span>, <span class="author">Vijgen L</span>, <span class="author">Peeters M</span>, <span class="author">Buelens A</span>, et al. <span class="articleTitle">Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies</span>. <span class="journalTitle">J Hepatol</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25445400">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000353124800007&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 15</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Hepatol&amp;rft.atitle=Virology%20analyses%20of%20HCV%20isolates%20from%20genotype%201%E2%80%90infected%20patients%20treated%20with%20simeprevir%20plus%20peginterferon%2Fribavirin%20in%20Phase%20IIb%2FIII%20studies&amp;rft.date=2014&amp;rft.aulast=Lenz&amp;rft.aufirst=O&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0039"><span class="bullet">39</span><cite id="hep27934-cit-0039">  <span class="author">Kwo P</span>, <span class="author">Lawitz E</span>, al. e. A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir(SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection with or without cirrhosis: OPTOMIST-1/2. EASL 2015 Conference 2015:Poster LP14. </cite></li><li id="hep27934-bib-0040"><span class="bullet">40</span><cite id="hep27934-cit-0040">  <span class="author">Manns M</span>, <span class="author">Pol S</span>, <span class="author">Jacobson IM</span>, <span class="author">Marcellin P</span>, <span class="author">Gordon SC</span>, <span class="author">Peng CY</span>, <span class="author">Chang TT</span>, et al. <span class="articleTitle">All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study</span>. <span class="journalTitle">Lancet</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2FS0140-6736%2814%2961059-X">CrossRef</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000343901700028&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 83</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=All%E2%80%90oral%20daclatasvir%20plus%20asunaprevir%20for%20hepatitis%20C%20virus%20genotype%201b%3A%20a%20multinational%2C%20phase%203%2C%20multicohort%20study&amp;rft.date=2014&amp;rft.aulast=Manns&amp;rft.aufirst=M&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0041"><span class="bullet">41</span><cite id="hep27934-cit-0041">  <span class="author">Lok AS</span>, <span class="author">Gardiner DF</span>, <span class="author">Hezode C</span>, <span class="author">Lawitz EJ</span>, <span class="author">Bourliere M</span>, <span class="author">Everson GT</span>, <span class="author">Marcellin P</span>, et al. <span class="articleTitle">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span>. <span class="journalTitle">J Hepatol</span> <span class="pubYear">2014</span>;<span class="vol">60</span>:<span class="pageFirst">490</span>-<span class="pageLast">499</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.jhep.2013.10.019">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24444658">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXjtlartw%253D%253D&amp;md5=78d492dccd0801d1f52e738444ad6d86">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000331498700007&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 69</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Hepatol&amp;rft.atitle=Randomized%20trial%20of%20daclatasvir%20and%20asunaprevir%20with%20or%20without%20PegIFN%2FRBV%20for%20hepatitis%20C%20virus%20genotype%201%20null%20responders&amp;rft.volume=60&amp;rft.spage=490&amp;rft.epage=499&amp;rft.date=2014&amp;rft.aulast=Lok&amp;rft.aufirst=AS&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0042"><span class="bullet">42</span><cite id="hep27934-cit-0042">  <span class="author">Lok AS</span>, <span class="author">Gardiner DF</span>, <span class="author">Lawitz E</span>, <span class="author">Martorell C</span>, <span class="author">Everson GT</span>, <span class="author">Ghalib R</span>, <span class="author">Reindollar R</span>, et al. <span class="articleTitle">Preliminary study of two antiviral agents for hepatitis C genotype 1</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2012</span>;<span class="vol">366</span>:<span class="pageFirst">216</span>-<span class="pageLast">224</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1104430">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/22256805">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC38Xht1yltrw%253D&amp;md5=b4c161259728cd88385471b43027d84b">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000299201400007&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 359</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Preliminary%20study%20of%20two%20antiviral%20agents%20for%20hepatitis%20C%20genotype%201&amp;rft.volume=366&amp;rft.spage=216&amp;rft.epage=224&amp;rft.date=2012&amp;rft.aulast=Lok&amp;rft.aufirst=AS&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0043"><span class="bullet">43</span><cite id="hep27934-cit-0043">  <span class="author">Everson GT</span>, <span class="author">Sims KD</span>, <span class="author">Rodriguez-Torres M</span>, <span class="author">Hezode C</span>, <span class="author">Lawitz E</span>, <span class="author">Bourliere M</span>, <span class="author">Loustaud-Ratti V</span>, et al. <span class="articleTitle">Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection</span>. <span class="journalTitle">Gastroenterology</span> <span class="pubYear">2014</span>;<span class="vol">146</span>:<span class="pageFirst">420</span>-<span class="pageLast">429</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1053%2Fj.gastro.2013.10.057">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24184132">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhsVyitr4%253D&amp;md5=f9f36092d115834c0c7ad9d79616ff8f">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000329757800023&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 103</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Efficacy%20of%20an%20interferon%E2%80%90%20and%20ribavirin%E2%80%90free%20regimen%20of%20daclatasvir%2C%20asunaprevir%2C%20and%20BMS%E2%80%90791325%20in%20treatment%E2%80%90naive%20patients%20with%20HCV%20genotype%201%20infection&amp;rft.volume=146&amp;rft.spage=420&amp;rft.epage=429&amp;rft.date=2014&amp;rft.aulast=Everson&amp;rft.aufirst=GT&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0044"><span class="bullet">44</span><cite id="hep27934-cit-0044">  <span class="author">Bronowicki JP</span>, <span class="author">Ratziu V</span>, <span class="author">Gadano A</span>, <span class="author">Thuluvath PJ</span>, <span class="author">Bessone F</span>, <span class="author">Martorell CT</span>, <span class="author">Pol S</span>, et al. <span class="articleTitle">Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C</span>. <span class="journalTitle">J Hepatol</span> <span class="pubYear">2014</span>;<span class="vol">61</span>:<span class="pageFirst">1220</span>-<span class="pageLast">1227</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.jhep.2014.07.011">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25038486">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhs1ShsLjI&amp;md5=1e973f11d6e15425c7f35daa8586afe8">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000345115600007&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 10</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Hepatol&amp;rft.atitle=Randomized%20trial%20of%20asunaprevir%20plus%20peginterferon%20alfa%20and%20ribavirin%20for%20previously%20untreated%20genotype%201%20or%204%20chronic%20hepatitis%20C&amp;rft.volume=61&amp;rft.spage=1220&amp;rft.epage=1227&amp;rft.date=2014&amp;rft.aulast=Bronowicki&amp;rft.aufirst=JP&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0045"><span class="bullet">45</span><cite id="hep27934-cit-0045">  <span class="author">Poordad F</span>, <span class="author">Hezode C</span>, <span class="author">Trinh R</span>, <span class="author">Kowdley KV</span>, <span class="author">Zeuzem S</span>, <span class="author">Agarwal K</span>, <span class="author">Shiffman ML</span>, et al. <span class="articleTitle">ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2014</span>;<span class="vol">370</span>:<span class="pageFirst">1973</span>-<span class="pageLast">1982</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1402869">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24725237">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhsVGkt77L&amp;md5=034ed3bbfbd2ae54d7a31d1da984456a">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000336125500005&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 225</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=ABT%E2%80%90450%2Fr%E2%80%90ombitasvir%20and%20dasabuvir%20with%20ribavirin%20for%20hepatitis%20C%20with%20cirrhosis&amp;rft.volume=370&amp;rft.spage=1973&amp;rft.epage=1982&amp;rft.date=2014&amp;rft.aulast=Poordad&amp;rft.aufirst=F&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0046"><span class="bullet">46</span><cite id="hep27934-cit-0046">  <span class="author">Zeuzem S</span>, <span class="author">Jacobson IM</span>, <span class="author">Baykal T</span>, <span class="author">Marinho RT</span>, <span class="author">Poordad F</span>, <span class="author">Bourliere M</span>, <span class="author">Sulkowski MS</span>, et al. <span class="articleTitle">Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2014</span>;<span class="vol">370</span>:<span class="pageFirst">1604</span>-<span class="pageLast">1614</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1401561">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24720679">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXnt1Grsrk%253D&amp;md5=d7ef38d9c7912aee7eb3ff73f51bc7c6">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000336120500007&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 169</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Retreatment%20of%20HCV%20with%20ABT%E2%80%90450%2Fr%E2%80%90ombitasvir%20and%20dasabuvir%20with%20ribavirin&amp;rft.volume=370&amp;rft.spage=1604&amp;rft.epage=1614&amp;rft.date=2014&amp;rft.aulast=Zeuzem&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0047"><span class="bullet">47</span><cite id="hep27934-cit-0047">  <span class="author">Feld JJ</span>, <span class="author">Kowdley KV</span>, <span class="author">Coakley E</span>, <span class="author">Sigal S</span>, <span class="author">Nelson DR</span>, <span class="author">Crawford D</span>, <span class="author">Weiland O</span>, et al. <span class="articleTitle">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2014</span>;<span class="vol">370</span>:<span class="pageFirst">1594</span>-<span class="pageLast">1603</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1315722">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24720703">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXnt1Grsrg%253D&amp;md5=cf434f93c12d137860c2e87cbaeb1ad8">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000336120500006&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 225</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Treatment%20of%20HCV%20with%20ABT%E2%80%90450%2Fr%E2%80%90ombitasvir%20and%20dasabuvir%20with%20ribavirin&amp;rft.volume=370&amp;rft.spage=1594&amp;rft.epage=1603&amp;rft.date=2014&amp;rft.aulast=Feld&amp;rft.aufirst=JJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0048"><span class="bullet">48</span><cite id="hep27934-cit-0048"><span class="groupName">U.S. Food and Drug Administration</span>. Viekira Pak product insert. <span class="pubYear">2014</span>; <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf" title="Link to external resource: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf</a>. </cite></li><li id="hep27934-bib-0049"><span class="bullet">49</span><cite id="hep27934-cit-0049">  <span class="author">Schnell G TR</span>, <span class="author">Beyer J</span>, <span class="author">Reisch T</span>, <span class="author">Krishnan P</span>, <span class="author">Baykal T</span>, <span class="author">Hall C</span>, Vilchez, <span class="author">Pilot-Matias T</span>, <span class="author">Collins C.</span> <span class="articleTitle">Identification and treatment of multiple subtypes of HCV genotype 4 in the PEARL-I study with ombitasvir and ABT-450/r&thinsp;&plusmn;&thinsp;ribavirin</span>. <span class="journalTitle">Hepatology</span> <span class="pubYear">2014</span>;<span class="vol">60</span>:<span class="pageFirst">1146A</span>, Abstract 1954. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000344483805029&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 1</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=Identification%20and%20treatment%20of%20multiple%20subtypes%20of%20HCV%20genotype%204%20in%20the%20PEARL%E2%80%90I%20study%20with%20ombitasvir%20and%20ABT%E2%80%90450%2Fr%E2%80%89%C2%B1%E2%80%89ribavirin&amp;rft.volume=60&amp;rft.spage=1146A&amp;rft.date=2014&amp;rft.aulast=Schnell&amp;rft.aufirst=G%20TR&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0050"><span class="bullet">50</span><cite id="hep27934-cit-0050">  <span class="author">Barnard RJ</span>, <span class="author">McHale CM</span>, <span class="author">Newhard W</span>, <span class="author">Cheney CA</span>, <span class="author">Graham DJ</span>, <span class="author">Himmelberger AL</span>, <span class="author">Strizki J</span>, et al. <span class="articleTitle">Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis</span>. <span class="journalTitle">Virology</span> <span class="pubYear">2013</span>;<span class="vol">443</span>:<span class="pageFirst">278</span>-<span class="pageLast">284</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.virol.2013.05.013">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23763767">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXptFKktrw%253D&amp;md5=dcb9559a6625c9def016ff907f95a0fd">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000322686700012&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 12</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Virology&amp;rft.atitle=Emergence%20of%20resistance%E2%80%90associated%20variants%20after%20failed%20triple%20therapy%20with%20vaniprevir%20in%20treatment%E2%80%90experienced%20non%E2%80%90cirrhotic%20patients%20with%20hepatitis%20C%E2%80%90genotype%201%20infection%3A%20a%20population%20and%20clonal%20analysis&amp;rft.volume=443&amp;rft.spage=278&amp;rft.epage=284&amp;rft.date=2013&amp;rft.aulast=Barnard&amp;rft.aufirst=RJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0051"><span class="bullet">51</span><cite id="hep27934-cit-0051">  <span class="author">Lawitz E</span>, <span class="author">Sulkowski M</span>, <span class="author">Jacobson I</span>, <span class="author">Kraft WK</span>, <span class="author">Maliakkal B</span>, <span class="author">Al-Ibrahim M</span>, <span class="author">Gordon SC</span>, et al. <span class="articleTitle">Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics</span>. <span class="journalTitle">Antiviral Res</span> <span class="pubYear">2013</span>;<span class="vol">99</span>:<span class="pageFirst">214</span>-<span class="pageLast">220</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.antiviral.2013.05.015">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23747481">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXhsFemtLrF&amp;md5=894e42055c4335ed72206583ed7f4e76">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000327108300003&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 11</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antiviral%20Res&amp;rft.atitle=Characterization%20of%20vaniprevir%2C%20a%20hepatitis%20C%20virus%20NS3%2F4A%20protease%20inhibitor%2C%20in%20patients%20with%20HCV%20genotype%201%20infection%3A%20safety%2C%20antiviral%20activity%2C%20resistance%2C%20and%20pharmacokinetics&amp;rft.volume=99&amp;rft.spage=214&amp;rft.epage=220&amp;rft.date=2013&amp;rft.aulast=Lawitz&amp;rft.aufirst=E&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0052"><span class="bullet">52</span><cite id="hep27934-cit-0052">  <span class="author">McGivern DR</span>, <span class="author">Masaki T</span>, <span class="author">Williford S</span>, <span class="author">Ingravallo P</span>, <span class="author">Feng Z</span>, <span class="author">Lahser F</span>, <span class="author">Asante-Appiah E</span>, et al. <span class="articleTitle">Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors</span>. <span class="journalTitle">Gastroenterology</span> <span class="pubYear">2014</span>;<span class="vol">147</span>:<span class="pageFirst">453</span>-<span class="pageLast">462 e457</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1053%2Fj.gastro.2014.04.021">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24768676">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhtVemtrzI&amp;md5=f169bc0b9500eebb36638d6092ff1bd2">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000340447800033&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 27</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Kinetic%20analyses%20reveal%20potent%20and%20early%20blockade%20of%20hepatitis%20C%20virus%20assembly%20by%20NS5A%20inhibitors&amp;rft.volume=147&amp;rft.spage=453&amp;rft.epage=462%20e457&amp;rft.date=2014&amp;rft.aulast=McGivern&amp;rft.aufirst=DR&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0053"><span class="bullet">53</span><cite id="hep27934-cit-0053">  <span class="author">Berger C</span>, <span class="author">Romero-Brey I</span>, <span class="author">Radujkovic D</span>, <span class="author">Terreux R</span>, <span class="author">Zayas M</span>, <span class="author">Paul D</span>, <span class="author">Harak C</span>, et al. <span class="articleTitle">Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus-Induced Membranous Replication Factories, Independent of RNA Replication</span>. <span class="journalTitle">Gastroenterology</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1053%2Fj.gastro.2014.07.019">CrossRef</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000344234200031&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 30</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Daclatasvir%E2%80%90Like%20Inhibitors%20of%20NS5A%20Block%20Early%20Biogenesis%20of%20Hepatitis%20C%20Virus%E2%80%90Induced%20Membranous%20Replication%20Factories%2C%20Independent%20of%20RNA%20Replication&amp;rft.date=2014&amp;rft.aulast=Berger&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0054"><span class="bullet">54</span><cite id="hep27934-cit-0054">  <span class="author">Fridell RA</span>, <span class="author">Wang C</span>, <span class="author">Sun JH</span>, <span class="author">O'Boyle DR, 2nd</span>, <span class="author">Nower P</span>, <span class="author">Valera L</span>, <span class="author">Qiu D</span>, et al. <span class="articleTitle">Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations</span>. <span class="journalTitle">Hepatology</span> <span class="pubYear">2011</span>;<span class="vol">54</span>:<span class="pageFirst">1924</span>-<span class="pageLast">1935</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list" data-on-platform="true" data-doi="10.1002/hep.24594"><li><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1002/hep.24594">Wiley Online Library</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/21809362">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3MXhsFCqsL3F&amp;md5=91e3b2b3af556824a378042c51bf017c">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000297974900005&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 110</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=Genotypic%20and%20phenotypic%20analysis%20of%20variants%20resistant%20to%20hepatitis%20C%20virus%20nonstructural%20protein%205A%20replication%20complex%20inhibitor%20BMS%E2%80%90790052%20in%20humans%3A%20in%20vitro%20and%20in%20vivo%20correlations&amp;rft.volume=54&amp;rft.spage=1924&amp;rft.epage=1935&amp;rft.date=2011&amp;rft.aulast=Fridell&amp;rft.aufirst=RA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0055"><span class="bullet">55</span><cite id="hep27934-cit-0055">  <span class="author">Dore GJ</span>, <span class="author">Lawitz E</span>, <span class="author">Hezode C</span>, <span class="author">Shafran SD</span>, <span class="author">Ramji A</span>, <span class="author">Tatum HA</span>, <span class="author">Taliani G</span>, et al. <span class="articleTitle">Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection</span>. <span class="journalTitle">Gastroenterology</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25311593">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000348050700024&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 8</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gastroenterology&amp;rft.atitle=Daclatasvir%20plus%20Peginterferon%20and%20Ribavirin%20is%20Non%E2%80%90inferior%20to%20Peginterferon%20and%20Ribavirin%20Alone%2C%20and%20Reduces%20Duration%20of%20Treatment%20for%20HCV%20Genotype%202%20or%203%20Infection&amp;rft.date=2014&amp;rft.aulast=Dore&amp;rft.aufirst=GJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0056"><span class="bullet">56</span><cite id="hep27934-cit-0056">  <span class="author">Lawitz E</span>, <span class="author">Sullivan G</span>, <span class="author">Rodriguez-Torres M</span>, <span class="author">Bennett M</span>, <span class="author">Poordad F</span>, <span class="author">Kapoor M</span>, <span class="author">Badri P</span>, et al. <span class="articleTitle">Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection</span>. <span class="journalTitle">J Infect</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25246359">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000348039900011&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 12</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Infect&amp;rft.atitle=Exploratory%20trial%20of%20ombitasvir%20and%20ABT%E2%80%90450%2Fr%20with%20or%20without%20ribavirin%20for%20HCV%20genotype%201%2C%202%2C%20and%203%20infection&amp;rft.date=2014&amp;rft.aulast=Lawitz&amp;rft.aufirst=E&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0057"><span class="bullet">57</span><cite id="hep27934-cit-0057"><span class="groupName">US Food and Drug Administration</span>. Harvoni product insert. <span class="pubYear">2014</span>; <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf" title="Link to external resource: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf</a>. </cite></li><li id="hep27934-bib-0058"><span class="bullet">58</span><cite id="hep27934-cit-0058">  <span class="author">Europeans Medicines Agency</span>. Daklinza European public assessment report. <span class="pubYear">2014</span>; <a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf" title="Link to external resource: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf" target="_blank">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf</a>. </cite></li><li id="hep27934-bib-0059"><span class="bullet">59</span><cite id="hep27934-cit-0059">  <span class="author">Nelson DR</span>, <span class="author">Cooper JN</span>, <span class="author">Lalezari JP</span>, <span class="author">Lawitz E</span>, <span class="author">Pockros PJ</span>, <span class="author">Gitlin N</span>, <span class="author">Freilich BF</span>, et al. <span class="articleTitle">All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study</span>. <span class="journalTitle">Hepatology</span> <span class="pubYear">2015</span>;<span class="vol">61</span>:<span class="pageFirst">1127</span>-<span class="pageLast">1135</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list" data-on-platform="true" data-doi="10.1002/hep.27726"><li><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1002/hep.27726">Wiley Online Library</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25614962">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2MXlt1WktLw%253D&amp;md5=cb50cc4c5efd4bcb06f780ccd6cee08f">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000352099700009&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 72</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=All%E2%80%90oral%2012%E2%80%90week%20treatment%20with%20daclatasvir%20plus%20sofosbuvir%20in%20patients%20with%20hepatitis%20C%20virus%20genotype%203%20infection%3A%20ALLY%E2%80%903%20phase%20III%20study&amp;rft.volume=61&amp;rft.spage=1127&amp;rft.epage=1135&amp;rft.date=2015&amp;rft.aulast=Nelson&amp;rft.aufirst=DR&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0060"><span class="bullet">60</span><cite id="hep27934-cit-0060">  <span class="author">Lawitz EJ</span>, <span class="author">Gruener D</span>, <span class="author">Hill JM</span>, <span class="author">Marbury T</span>, <span class="author">Moorehead L</span>, <span class="author">Mathias A</span>, <span class="author">Cheng G</span>, et al. <span class="articleTitle">A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C</span>. <span class="journalTitle">J Hepatol</span> <span class="pubYear">2012</span>;<span class="vol">57</span>:<span class="pageFirst">24</span>-<span class="pageLast">31</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.jhep.2011.12.029">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/22314425">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC38XovV2ns7s%253D&amp;md5=ade23a7ce950c1c83e0bb36f97b18e7d">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000305811300006&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 61</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Hepatol&amp;rft.atitle=A%20phase%201%2C%20randomized%2C%20placebo%E2%80%90controlled%2C%203%E2%80%90day%2C%20dose%E2%80%90ranging%20study%20of%20GS%E2%80%905885%2C%20an%20NS5A%20inhibitor%2C%20in%20patients%20with%20genotype%201%20hepatitis%20C&amp;rft.volume=57&amp;rft.spage=24&amp;rft.epage=31&amp;rft.date=2012&amp;rft.aulast=Lawitz&amp;rft.aufirst=EJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0061"><span class="bullet">61</span><cite id="hep27934-cit-0061">  <span class="author">Wong KA</span>, <span class="author">Worth A</span>, <span class="author">Martin R</span>, <span class="author">Svarovskaia E</span>, <span class="author">Brainard DM</span>, <span class="author">Lawitz E</span>, <span class="author">Miller MD</span>, et al. <span class="articleTitle">Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2013</span>;<span class="vol">57</span>:<span class="pageFirst">6333</span>-<span class="pageLast">6340</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.02193-12">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23877691">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXhvVCjurzI&amp;md5=9a9c72d816193e02c0b730e1b001b4d2">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000328959900065&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 25</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=Characterization%20of%20Hepatitis%20C%20virus%20resistance%20from%20a%20multiple%E2%80%90dose%20clinical%20trial%20of%20the%20novel%20NS5A%20inhibitor%20GS%E2%80%905885&amp;rft.volume=57&amp;rft.spage=6333&amp;rft.epage=6340&amp;rft.date=2013&amp;rft.aulast=Wong&amp;rft.aufirst=KA&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0062"><span class="bullet">62</span><cite id="hep27934-cit-0062">  <span class="author">Afdhal N</span>, <span class="author">Zeuzem S</span>, <span class="author">Kwo P</span>, <span class="author">Chojkier M</span>, <span class="author">Gitlin N</span>, <span class="author">Puoti M</span>, <span class="author">Romero-Gomez M</span>, et al. <span class="articleTitle">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2014</span>;<span class="vol">370</span>:<span class="pageFirst">1889</span>-<span class="pageLast">1898</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1402454">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24725239">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhsVGksbnM&amp;md5=07aea2116fc84cc9122eeb3ee43e14a0">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000336123600005&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 369</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Ledipasvir%20and%20sofosbuvir%20for%20untreated%20HCV%20genotype%201%20infection&amp;rft.volume=370&amp;rft.spage=1889&amp;rft.epage=1898&amp;rft.date=2014&amp;rft.aulast=Afdhal&amp;rft.aufirst=N&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0063"><span class="bullet">63</span><cite id="hep27934-cit-0063">  <span class="author">Joyce CM</span>, <span class="author">Steitz TA.</span> <span class="articleTitle">Polymerase structures and function: variations on a theme?</span> <span class="journalTitle">J Bacteriol</span> <span class="pubYear">1995</span>;<span class="vol">177</span>:<span class="pageFirst">6321</span>-<span class="pageLast">6329</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/7592405">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=A1995TE36700001&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 148</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Bacteriol&amp;rft.atitle=Polymerase%20structures%20and%20function%3A%20variations%20on%20a%20theme%3F&amp;rft.volume=177&amp;rft.spage=6321&amp;rft.epage=6329&amp;rft.date=1995&amp;rft.aulast=Joyce&amp;rft.aufirst=CM&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0064"><span class="bullet">64</span><cite id="hep27934-cit-0064">  <span class="author">Gentile I</span>, <span class="author">Buonomo AR</span>, <span class="author">Zappulo E</span>, <span class="author">Coppola N</span>, <span class="author">Borgia G.</span> <span class="articleTitle">GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection</span>. <span class="journalTitle">Expert Rev Anti Infect Ther</span> <span class="pubYear">2014</span>:<span class="pageFirst">1</span>-<span class="pageLast">8</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/442559">PubMed</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Expert%20Rev%20Anti%20Infect%20Ther&amp;rft.atitle=GS%E2%80%909669%3A%20a%20novel%20non%E2%80%90nucleoside%20inhibitor%20of%20viral%20polymerase%20for%20the%20treatment%20of%20hepatitis%20C%20virus%20infection&amp;rft.spage=1&amp;rft.epage=8&amp;rft.date=2014&amp;rft.aulast=Gentile&amp;rft.aufirst=I&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0065"><span class="bullet">65</span><cite id="hep27934-cit-0065">  <span class="author">Gane EJ</span>, <span class="author">Stedman CA</span>, <span class="author">Hyland RH</span>, <span class="author">Ding X</span>, <span class="author">Svarovskaia E</span>, <span class="author">Symonds WT</span>, <span class="author">Hindes RG</span>, et al. <span class="articleTitle">Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2013</span>;<span class="vol">368</span>:<span class="pageFirst">34</span>-<span class="pageLast">44</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1208953">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23281974">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXlvFajtg%253D%253D&amp;md5=58c3106572a17b9b2264661cdbae191a">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000312930600003&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 287</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Nucleotide%20polymerase%20inhibitor%20sofosbuvir%20plus%20ribavirin%20for%20hepatitis%20C&amp;rft.volume=368&amp;rft.spage=34&amp;rft.epage=44&amp;rft.date=2013&amp;rft.aulast=Gane&amp;rft.aufirst=EJ&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0066"><span class="bullet">66</span><cite id="hep27934-cit-0066">  <span class="author">Zeuzem S</span>, <span class="author">Dusheiko GM</span>, <span class="author">Salupere R</span>, <span class="author">Mangia A</span>, <span class="author">Flisiak R</span>, <span class="author">Hyland RH</span>, <span class="author">Illeperuma A</span>, et al. <span class="articleTitle">Sofosbuvir and ribavirin in HCV genotypes 2 and 3</span>. <span class="journalTitle">N Engl J Med</span> <span class="pubYear">2014</span>;<span class="vol">370</span>:<span class="pageFirst">1993</span>-<span class="pageLast">2001</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1056%2FNEJMoa1316145">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24795201">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhsVGksbnK&amp;md5=689c276b6730abd6ee3276f964a58775">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000336125500007&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 218</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N%20Engl%20J%20Med&amp;rft.atitle=Sofosbuvir%20and%20ribavirin%20in%20HCV%20genotypes%202%20and%203&amp;rft.volume=370&amp;rft.spage=1993&amp;rft.epage=2001&amp;rft.date=2014&amp;rft.aulast=Zeuzem&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0067"><span class="bullet">67</span><cite id="hep27934-cit-0067">  <span class="author">Donaldson EF</span>, <span class="author">Harrington PR</span>, <span class="author">O'Rear JJ</span>, <span class="author">Naeger LK.</span> <span class="articleTitle">Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir</span>. <span class="journalTitle">Hepatology</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25123381">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000347005100013&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 26</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatology&amp;rft.atitle=Clinical%20evidence%20and%20bioinformatics%20characterization%20of%20potential%20hepatitis%20C%20virus%20resistance%20pathways%20for%20Sofosbuvir&amp;rft.date=2014&amp;rft.aulast=Donaldson&amp;rft.aufirst=EF&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0068"><span class="bullet">68</span><cite id="hep27934-cit-0068">  <span class="author"><b>Svarovskaia</b> ES</span>, <span class="author"><b>Dvory-Sobol</b> H</span>, <span class="author">Parkin N</span>, <span class="author">Hebner C</span>, <span class="author">Gontcharova V</span>, <span class="author">Martin R</span>, <span class="author">Ouyang W</span>, et al. <span class="articleTitle">Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials</span>. <span class="journalTitle">Clin Infect Dis</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1093%2Fcid%2Fciu697">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/25266287">PubMed</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000345911500007&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 23</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clin%20Infect%20Dis&amp;rft.atitle=Infrequent%20Development%20of%20Resistance%20in%20Genotype%201%E2%80%906%20Hepatitis%20C%20Virus%E2%80%90Infected%20Subjects%20Treated%20With%20Sofosbuvir%20in%20Phase%202%20and%203%20Clinical%20Trials&amp;rft.date=2014&amp;rft.aulast=Svarovskaia&amp;rft.aufirst=ES&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0069"><span class="bullet">69</span><cite id="hep27934-cit-0069">  <span class="author">Sims KD</span>, <span class="author">Lemm J</span>, <span class="author">Eley T</span>, <span class="author">Liu M</span>, <span class="author">Berglind A</span>, <span class="author">Sherman D</span>, <span class="author">Lawitz E</span>, et al. <span class="articleTitle">Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection</span>. <span class="journalTitle">Antimicrob Agents Chemother</span> <span class="pubYear">2014</span>;<span class="vol">58</span>:<span class="pageFirst">3496</span>-<span class="pageLast">3503</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1128%2FAAC.02579-13">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24733462">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhtlCntbvF&amp;md5=61f497182153d723f5b1b749388f2275">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000338776900063&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 8</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antimicrob%20Agents%20Chemother&amp;rft.atitle=Randomized%2C%20Placebo%E2%80%90Controlled%2C%20Single%E2%80%90Ascending%E2%80%90Dose%20Study%20of%20BMS%E2%80%90791325%2C%20a%20Hepatitis%20C%20Virus%20%28HCV%29%20NS5B%20Polymerase%20Inhibitor%2C%20in%20HCV%20Genotype%201%20Infection&amp;rft.volume=58&amp;rft.spage=3496&amp;rft.epage=3503&amp;rft.date=2014&amp;rft.aulast=Sims&amp;rft.aufirst=KD&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0070"><span class="bullet">70</span><cite id="hep27934-cit-0070">  <span class="author">Wyles DL.</span> <span class="articleTitle">Antiviral resistance and the future landscape of hepatitis C virus infection therapy</span>. <span class="journalTitle">J Infect Dis</span> <span class="pubYear">2013</span>;<span class="vol">207</span> <span class="citedIssue">Suppl 1</span>:<span class="pageFirst">S33</span>-<span class="pageLast">39</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1093%2Finfdis%2Fjis761">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/23390303">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC3sXisVansL0%253D&amp;md5=27203212aad2d6df807de83234b0c2c9">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000314895000006&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 27</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Infect%20Dis&amp;rft.atitle=Antiviral%20resistance%20and%20the%20future%20landscape%20of%20hepatitis%20C%20virus%20infection%20therapy&amp;rft.volume=207&amp;rft.issue=Suppl%201&amp;rft.spage=S33&amp;rft.epage=39&amp;rft.date=2013&amp;rft.aulast=Wyles&amp;rft.aufirst=DL.&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0071"><span class="bullet">71</span><cite id="hep27934-cit-0071">  <span class="author">Poveda E</span>, <span class="author">Wyles DL</span>, <span class="author">Mena A</span>, <span class="author">Pedreira JD</span>, <span class="author">Castro-Iglesias A</span>, <span class="author">Cachay E.</span> <span class="articleTitle">Update on hepatitis C virus resistance to direct-acting antiviral agents</span>. <span class="journalTitle">Antiviral Res</span> <span class="pubYear">2014</span>;<span class="vol">108</span>:<span class="pageFirst">181</span>-<span class="pageLast">191</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://dx.doi.org/10.1016%2Fj.antiviral.2014.05.015">CrossRef</a> | </li><li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed/24911972">PubMed</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXhtFGqsrbM&amp;md5=aa5002148c177d7b9550ae39d148f57e">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000340220400022&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 53</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antiviral%20Res&amp;rft.atitle=Update%20on%20hepatitis%20C%20virus%20resistance%20to%20direct%E2%80%90acting%20antiviral%20agents&amp;rft.volume=108&amp;rft.spage=181&amp;rft.epage=191&amp;rft.date=2014&amp;rft.aulast=Poveda&amp;rft.aufirst=E&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0072"><span class="bullet">72</span><cite id="hep27934-cit-0072">  <span class="author">Gordon SC</span>, <span class="author">Muir AJ</span>, <span class="author">Lim JK</span>, <span class="author">Pearlman B</span>, <span class="author">Argo CK</span>, <span class="author">Ramani A</span>, <span class="author">Maliakkal B</span>, et al. <span class="articleTitle">Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET</span>. <span class="journalTitle">J Hepatol</span> <span class="pubYear">2014</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=J%20Hepatol&amp;rft.atitle=Safety%20profile%20of%20boceprevir%20and%20telaprevir%20in%20chronic%20hepatitis%20C%3A%20Real%20world%20experience%20from%20HCV%E2%80%90TARGET&amp;rft.date=2014&amp;rft.aulast=Gordon&amp;rft.aufirst=SC&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0073"><span class="bullet">73</span><cite id="hep27934-cit-0073">  <span class="author">McPhee F.</span> <span class="articleTitle">Clinical resistance to NS5A inhibitors: virologic escape and long-term persistence</span>. <span class="journalTitle">Antiviral Therapy</span> <span class="pubYear">2014</span>;<span class="vol">19</span>:<span class="pageFirst">A20</span>, Abstract P18. </cite><ul class="article-section__references-list-additional u-horizontal-list"><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000354380300019&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg; Times Cited: 2</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Antiviral%20Therapy&amp;rft.atitle=Clinical%20resistance%20to%20NS5A%20inhibitors%3A%20virologic%20escape%20and%20long%E2%80%90term%20persistence&amp;rft.volume=19&amp;rft.spage=A20&amp;rft.date=2014&amp;rft.aulast=McPhee&amp;rft.aufirst=F.&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li><li id="hep27934-bib-0074"><span class="bullet">74</span><cite id="hep27934-cit-0074"><span class="groupName">American Association for the Study of Liver Diseases</span>. Recommendations for Testing, Managing, and Treating Hepatitis C. <span class="pubYear">2014</span>; <a href="http://hcvguidelines.org/full-report/initial-treatment-hcv-infection-patients-starting-treatment" title="Link to external resource: http://hcvguidelines.org/full-report/initial-treatment-hcv-infection-patients-starting-treatment" target="_blank">http://hcvguidelines.org/full-report/initial-treatment-hcv-infection-patients-starting-treatment</a>. </cite></li><li id="hep27934-bib-0075"><span class="bullet">75</span><cite id="hep27934-cit-0075"><span class="groupName">European Association for the Study of the Liver</span>. EASL Recommendations on the Treatment of Hepatitis C. <span class="pubYear">2014</span>; <a href="http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html" title="Link to external resource: http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html" target="_blank">http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html</a>. </cite></li><li id="hep27934-bib-0076"><span class="bullet">76</span><cite id="hep27934-cit-0076"><span class="groupName">Drafting Committee for Hepatitis Management Guidelines The Japan Society of Hepatology</span>. <span class="articleTitle">JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1</span>. <span class="journalTitle">Hepatol Res</span> <span class="pubYear">2014</span>;<span class="vol">44</span> <span class="citedIssue">Suppl S1</span>:<span class="pageFirst">59</span>-<span class="pageLast">70</span>. </cite><ul class="article-section__references-list-additional u-horizontal-list" data-on-platform="true" data-doi="10.1111/hepr.12272"><li><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/hepr.12272">Wiley Online Library</a> | </li><li><a target="_blank" href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&amp;action=reflink&amp;origin=wiley&amp;version=1%2E0&amp;coi=1%3aCAS%3a528%3aDC%252BC2cXnt1GjtQ%253D%253D&amp;md5=2c521e047b05cfe6d3ce1b5e9ab0b513">CAS</a> | </li><li><a target="_blank" href="http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;SrcApp=Wiley_Online_Library&amp;SrcAuth=LinksAMR&amp;KeyUT=000337516500002&amp;DestLinkType=FullRecord&amp;DestApp=ALL_WOS&amp;UsrCustomerID=5d29b08d2a4045cc6e96df01e7663ac0">Web of Science&reg;</a> | </li><li><a target="_blank" class="js__analytics" data-analytics="open-url" href="http://sfx.metabib.ch/sfx_locater?url_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Hepatol%20Res&amp;rft.atitle=JSH%20Guidelines%20for%20the%20Management%20of%20Hepatitis%20C%20Virus%20Infection%3A%20A%202014%20Update%20for%20Genotype%201&amp;rft.volume=44&amp;rft.issue=Suppl%20S1&amp;rft.spage=59&amp;rft.epage=70&amp;rft.date=2014&amp;rfr_id=info%3Asid%2Fwiley.com%3AOnlineLibrary">University of Zurich</a></li></ul></li></ul></div></section><section id="related-content" class="article-footer__section article-section"><h3 class="article-footer__section-title js-footer-title"><span class="icon icon__double-chevron"></span>Related content         </h3><div class="article-info__section-content js-footer-info"><section class="results"><h4 class="results__title">Articles related to the one you are viewing</h4><div class="related-articles js-module" data-module="related-articles" data-url="http://onlinelibrary.wiley.com/enhanced/related/doi/10.1002/hep.27934/"><noscript><p class="results__summary">Please enable Javascript to view the related content of this article.</p></noscript></div></section></div></section><section id="footer-citing" class="article-footer__section citations__section"><h3 class="article-footer__section-title js-footer-title"><span class="icon icon__double-chevron"></span>Citing Literature             </h3><div id="js-citations__section" class="article-info__section-content js-footer-info"><div class="modal__header"><ul class="cited-info__list u-horizontal-list"><li class="cited-info__item"><span class="cited-info__text">Number of times cited</span>: <span id="js-citations__counter">73</span></li></ul></div><div class="modal__scrollable"><ol class="article-section__citation-list"><li><span class="bullet">1</span><cite><span class="author">Rajeev M. Menon</span>, <span class="author">Akshanth R. Polepally</span>, <span class="author">Amit Khatri</span>, <span class="author">Walid M. Awni</span>, <span class="author">Sandeep Dutta</span>, Clinical Pharmacokinetics of Paritaprevir, <span class="journalTitle">Clinical Pharmacokinetics</span>, <span class="pubYear">2017</span></cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1007/s40262-017-0520-x" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">2</span><cite><span class="author">Bianca Bruzzone</span>, <span class="author">Pasqualina De Leo</span>, <span class="author">Laura Sticchi</span>, <span class="author">Paola Canepa</span>, <span class="author">Emanuela Rappazzo</span>, <span class="author">Marco Anselmo</span>, <span class="author">Giancarlo Icardi</span>, Diagnostic and Therapeutic Implications in a Case of Mixed Hepatitis C Virus (HCV) Infection, <span class="journalTitle">Hepatitis Monthly</span>, <span class="pubYear">2017</span>, <span class="vol">17</span>, 3</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.5812/hepatmon.44774" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">3</span><cite><span class="author">Adriano M. Pellicelli</span>, <span class="author">Valeria Pace Palitti</span>, <span class="author">Pascal Vignally</span>, <span class="author">Francesca Ceccherini-Silberstein</span>, <span class="author">Massimo Siciliano</span>, <span class="author">Valerio Giannelli</span>, <span class="author">Alessandra Moretti</span>, <span class="author">Pierluigi Tarquini</span>, <span class="author">Gaetano Scifo</span>, <span class="author">Vincenzo Messina</span>, <span class="author">Antonio Ascione</span>, <span class="author">Antonio Izzi</span>, <span class="author">Massimo Marignani</span>, <span class="author">Cecilia D'Ambrosio</span>, <span class="author">Lucia Fondacaro</span>, <span class="author">Giuseppe M. Ettorre</span>, <span class="author">Pasquale Ialongo</span>, <span class="author">Rodolfo Sacco</span>, <span class="author">Carlo F. Perno</span>, <span class="author">Giorgio Barbarini</span>, Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study, <span class="journalTitle">Liver International</span>, <span class="pubYear">2017</span>, <span class="vol">37</span>, 5, 653</cite><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/liv.13288" class="article-section__citation-link">Wiley Online Library</a></li><li><span class="bullet">4</span><cite><span class="author">Youki Ueda</span>, <span class="author">Hiromichi Dansako</span>, <span class="author">Shinya Satoh</span>, <span class="author">Hye-Sook Kim</span>, <span class="author">Yusuke Wataya</span>, <span class="author">Hiroyuki Doi</span>, <span class="author">Masanori Ikeda</span>, <span class="author">Nobuyuki Kato</span>, Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems, <span class="journalTitle">Virus Research</span>, <span class="pubYear">2017</span>, <span class="vol">235</span>, 37</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/j.virusres.2017.03.015" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">5</span><cite><span class="author">Lize Cuypers</span>, <span class="author">Pieter Libin</span>, <span class="author">Yoeri Schrooten</span>, <span class="author">Kristof Theys</span>, <span class="author">Velia Chiara Di Maio</span>, <span class="author">Valeria Cento</span>, <span class="author">Maja M. Lunar</span>, <span class="author">Frederik Nevens</span>, <span class="author">Mario Poljak</span>, <span class="author">Francesca Ceccherini-Silberstein</span>, <span class="author">Ann Now&eacute;</span>, <span class="author">Kristel Van Laethem</span>, <span class="author">Anne-Mieke Vandamme</span>, Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning, <span class="journalTitle">Infection, Genetics and Evolution</span>, <span class="pubYear">2017</span>, <span class="vol">53</span>, 15</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/j.meegid.2017.05.007" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">6</span><cite><span class="author">Lucas A. Hill</span>, <span class="author">David L. Wyles</span>, Future Paradigms of HCV Management with Resistance Testing, <span class="journalTitle">Current Hepatology Reports</span>, <span class="pubYear">2017</span>, <span class="vol">16</span>, 1, 1</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1007/s11901-017-0328-z" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">7</span><cite><span class="author">Giovanna Russelli</span>, <span class="author">Paola Pizzillo</span>, <span class="author">Gioacchin Iannolo</span>, <span class="author">Floriana Barbera</span>, <span class="author">Fabio Tuzzolino</span>, <span class="author">Rosa Liotta</span>, <span class="author">Mario Traina</span>, <span class="author">Giovanni Vizzini</span>, <span class="author">Bruno Gridelli</span>, <span class="author">Ester Badami</span>, <span class="author">Pier Giulio Conaldi</span>, <span class="author">Birke Bartosch</span>, HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation, <span class="journalTitle">PLOS ONE</span>, <span class="pubYear">2017</span>, <span class="vol">12</span>, 7, e0181683</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1371/journal.pone.0181683" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">8</span><cite><span class="author">Ashley N. Matthew</span>, <span class="author">Jacqueto Zephyr</span>, <span class="author">Caitlin. J. Hill</span>, <span class="author">Muhammad Jahangir</span>, <span class="author">Alicia Newton</span>, <span class="author">Christos J. Petropoulos</span>, <span class="author">Wei Huang</span>, <span class="author">Nese Kurt-Yilmaz</span>, <span class="author">Celia A. Schiffer</span>, <span class="author">Akbar Ali</span>, Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants, <span class="journalTitle">Journal of Medicinal Chemistry</span>, <span class="pubYear">2017</span>, <span class="vol">60</span>, 13, 5699</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1021/acs.jmedchem.7b00426" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">9</span><cite><span class="author">Kanako Yoshida</span>, <span class="author">Hoang Hai</span>, <span class="author">Akihiro Tamori</span>, <span class="author">Yuga Teranishi</span>, <span class="author">Ritsuzo Kozuka</span>, <span class="author">Hiroyuki Motoyama</span>, <span class="author">Etsushi Kawamura</span>, <span class="author">Atsushi Hagihara</span>, <span class="author">Sawako Uchida-Kobayashi</span>, <span class="author">Hiroyasu Morikawa</span>, <span class="author">Masaru Enomoto</span>, <span class="author">Yoshiki Murakami</span>, <span class="author">Norifumi Kawada</span>, Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed, <span class="journalTitle">International Journal of Molecular Sciences</span>, <span class="pubYear">2017</span>, <span class="vol">18</span>, 5, 962</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.3390/ijms18050962" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">10</span><cite><span class="author">Velia C. Di Maio</span>, <span class="author">Valeria Cento</span>, <span class="author">Ilaria Lenci</span>, <span class="author">Marianna Aragri</span>, <span class="author">Piera Rossi</span>, <span class="author">Silvia Barbaliscia</span>, <span class="author">Michela Melis</span>, <span class="author">Gabriella Verucchi</span>, <span class="author">Carlo F. Magni</span>, <span class="author">Elisabetta Teti</span>, <span class="author">Ada Bertoli</span>, <span class="author">FrancescoPaolo Antonucci</span>, <span class="author">Maria C. Bellocchi</span>, <span class="author">Valeria Micheli</span>, <span class="author">Chiara Masetti</span>, <span class="author">Simona Landonio</span>, <span class="author">Simona Francioso</span>, <span class="author">Francesco Santopaolo</span>, <span class="author">Adriano M. Pellicelli</span>, <span class="author">Vincenza Calvaruso</span>, <span class="author">Laura Gianserra</span>, <span class="author">Massimo Siciliano</span>, <span class="author">Dante Romagnoli</span>, <span class="author">Raffaele Cozzolongo</span>, <span class="author">Antonio Grieco</span>, <span class="author">Jacopo Vecchiet</span>, <span class="author">Filomena Morisco</span>, <span class="author">Manuela Merli</span>, <span class="author">Giuseppina Brancaccio</span>, <span class="author">Antonio Di Biagio</span>, <span class="author">Elisabetta Loggi</span>, <span class="author">Claudio M. Mastroianni</span>, <span class="author">Valeria Pace Palitti</span>, <span class="author">Pierluigi Tarquini</span>, <span class="author">Massimo Puoti</span>, <span class="author">Gloria Taliani</span>, <span class="author">Loredana Sarmati</span>, <span class="author">Antonino Picciotto</span>, <span class="author">Vincenzo Vullo</span>, <span class="author">Nicola Caporaso</span>, <span class="author">Maurizio Paoloni</span>, <span class="author">Caterina Pasquazzi</span>, <span class="author">Giuliano Rizzardini</span>, <span class="author">Giustino Parruti</span>, <span class="author">Antonio Crax&igrave;</span>, <span class="author">Sergio Babudieri</span>, <span class="author">Massimo Andreoni</span>, <span class="author">Mario Angelico</span>, <span class="author">Carlo F. Perno</span>, <span class="author">Francesca Ceccherini-Silberstein</span>, Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies, <span class="journalTitle">Liver International</span>, <span class="pubYear">2017</span>, <span class="vol">37</span>, 4, 514</cite><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/liv.13327" class="article-section__citation-link">Wiley Online Library</a></li><li><span class="bullet">11</span><cite><span class="author">Caroline Furtado Noble</span>, <span class="author">Fernanda Malta</span>, <span class="author">Gaspar Lisboa-Neto</span>, <span class="author">Michele Soares Gomes-Gouv&ecirc;a</span>, <span class="author">Andrea Gurgel Batista Leite</span>, <span class="author">Vanessa Fusco Duarte de Castro</span>, <span class="author">Rubia Anita Ferraz Santana</span>, <span class="author">Flair Jos&eacute; Carrilho</span>, <span class="author">Maria C&aacute;ssia Mendes-Correa</span>, <span class="author">Jo&atilde;o Renato Rebello Pinho</span>, Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV, <span class="journalTitle">Archives of Virology</span>, <span class="pubYear">2017</span>, <span class="vol">162</span>, 1, 165</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1007/s00705-016-3094-2" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">12</span><cite><span class="author">Giulia Morsica</span>, <span class="author">Andrea Andolina</span>, <span class="author">Marco Merli</span>, <span class="author">Emanuela Messina</span>, <span class="author">Hamid Hasson</span>, <span class="author">Adriano Lazzarin</span>, <span class="author">Caterina Uberti-Foppa</span>, <span class="author">Sabrina Bagaglio</span>, NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B, <span class="journalTitle">Archives of Virology</span>, <span class="pubYear">2017</span>, <span class="vol">162</span>, 8, 2271</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1007/s00705-017-3341-1" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">13</span><cite><span class="author">Stefan Zeuzem</span>, <span class="author">Masashi Mizokami</span>, <span class="author">Stephen Pianko</span>, <span class="author">Alessandra Mangia</span>, <span class="author">Kwang-Hyub Han</span>, <span class="author">Ross Martin</span>, <span class="author">Evguenia Svarovskaia</span>, <span class="author">Hadas Dvory-Sobol</span>, <span class="author">Brian Doehle</span>, <span class="author">Charlotte Hedskog</span>, <span class="author">Chohee Yun</span>, <span class="author">Diana M. Brainard</span>, <span class="author">Steven Knox</span>, <span class="author">John G. McHutchison</span>, <span class="author">Michael D. Miller</span>, <span class="author">Hongmei Mo</span>, <span class="author">Wan-Long Chuang</span>, <span class="author">Ira Jacobson</span>, <span class="author">Gregory J. Dore</span>, <span class="author">Mark Sulkowski</span>, NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome, <span class="journalTitle">Journal of Hepatology</span>, <span class="pubYear">2017</span>, <span class="vol">66</span>, 5, 910</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/j.jhep.2017.01.007" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">14</span><cite><span class="author">Robert Flisiak</span>, <span class="author">Marta Flisiak-Jackiewicz</span>, Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C, <span class="journalTitle">Expert Review of Gastroenterology &amp; Hepatology</span>, <span class="pubYear">2017</span>, <span class="vol">11</span>, 6, 559</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1080/17474124.2017.1309284" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">15</span><cite><span class="author">V. Cento</span>, <span class="author">S. Barbaliscia</span>, <span class="author">I. Lenci</span>, <span class="author">T. Ruggiero</span>, <span class="author">C.F. Magni</span>, <span class="author">S. Paolucci</span>, <span class="author">S. Babudieri</span>, <span class="author">M. Siciliano</span>, <span class="author">C. Pasquazzi</span>, <span class="author">A. Ciancio</span>, <span class="author">C.F. Perno</span>, <span class="author">F. Ceccherini-Silberstein</span>, <span class="author">V. Micheli</span>, <span class="author">Y. Troshina</span>, <span class="author">E. Biliotti</span>, <span class="author">M. Milana</span>, <span class="author">M. Melis</span>, <span class="author">E. Teti</span>, <span class="author">L. Lambiase</span>, <span class="author">B. Menzaghi</span>, <span class="author">L.A. Nicolini</span>, <span class="author">S. Marenco</span>, <span class="author">V.C. Di Maio</span>, <span class="author">M. Aragri</span>, <span class="author">A. Pecchioli</span>, <span class="author">A. Bertoli</span>, <span class="author">C. Sarrecchia</span>, <span class="author">M. Macera</span>, <span class="author">N. Coppola</span>, <span class="author">M. Puoti</span>, <span class="author">D. Romagnoli</span>, <span class="author">A. Pellicelli</span>, <span class="author">S. Bonora</span>, <span class="author">S. Novati</span>, <span class="author">F. Baldanti</span>, <span class="author">V. Ghisetti</span>, <span class="author">M. Andreoni</span>, <span class="author">G. Taliani</span>, <span class="author">G. Rizzardini</span>, <span class="author">M. Angelico</span>, Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life, <span class="journalTitle">Clinical Microbiology and Infection</span>, <span class="pubYear">2017</span></cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1016/j.cmi.2017.04.005" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">16</span><cite><span class="author">Adam Doyle</span>, <span class="author">Jordan J. Feld</span>, Overcoming the resistance to resistance testing: Collecting the data, <span class="journalTitle">Liver International</span>, <span class="pubYear">2017</span>, <span class="vol">37</span>, 4, 506</cite><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/liv.13360" class="article-section__citation-link">Wiley Online Library</a></li><li><span class="bullet">17</span><cite><span class="author">Rita C.F. Tavares</span>, <span class="author">Ana C.C.A. Feldner</span>, <span class="author">Jo&atilde;o R.R. Pinho</span>, <span class="author">Silvia N.O. Uehara</span>, <span class="author">Christini T. Emori</span>, <span class="author">Roberto J. Carvalho-Filho</span>, <span class="author">Ivonete S.S. Silva</span>, <span class="author">R&uacute;bia A.F. Santana</span>, <span class="author">Vanessa F.D. de Castro</span>, <span class="author">Greg&oacute;rio T. F. Castoli</span>, <span class="author">Charliana U. Cristov&atilde;o</span>, <span class="author">Maria L.C.G. Ferraz</span>, Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection, <span class="journalTitle">European Journal of Gastroenterology &amp; Hepatology</span>, <span class="pubYear">2017</span>, <span class="vol">29</span>, 7, 754</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1097/MEG.0000000000000866" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">18</span><cite><span class="author">Maemu Petronella Gededzha</span>, <span class="author">M. Jeffrey Mphahlele</span>, <span class="author">Jason T. Blackard</span>, <span class="author">Selokela Gloria Selabe</span>, Prevalence of NS5B Resistance Mutations in Hepatitis C Virus (HCV) Treatment Naive South Africans, <span class="journalTitle">Hepatitis Monthly</span>, <span class="pubYear">2017</span>, <span class="vol">17</span>, 6</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.5812/hepatmon.14248" class="article-section__citation-link" target="_blank">CrossRef</a></li><li><span class="bullet">19</span><cite><span class="author">Wendy Carter</span>, <span class="author">Sarah Connelly</span>, <span class="author">Kimberly Struble</span>, Reinventing HCV Treatment: Past and Future Perspectives, <span class="journalTitle">The Journal of Clinical Pharmacology</span>, <span class="pubYear">2017</span>, <span class="vol">57</span>, 3, 287</cite><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1002/jcph.830" class="article-section__citation-link">Wiley Online Library</a></li><li><span class="bullet">20</span><cite><span class="author">Sabrina Bagaglio</span>, <span class="author">Caterina Uberti-Foppa</span>, <span class="author">Giulia Morsica</span>, Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use, <span class="journalTitle">Drugs</span>, <span class="pubYear">2017</span>, <span class="vol">77</span>, 10, 1043</cite><a href="http://onlinelibrary.wiley.com/resolve/reference/XREF?id=10.1007/s40265-017-0753-x" class="article-section__citation-link" target="_blank">CrossRef</a></li></ol></div><p class="weight-bold"><a href="http://onlinelibrary.wiley.com/enhanced/showAllCitations/doi/10.1002/hep.27934" class="js-module" data-module="fragment" data-fragment="large">                     View all 73 citations                 </a></p></div></section></footer></article>                 </article>                             </article>                                                       <div class="l-article-support">     <div class="skyscraper--left">              <div id="skyscraper" class="skyscraper">         <aside id="advert-skyscraper" class="advert-skyscraper" role="complementary">             <div class="skyscraper__title">Advertisement</div>             <script>
                googletag.cmd.push ( function () {
                    googletag.display ( 'advert-skyscraper' );
                });
            </script>             <noscript>
                <a href="http://pubads.g.doubleclick.net/gampad/jump?iu=/2215/wly.gastro.hep_000059/hepatology_HEP&amp;sz=160x600|160x320|160x160|120x600&amp;tile=2&amp;c=44324642" target="_blank">
                    <img src="http://pubads.g.doubleclick.net/gampad/ad?iu=/2215/wly.gastro.hep_000059/hepatology_HEP&amp;sz=160x600|160x320|160x160|120x600&amp;tile=2&amp;c=44324642" />
                </a>
            </noscript>         </aside>     </div>     </div>      <div class="article-support js-article-support js-module" data-module="infopane">                 <div class="article-support__links js-article-support-links">             <nav class="article-support__list-wrapper js-article-support-list-wrapper" role="navigation" aria-label="AA Article Features">                 <ul class="article-support__list js-article-support-list u-list-plain">                                          <li class="article-support__item--pdf ">                         <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/pdf" class="article-support__item-link js-infopane-pdf " data-support-type="PDF_options">                             <span class="icon-aa icon-aa__sidepane icon-aa__sidepane--pdf"></span>                             <span class="article-support__item-text">PDF</span>                         </a>                     </li>                                                              <li class="article-support__item--epdf">                         <a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.27934/epdf" class="article-support__item-link js-infopane-epdf">                             <span class="icon-aa icon-aa__sidepane icon-aa__sidepane--pdf"></span>                             <span class="article-support__item-text">PDF</span>                         </a>                     </li>                                                              <li>                         <a href="#footer-article-info" class="article-support__item-link js-infopane-toggle" data-support-type="Information">                             <span class="icon-aa icon-aa__sidepane icon-aa__sidepane--info"></span>                             <span class="article-support__item-text">Info</span>                         </a>                     </li>                                                              <li>                         <a href="#references-section" class="article-support__item-link js-infopane-toggle" data-support-type="References" data-target-scroll="false">                             <span class="icon-aa icon-aa__sidepane icon-aa__sidepane--ref"></span>                             <span class="article-support__item-text">References</span>                         </a>                     </li>                                                              <li class="article-support__item-figure-viewer">                         <a href="http://onlinelibrary.wiley.com/enhanced/figures/doi/10.1002/hep.27934" data-module="figure-viewer-modal" class="js-module article-support__item-link" id="js-figure-viewer__link" target="figureViewer">                             <span class="icon-aa icon-aa__sidepane icon-aa__sidepane--fig"></span>                             <span class="article-support__item-text">Figures</span>                         </a>                     </li>                                                          </ul>             </nav>         </div>                                  <div class="article-support__pane js-article-support-pane is-hidden">             <div class="article-support__pane-title-bar">                 <div class="article-support__pane-title js-article-support-title"></div>                 <div class="article-support__pane-close js-article-support-close">                     <a href="#" class="article-support__pane-close__link" data-close="close" title="Close article support pane">                         <span class="icon icon__infopane-close"></span>                         <span class="is-accessible">Close article support pane</span>                     </a>                 </div>             </div>             <div class="article-support__pane-content js-article-support-content"></div>         </div>              </div> </div>                 </div>     </div> </div>  <div id="region__footer">     <!-- RenderByLocation - structure: Hub Footer - title: AASLD Hub Footer - ident: 76ab1e48-b113-44d9-81a6-7889a4375b10 --><footer class="footer footer--hub" role="contentinfo">    <div class="footer__copy">    <p class="footer__text">&copy; 2017 American Association for the Study of Liver Diseases</p>   </div>   <nav class="footer__nav" role="navigation" aria-label="AASLD Society Footer">   <ul class="footer__list footer__list--logo">    <li>          <h2 class="footer__logo">       <a href="http://aasldpubs.onlinelibrary.wiley.com/hub/">        <img alt="American Association for the Study of Liver Diseases" src="http://cdn.wol2.wiley.com/external/aasld/images/footer_branding.svg?v=1.14" onerror="this.src=this.src.replace('svg','png');" />       </a>      </h2>        </li>   </ul>   <ul class="footer__list"> <li><a class="footer__link" target="_blank" href="http://www.aasld.org/"><b>AASLD.org</b></a></li> </ul> <ul class="footer__list"> <li><a class="footer__link" target="_blank" href="http://www.aasld.org/membership">Membership </a></li> </ul> <ul class="footer__list"> <li><a class="footer__link" target="_blank" href="http://www.aasld.org/about-aasld/contact-us">Contact Us </a></li>   </ul>  </nav> </footer><!--  End RenderByLocation (76ab1e48-b113-44d9-81a6-7889a4375b10) -->     <!-- START: Footer --> <div class="stripe" role="presentation">     <div class="fill fill--1"></div>     <div class="fill fill--2"></div>     <div class="fill fill--3"></div>     <div class="fill fill--4"></div> </div> <footer class="footer footer--wiley" role="contentinfo">     <nav class="footer__nav" role="navigation" aria-label="Wiley Online Library Footer">                     <ul class="footer__list footer__list--logo">                 <li>                     <h2 class="footer__logo">                         <a href="http://onlinelibrary.wiley.com">                             <img src="/enhanced/static/common/images/brand/wiley/footer-logo.svg?version=1.15.0" onerror="this.src=this.src.replace('svg','png');" alt="Wiley" />                         </a>                     </h2>                 </li>             </ul>                 <ul class="footer__list">   <li><a class="footer__link" href="http://journalshelp.wiley.com/">Help &amp; Support</a></li>   <li><a class="footer__link" href="http://olabout.wiley.com/WileyCDA/Section/id-390001.html">About Us</a></li> </ul>  <ul class="footer__list">   <li><a class="footer__link" href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">Cookies</a> &amp; <a class="footer__link" href="http://onlinelibrary.wiley.com/privacyPolicy">Privacy</a></li>   <li><a class="footer__link" href="http://www.wileyjobnetwork.com/">Wiley Job Network</a></li> </ul>  <ul class="footer__list">   <li><a class="footer__link" href="http://onlinelibrary.wiley.com/termsAndConditions">Terms of Service</a></li>   <li><a class="footer__link" href="http://olabout.wiley.com/WileyCDA/Section/id-390236.html">Advertisers</a> &amp; <a class="footer__link" href="http://olabout.wiley.com/WileyCDA/Section/id-390243.html">Agents</a></li> </ul>     </nav>     <div class="footer__copy" aria-label="Learn more about Wiley">         <p class="footer__text footer__text--slogan">Powered by <a href="http://onlinelibrary.wiley.com" class="footer__link footer__link--active">Wiley Online Library</a></p> <p class="footer__text">Copyright &copy; 1999 - 2017 <a href="http://www.wiley.com" class="footer__link footer__link--active">John Wiley &amp; Sons, Inc.</a> All Rights Reserved</p>     </div> </footer>           <script>
//<![CDATA[
    
    Modernizr.load([
        {
            load    : '/enhanced/static/common/js/vendor/wiley-require.js',
            callback: function() {

                
                var interval = setInterval(function() {
                    if ( typeof WILEY !== 'undefined' && WILEY.requirejs ) {
                        // Stop us from having to load an extra RequireJS for Cochrane
                        window.define       = WILEY.define;
                        window.require      = WILEY.require;
                        window.requirejs    = WILEY.requirejs;

                        WILEY.requirejs([
                                '/enhanced/static/common/js/wiley-common.js?version=1.15.0',
                                '/enhanced/static/js/wiley-article.js?version=1.15.0'
                            ], function() {
                            WILEY.requirejs([
                                'common/modules/main',
                                'modules/main-article'

                                                                                                            ,'http://cdn.wol2.wiley.com/external/aasld/shared/scripts/wiley.js'
                                                                                                ]

                            
                            );
                        });

                        clearInterval(interval);
                    }
                }, 100 );
            }
        }
        ]);
//]]>
</script>     </div> </div>      <script type="text/javascript">_satellite.pageBottom();</script>  </div> </body> </html>